var title_f38_24_39296="Drop arm test";
var content_f38_24_39296=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1124px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/82880/Drop_arm_test_video.mp4?title=Drop+arm+test\" style=\"width:480px;height:288px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Drop arm test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The drop arm test assesses the ability of the patient to lower his or her arms from a fully abducted position. A positive test occurs when the patient is unable to lower the affected arm with the same smooth coordinated motion as the unaffected arm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Simons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_24_39296=[""].join("\n");
var outline_f38_24_39296=null;
var title_f38_24_39297="Nail lichen planus pterygium";
var content_f38_24_39297=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pterygium in lichen planus of the nail",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 426px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The proximal nail fold is adherent to the nail bed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission: from Dr. Bethanee Schlosser.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_24_39297=[""].join("\n");
var outline_f38_24_39297=null;
var title_f38_24_39298="Patient information: Angioplasty and stenting for the heart (The Basics)";
var content_f38_24_39298=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86375\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/10/8356\">",
"         Coronary heart disease",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/60/16324\">",
"          Angioplasty",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/38/24175\">",
"           Heart stent",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?34/53/35667\">",
"         Patient information: Cardiac catheterization (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?20/34/21027\">",
"         Patient information: Chest pain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/10/27809\">",
"         Patient information: Coronary heart disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?9/53/10068\">",
"         Patient information: Heart attack (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/27/21940\">",
"         Patient information: Medicines after a heart attack (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/35/1587\">",
"         Patient information: Medicines for angina (chest pain) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/1/31766\">",
"         Patient information: Angina treatment &mdash; medical therapy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?42/10/43170\">",
"         Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Angioplasty and stenting for the heart (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H88361151\">",
"      <span class=\"h1\">",
"       What is angioplasty and stenting?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Angioplasty and stenting are procedures used to treat some people with coronary heart disease. These procedures open narrowed or blocked arteries in the heart (",
"      <a class=\"graphic graphic_figure graphicRef61785 \" href=\"mobipreview.htm?8/10/8356\">",
"       figure 1",
"      </a>",
"      ). They are usually done together but sometimes, angioplasty is done without stenting.",
"     </p>",
"     <p>",
"      Before the procedure, you will have a test called a &ldquo;coronary angiogram.&rdquo; This test checks how many of your heart arteries are blocked and how serious the blockages are. For this test, the doctor puts the thin plastic tube (called a &ldquo;catheter&rdquo;) into a small cut at the top of your thigh or near your wrist. He or she then moves the tube through your blood vessels to your heart (",
"      <a class=\"graphic graphic_figure graphicRef86000 \" href=\"mobipreview.htm?15/60/16324\">",
"       figure 2",
"      </a>",
"      ) and pushes a dye into the catheter. The dye shows up on special X-ray pictures.",
"     </p>",
"     <p>",
"      Depending on the results, your doctor might do angioplasty with stenting right away. For this procedure, the doctor will advance a plastic tube with a tiny balloon at the end of it to your heart. After it reaches the narrowed or blocked artery, the doctor will inflate the balloon. This opens up the artery and helps restore blood flow to the heart. Usually, the doctor places a stent where the blockage was.",
"     </p>",
"     <p>",
"      A heart stent is a tiny metal tube that helps prop open an artery in the heart (",
"      <a class=\"graphic graphic_figure graphicRef86256 \" href=\"mobipreview.htm?23/38/24175\">",
"       figure 3",
"      </a>",
"      ). Many heart stents are coated with a medicine that helps keep the artery from getting narrow or blocked again.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H88361219\">",
"      <span class=\"h1\">",
"       Why might I need angioplasty and a stent?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor might recommend angioplasty and a stent if you have coronary heart disease and:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Chest pain (&ldquo;called angina&rdquo;) that does not get better when you take medicines",
"       </li>",
"       <li>",
"        One or more heart arteries that are very narrow",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People who are having a heart attack or had a heart attack a short time ago also sometimes need angioplasty and stent placement.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H88361236\">",
"      <span class=\"h1\">",
"       How do I prepare for the procedure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should not eat or drink anything for 6 to 8 hours before the procedure. You might need to change your medicines or stop taking some of them beforehand. Follow all the instructions your doctor gives you. If you don&rsquo;t feel well on the day of the procedure, tell your doctor.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H88361253\">",
"      <span class=\"h1\">",
"       What happens after the procedure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After the procedure, your doctor will remove the tube from your body and put pressure on the small cut to prevent bleeding. You will probably need to stay in the hospital overnight. Before you leave, your doctor will tell you when you can drive and do your usual activities again.",
"     </p>",
"     <p>",
"      If you got a stent, your doctor will prescribe",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/12/6342?source=see_link\">",
"       aspirin",
"      </a>",
"      and another medicine to help prevent clots inside the stent.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H88361270\">",
"      <span class=\"h1\">",
"       What problems can happen after the procedure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common problems are bleeding, bruising, and soreness in the area where the tube was put in. These problems can last for a few days, especially if the tube was put in the leg.",
"     </p>",
"     <p>",
"      Other problems can happen during or after an angioplasty, but they are rare. They include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A small tear in the inside of a coronary artery, which usually heals by itself. Some people with this problem need another procedure or (in rare cases) surgery to fix the tear.",
"       </li>",
"       <li>",
"        Heart damage",
"       </li>",
"       <li>",
"        A blood clot inside the stent. This can block blood flow to the heart and cause a heart attack or even death. It can happen as early as 1 day or as late as 1 year or more after you get a stent. But most clots happen in the first 30 days after the procedure.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H88361287\">",
"      <span class=\"h1\">",
"       When should I call my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call your doctor or nurse if any of the following happen after your angioplasty:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You have chest pain that does not get better with 1 dose of sublingual (under the tongue)",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/10/9382?source=see_link\">",
"         nitroglycerin",
"        </a>",
"       </li>",
"       <li>",
"        You get a fever or have pain, swelling, or redness where the tube went in",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H88361304\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/53/35667?source=see_link\">",
"       Patient information: Cardiac catheterization (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/34/21027?source=see_link\">",
"       Patient information: Chest pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/10/27809?source=see_link\">",
"       Patient information: Coronary heart disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/53/10068?source=see_link\">",
"       Patient information: Heart attack (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/35/1587?source=see_link\">",
"       Patient information: Medicines for angina (chest pain) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/27/21940?source=see_link\">",
"       Patient information: Medicines after a heart attack (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/1/31766?source=see_link\">",
"       Patient information: Angina treatment &mdash; medical therapy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/10/43170?source=see_link\">",
"       Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/24/39298?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86375 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-D86B8ADF8C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_24_39298=[""].join("\n");
var outline_f38_24_39298=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88361151\">",
"      What is angioplasty and stenting?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88361219\">",
"      Why might I need angioplasty and a stent?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88361236\">",
"      How do I prepare for the procedure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88361253\">",
"      What happens after the procedure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88361270\">",
"      What problems can happen after the procedure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88361287\">",
"      When should I call my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88361304\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86375\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/10/8356\">",
"      Coronary heart disease",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/60/16324\">",
"       Angioplasty",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/38/24175\">",
"        Heart stent",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/1/31766?source=related_link\">",
"      Patient information: Angina treatment &mdash; medical therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/10/43170?source=related_link\">",
"      Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/53/35667?source=related_link\">",
"      Patient information: Cardiac catheterization (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/34/21027?source=related_link\">",
"      Patient information: Chest pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/10/27809?source=related_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/53/10068?source=related_link\">",
"      Patient information: Heart attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/27/21940?source=related_link\">",
"      Patient information: Medicines after a heart attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/35/1587?source=related_link\">",
"      Patient information: Medicines for angina (chest pain) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_24_39299="Lactulose: Pediatric drug information";
var content_f38_24_39299=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lactulose: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33316?source=see_link\">",
"    see \"Lactulose: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/59/19380?source=see_link\">",
"    see \"Lactulose: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F186541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Constulose;",
"     </li>",
"     <li>",
"      Enulose;",
"     </li>",
"     <li>",
"      Generlac;",
"     </li>",
"     <li>",
"      Kristalose&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F186542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Acilac;",
"     </li>",
"     <li>",
"      Apo-Lactulose&reg;;",
"     </li>",
"     <li>",
"      Laxilose;",
"     </li>",
"     <li>",
"      PMS-Lactulose",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Ammonium Detoxicant",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Hyperammonemia Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Laxative, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1059630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33316?source=see_link\">",
"      see \"Lactulose: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Constipation:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 0.7-2 g/kg/",
"     <b>",
"      day",
"     </b>",
"     (1-3 mL/kg/",
"     <b>",
"      day",
"     </b>",
"     ) in divided doses, maximum daily dose: 40 g/",
"     <b>",
"      day",
"     </b>",
"     (60 mL/",
"     <b>",
"      day",
"     </b>",
"     ) (NASPGHAN, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 10-20 g (15-30 mL) daily; may increase to 40 g (60 mL) daily if necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Portal systemic encephalopathy, acute treatment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 20-30 g (30-45 mL) every 1 hour to induce rapid laxation; reduce to 20-30 g (30-45 mL) 3-4 times daily after laxation is achieved titrate to produce 2-3 soft stools/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectal administration (retention enema): 200 g (300 mL) diluted with 700 mL of  water or NS via rectal balloon catheter; retain for 30-60 minutes may be repeated every 4-6 hours; transition to oral treatment prior to discontinuing rectal administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Portal systemic encephalopathy, prevention:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 1.7-6.7 g/",
"     <b>",
"      day",
"     </b>",
"     (2.5-10 mL/",
"     <b>",
"      day",
"     </b>",
"     ) in divided doses; adjust dosage to produce 2-3 stools/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 26.7-60 g/",
"     <b>",
"      day",
"     </b>",
"     (40-90 mL/",
"     <b>",
"      day",
"     </b>",
"     ) in divided doses; adjust dosage to produce 2-3 stools/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 20-30 g (30-45 mL) 3-4 times daily; adjust dose every 1-2 days to produce 2-3 soft stools/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F186523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Crystals for solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kristalose&reg;: 10 g/packet (30s); 20 g/packet (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 10 g/15 mL (15 mL, 30 mL, 237 mL, 473 mL, 500 mL, 946 mL, 1892 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Constulose: 10 g/15 mL (237 mL [DSC], 946 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Enulose: 10 g/15 mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral/rectal: 10 g/15 mL (237 mL, 473 mL, 946 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Generlac: 10 g/15 mL (473 mL, 1892 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F186508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes crystals for solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with juice, milk, or water; dissolve crystals in 4 ounces of water or juice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rectal: Mix with water or normal saline; administer as retention enema using a rectal balloon catheter; retain for 30-60 minutes",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1059633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature. Solution: Do not freeze. Protect from light. Discard solution if cloudy or very dark. Prolonged exposure to cold temperatures will cause thickening which will return to normal upon warming to room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of portal-systemic encephalopathy (PSE) (FDA approved in infants, children, adolescents, and adults); treatment of constipation (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F186591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lactulose may be confused with lactose",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F186589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Dehydration, hypernatremia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal discomfort, abdominal distention, belching, cramping, diarrhea (excessive dose), flatulence, nausea, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lactulose or any component; patients requiring low galactose diet",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1059629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with diabetes mellitus (contains galactose and lactose); do not use with other laxatives especially when initiating PSE treatment as increased loose stools may falsely suggest adequate lactulose dosage. Electrolyte imbalance may occur when lactulose is used &gt;6 months or in patients predisposed to electrolyte abnormalities; hepatic disease may predispose patients to electrolyte imbalance; infants receiving lactulose may develop hyponatremia and dehydration.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1059628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     During proctoscopy or colonoscopy procedures involving electrocautery, a theoretical risk of reaction between hydrogen gas accumulation and electrical spark may exist; thorough bowel cleansing with a non-fermentable solution is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F186517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1059644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in patients on galactose-restricted diet",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F186519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13763432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1059635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum ammonia, serum electrolytes, fluid status, stool output",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1059627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The bacterial degradation of lactulose resulting in an acidic pH inhibits the diffusion of NH",
"     <sub>",
"      3",
"     </sub>",
"     into the blood by causing the conversion of NH",
"     <sub>",
"      3",
"     </sub>",
"     to NH",
"     <sub>",
"      4",
"     </sub>",
"     +; also enhances the diffusion of NH",
"     <sub>",
"      3",
"     </sub>",
"     from the blood into the gut where conversion to NH",
"     <sub>",
"      4",
"     </sub>",
"     + occurs; produces an osmotic effect in the colon with resultant distention promoting peristalsis and elimination of NH",
"     <sub>",
"      4",
"     </sub>",
"     + from the body",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F13451167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Constipation: Up to 24-48 hours to produce a normal bowel movement",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Encephalopathy: At least 24-48 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1059641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Not absorbed appreciably",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: By colonic flora to lactic acid and acetic acid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily in feces; urine (&le;3%)",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1059643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Upon discontinuation of therapy, allow 24-48 hours for resumption of normal bowel movements",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Constipation Guideline Committee of the North American Society for  Pediatric Gastroenterology, Hepatology and Nutrition, \"Evaluation and Treatment of Constipation in Infants and Children: Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition,\"",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2006, 43(3):e1-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/24/39299/abstract-text/16954945 /pubmed\" id=\"16954945 \" target=\"_blank\">",
"        16954945",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pijpers MA, Tabbers MM, Benninga MA, et al, \"Currently Recommended Treatments of Childhood Constipation Are Not Evidence Based: A Systematic Literature Review on the Effect of Laxative Treatment and Dietary Measures,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 2009, 94(2):117-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/24/39299/abstract-text/18713795/pubmed\" id=\"18713795\" target=\"_blank\">",
"        18713795",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13405 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-6D749065E6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_24_39299=[""].join("\n");
var outline_f38_24_39299=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186541\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186542\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059636\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059630\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186523\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186508\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059639\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059633\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059638\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186591\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186589\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059642\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059629\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059628\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299571\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186517\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059644\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186519\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13763432\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059635\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059627\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13451167\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059641\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059643\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13405\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13405|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33316?source=related_link\">",
"      Lactulose: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/59/19380?source=related_link\">",
"      Lactulose: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_24_39300="Hearing amplification in adults";
var content_f38_24_39300=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hearing amplification in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/24/39300/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/24/39300/contributors\">",
"     Peter C Weber, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/24/39300/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/24/39300/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/24/39300/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/24/39300/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/24/39300/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Devices that amplify sound are integral to the management of hearing impairment. These include hearing aids, amplified telephones, and portable devices that can be used to amplify the sound coming from electronic systems at public events. Implantable hearing devices (eg, cochlear implants, osseointegrated implants, and electrically-driven middle ear implants) are integral in providing hearing for adults in whom traditional hearing amplification devices do not provide adequate hearing.",
"   </p>",
"   <p>",
"    Hearing amplification devices for adults are discussed here. Hearing amplification devices for children and the differential diagnosis of hearing loss are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29927?source=see_link\">",
"     \"Treatment of hearing impairment in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/15/10490?source=see_link\">",
"     \"Etiology of hearing loss in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEARING AIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most hearing impairments can be helped with a modern hearing aid. Young, middle-aged, and independent elderly individuals who have hearing difficulties that interfere with work and social interactions, and who are highly motivated to improve their hearing, make excellent candidates for hearing amplification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39300/abstract/1\">",
"     1",
"    </a>",
"    ]. However, less than one-half of the elderly population with significant hearing impairment, who would benefit from hearing amplification, actually wears a hearing aid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39300/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. In a report using data from the US National Health and nutritional Examination surveys (NHANES), only one in seven individuals 50 years and older with hearing loss uses a hearing aid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39300/abstract/5\">",
"     5",
"    </a>",
"    ]. Reasons cited for this low number include lack of appreciation of the consequences of hearing loss, absence of insurance reimbursement, and fear of social stigmatization. In older individuals, social withdrawal, lack of motivation, or inability to adapt to using new technology may also play a role. This occurs despite the fact that part of the social withdrawal may be due to frustration with the inability to hear. Most of these individuals would benefit from a hearing aid trial, except for those with severe hearing impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39300/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many widely advertised hearing aids intended for general use and not chosen for a specific patient are of poor quality with problems with feedback and reliability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Identifying appropriate candidates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in providing hearing amplification is for the audiologist and patient to agree that the patient needs and is likely to benefit from a hearing aid. This mutual decision is based upon:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The audiogram.",
"     </li>",
"     <li>",
"      A specific hearing difficulty assessment. Patients with poor results on audiometric word discrimination testing may not achieve significant benefit from a hearing aid. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39429?source=see_link&amp;anchor=H14#H14\">",
"       \"Evaluation of hearing loss in adults\", section on 'Speech audiometry'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The lifestyle of the patient.",
"     </li>",
"     <li>",
"      The patient's motivation level.",
"     </li>",
"     <li>",
"      A realistic discussion about what a hearing aid can and cannot do.",
"      <br/>",
"      <br/>",
"      One common misconception is that the aid restores normal hearing just as corrective lenses restore normal vision. Hearing aids do not restore hearing to normal. As a general rule, a hearing aid usually improves hearing by one-half of the loss. As an example, a patient with a 60 dB hearing loss could expect to hear in the 30 dB range with hearing amplification. Thus, the goal of hearing amplification is not to restore normal hearing, but to significantly improve communicative ability and quality of life.",
"     </li>",
"     <li>",
"      Age alone is not a factor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A study found that digital hearing aids led to equivalent improvement in speech performance in patients with impaired hearing who were over 80 years of age, compared to those 65 to 80 years old [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39300/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Unilateral or bilateral hearing aids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Binaural fitting provides the most benefit, including balanced hearing, sound localization, directional hearing, better speech understanding, and better hearing in noisy situations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39300/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. Binaural fitting may not be successful in patients with large hearing asymmetries, or if caring for two hearing aids would be difficult. Patients with financial constraints may benefit more from two simple hearing aids than one more complex device. One hearing aid may be sufficient when hearing loss is minimal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cosmetic and other issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients would like to avoid anyone knowing that they wear a hearing aid, and thus commonly ask for the mini, completely in the canal, or in-the-ear type aids.",
"   </p>",
"   <p>",
"    However, not all patients are candidates for this small device. In patients with severe or even large moderate hearing losses, a behind-the-ear hearing aid may be necessary in order to generate enough power to facilitate better hearing. Additionally, smaller devices can offer fewer features because of size limitations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39300/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Open mold hearing aids are popular for their non-occlusive fitting and improved performance for high frequency loss compared to traditional aids. These aids are also small.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Electronic capabilities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hearing aids have differing levels of electronic features. Options include digital or analog compression, and some hearing aids are programmable, while others are not. All of these options incur variable cost and benefits.",
"   </p>",
"   <p>",
"    Hearing aids, specifically designed for patients with high frequency hearing loss, are available that do not have the occlusive effect of conventional hearing aids. A tiny piece fits behind the ear and a thin transparent plastic tube sits slightly in the ear canal. These aids do produce static, however, similar to conventional aids.",
"   </p>",
"   <p>",
"    Further advances in electronic technology, such as digital hearing aids, are moving faster than the research to determine the most effective signal processing method. In the near future, there should be additional significant improvements in hearing aids that will provide a better quality of life to the hearing-impaired population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39300/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Fitting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hearing aids must be properly fit, and digital hearing aids must be properly programmed. Not all dispensers of hearing aids take the time required to do this properly; it may make sense to suggest to patients that they see a licensed audiologist for this purpose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39300/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A trial period is typically offered, during which the patient uses the hearing aid for 30 days. The cost of the aid is refundable except for a modest fitting fee.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     BONE CONDUCTION HEARING DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain patients who are unable to benefit from standard air conduction hearing devices (a conventional hearing aid) may benefit from a device that transmits sound directly through the skull. Bone conduction hearing aids can be held against the skull with a steel-spring headband; however, this is typically painful, cumbersome, produces skull deformities, and does not achieve good quality hearing.",
"   </p>",
"   <p>",
"    In contrast, an implantable bone conduction hearing aid has significant advantages. The main implantable system available is a bone-anchored prosthetic device known as Baha&reg;. A small titanium screw is inserted and osteointegrates with the bone of the skull over approximately three months (the process is longer in children). An abutment is attached to the screw such that a small portion of the abutment sticks out through the skin and forms an attachment point for a removable bone conduction hearing aid. The sound quality is far superior to that of traditional bone conduction hearing aids, and there is no pain or discomfort.",
"   </p>",
"   <p>",
"    Potential indications for such an implantable system include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Congenital atresia of the ear canal such that it does not exist or cannot accommodate a standard hearing aid",
"     </li>",
"     <li>",
"      Chronic infection of the middle or outer ear that is exacerbated by a standard hearing aid",
"     </li>",
"     <li>",
"      Allergic reactions to standard hearing aids",
"     </li>",
"     <li>",
"      Single-sided deafness as may occur after removal of an acoustic neuroma, from trauma, or from a viral or vascular insult",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A case series report in patients with single-sided deafness demonstrated improved speech discrimination with a bone-anchored hearing aid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39300/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OTHER AMPLIFICATION DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apart from hearing aids, other devices are available to amplify sounds for patients with hearing loss. These include amplified telephones and portable amplification systems. These latter use infrared technology to send sound to a headset from an external source, such as the audio output from a television set or the sound system in a public theater or church [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39300/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Emerging technology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progress in wireless and digital chip technology, combined with advances in cognitive and medical science, promise the potential for greater individualization of devices to improve hearing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39300/abstract/15\">",
"     15",
"    </a>",
"    ]. Improvements in directional microphone technology allow isolation of desired sounds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39300/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies are ongoing of hearing aids that are surgically implanted in the middle ear. One device, the Esteem&reg;, is approved by the US Food and Drug Administration for severe hearing loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39300/abstract/16\">",
"     16",
"    </a>",
"    ]. It is only offered in a limited number of centers, is not covered by insurance, and is expensive. Other devices are not yet available to the general public. Long-term efficacy of these devices is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39300/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A new type of hearing aid (Lyric&reg;) is placed on the eardrum by a clinician and replaced every three to four months. It is available only in select areas, and is costly; its effectiveness is still to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     COCHLEAR IMPLANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cochlear implants are surgically implanted prosthetic devices that use electrical stimulation to provide hearing (",
"    <a class=\"graphic graphic_figure graphicRef70810 \" href=\"mobipreview.htm?28/54/29541\">",
"     figure 1",
"    </a>",
"    ). The criteria for selecting cochlear implantation include moderate to severe bilateral sensorineural hearing loss and little or no benefit from hearing aid trial. Patients need not be totally deaf; patients with no useful speech discrimination with conventional hearing aids (eg, worse than 60 percent sentence recognition in best-aided conditions) are potential candidates for a cochlear implant. Some surgeons also offer cochlear implants to patients with unilateral severe sensorineural hearing loss, with or without tinnitus.",
"   </p>",
"   <p>",
"    The benefits and risks of cochlear implants in adults are generally similar to those in children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29927?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of hearing impairment in children\", section on 'Cochlear implants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Differences between cochlear implants in children and adults include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The best candidates for cochlear implants are postlingual (had speech and language skills before losing their hearing), and most adult candidates for a cochlear implant fall into this category.",
"     </li>",
"     <li>",
"      Adults typically perceive more of a mechanical sound after implantation; the sound typically becomes more natural after four to eight weeks.",
"     </li>",
"     <li>",
"      Adults are now benefiting from bilateral implants, which improve speech perception and allow patients to hear better in conditions with background noise (such as restaurants), localize sound, and hear sound coming from either side without having to turn one's head [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/24/39300/abstract/18\">",
"       18",
"      </a>",
"      ]. A case-control study found that compared to unilateral implants, bilateral cochlear implants resulted in significant improvement in quality of life, with positive impact on hearing, vocalization, mood and cognition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/24/39300/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2707146\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in providing hearing amplification is to determine whether a patient will benefit from a hearing aid. This is based upon:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Audiogram testing",
"     </li>",
"     <li>",
"      Audiometric word discrimination",
"     </li>",
"     <li>",
"      Patient lifestyle",
"     </li>",
"     <li>",
"      Motivation level of the patient",
"     </li>",
"     <li>",
"      A discussion with patient about a hearing aid's maximum benefits",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Identifying appropriate candidates'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients who are unable to benefit from a standard air conduction device (a conventional hearing aid) may benefit from a bone conduction hearing device that transmits sound directly through the skull. Potential indications for such an implantable system include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital atresia of the ear canal",
"     </li>",
"     <li>",
"      Chronic infection of the middle or outer ear",
"     </li>",
"     <li>",
"      Allergic reactions to standard hearing aids",
"     </li>",
"     <li>",
"      Single-sided deafness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Bone conduction hearing devices'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Cochlear implants are surgically implanted prosthetic devices that use electrical stimulation to provide hearing. The criteria for selecting cochlear implantation include moderately to severe bilateral sensorineural hearing loss and little or no benefit from conventional hearing aid use. Bilateral implants may lead to significant improvement in hearing, vocalization, quality of life, mood, and cognition. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Cochlear implants'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39300/abstract/1\">",
"      Klein AJ, Weber PC. Hearing aids. Med Clin North Am 1999; 83:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39300/abstract/2\">",
"      Smeeth L, Fletcher AE, Ng ES, et al. Reduced hearing, ownership, and use of hearing aids in elderly people in the UK--the MRC Trial of the Assessment and Management of Older People in the Community: a cross-sectional survey. Lancet 2002; 359:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39300/abstract/3\">",
"      Lin FR, Thorpe R, Gordon-Salant S, Ferrucci L. Hearing loss prevalence and risk factors among older adults in the United States. J Gerontol A Biol Sci Med Sci 2011; 66:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39300/abstract/4\">",
"      Kricos PB, Erdman S, Bratt GW, Williams DW. Psychosocial correlates of hearing aid adjustment. J Am Acad Audiol 2007; 18:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39300/abstract/5\">",
"      Chien W, Lin FR. Prevalence of hearing aid use among older adults in the United States. Arch Intern Med 2012; 172:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39300/abstract/6\">",
"      Chang WH, Tseng HC, Chao TK, et al. Measurement of hearing aid outcome in the elderly: comparison between young and old elderly. Otolaryngol Head Neck Surg 2008; 138:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39300/abstract/7\">",
"      Jerger J, Darling R, Florin E. Efficacy of the cued-listening task in the evaluation of binaural hearing aids. J Am Acad Audiol 1994; 5:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39300/abstract/8\">",
"      Kimberley BP, Dymond R, Gamer A. Bilateral digital hearing aids for binaural hearing. Ear Nose Throat J 1994; 73:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39300/abstract/9\">",
"      Kollmeir, B, Peissing, J, Hohmann, V. Binaural noise reduction hearing aid scheme with real-time processing in the frequency domain. Scand Audiol 1984; 38 Suppl:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39300/abstract/10\">",
"      Cook JA, Hawkins DB. Hearing loss and hearing aid treatment options. Mayo Clin Proc 2006; 81:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39300/abstract/11\">",
"      Kim HH, Barrs DM. Hearing aids: a review of what's new. Otolaryngol Head Neck Surg 2006; 134:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39300/abstract/12\">",
"      Jackler RK. A 73-year-old man with hearing loss. JAMA 2003; 289:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39300/abstract/13\">",
"      Yuen HW, Bodmer D, Smilsky K, et al. Management of single-sided deafness with the bone-anchored hearing aid. Otolaryngol Head Neck Surg 2009; 141:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39300/abstract/14\">",
"      Lee CE, Christensen L, Richter GT, Dornhoffer JL. Arkansas BAHA experience: transcalvarial fixture placement using osseointegration surgical hardware. Otol Neurotol 2011; 32:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39300/abstract/15\">",
"      Edwards B. The future of hearing aid technology. Trends Amplif 2007; 11:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39300/abstract/16\">",
"      Barbara M, Biagini M, Monini S. The totally implantable middle ear device 'Esteem' for rehabilitation of severe sensorineural hearing loss. Acta Otolaryngol 2011; 131:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39300/abstract/17\">",
"      Backous DD, Duke W. Implantable middle ear hearing devices: current state of technology and market challenges. Curr Opin Otolaryngol Head Neck Surg 2006; 14:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39300/abstract/18\">",
"      Basura GJ, Eapen R, Buchman CA. Bilateral cochlear implantation: current concepts, indications, and results. Laryngoscope 2009; 119:2395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39300/abstract/19\">",
"      Bichey BG, Miyamoto RT. Outcomes in bilateral cochlear implantation. Otolaryngol Head Neck Surg 2008; 138:655.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6849 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.124.11.8-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_24_39300=[""].join("\n");
var outline_f38_24_39300=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2707146\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEARING AIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Identifying appropriate candidates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Unilateral or bilateral hearing aids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cosmetic and other issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Electronic capabilities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Fitting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      BONE CONDUCTION HEARING DEVICES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OTHER AMPLIFICATION DEVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Emerging technology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      COCHLEAR IMPLANTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2707146\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6849\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6849|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/54/29541\" title=\"figure 1\">",
"      Cochlear implants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/15/10490?source=related_link\">",
"      Etiology of hearing loss in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39429?source=related_link\">",
"      Evaluation of hearing loss in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29927?source=related_link\">",
"      Treatment of hearing impairment in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_24_39301="Finasteride: Drug information";
var content_f38_24_39301=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Finasteride: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/44/12996?source=see_link\">",
"    see \"Finasteride: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F171302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Propecia&reg;;",
"     </li>",
"     <li>",
"      Proscar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F171303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Finasteride;",
"     </li>",
"     <li>",
"      CO Finasteride;",
"     </li>",
"     <li>",
"      JAMP-Finasteride;",
"     </li>",
"     <li>",
"      Mint-Finasteride;",
"     </li>",
"     <li>",
"      Mylan-Finasteride;",
"     </li>",
"     <li>",
"      PMS-Finasteride;",
"     </li>",
"     <li>",
"      Propecia&reg;;",
"     </li>",
"     <li>",
"      Proscar&reg;;",
"     </li>",
"     <li>",
"      ratio-Finasteride;",
"     </li>",
"     <li>",
"      Sandoz-Finasteride;",
"     </li>",
"     <li>",
"      Teva-Finasteride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F171346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      5 Alpha-Reductase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F171305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Benign prostatic hyperplasia (Proscar&reg;):",
"     </b>",
"     Oral: 5 mg once daily as a single dose; clinical responses occur within 12 weeks to 6 months of initiation of therapy; long-term administration is recommended for maximal response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Male pattern baldness (Propecia&reg;):",
"     </b>",
"     Oral: 1 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Female hirsutism (unlabeled use):",
"     </b>",
"     Oral: 5 mg/day (Moghetti, 2000)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F171306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F171307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment is necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F171308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with liver function abnormalities because finasteride is metabolized extensively in the liver",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F171276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 1 mg, 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Propecia&reg;: 1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Proscar&reg;: 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F171262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F171280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals. Women of childbearing age should not touch or handle broken tablets.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F171279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Propecia&reg;: Treatment of male pattern hair loss in",
"     <b>",
"      men only",
"     </b>",
"     . Safety and efficacy were demonstrated in men between 18-41 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Proscar&reg;: Treatment of symptomatic benign prostatic hyperplasia (BPH); can be used in combination with an alpha-blocker, doxazosin",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F171342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of female hirsutism",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F171352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Finasteride may be confused with furosemide",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Proscar&reg; may be confused with ProSom, Provera&reg;, PROzac&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F171344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     &ldquo;Combination therapy&rdquo; refers to finasteride and doxazosin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Impotence (5% to 19%; combination therapy 23%), libido decreased (2% to 10%; combination therapy 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (5%; combination therapy 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension (9%; combination therapy 18%), edema (1%; combination therapy 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (7%; combination therapy 23%), somnolence (2%; combination therapy 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Ejaculation disturbances (&lt;1% to 7%; combination therapy 14%), decreased volume of ejaculate (2% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Gynecomastia (1% to 2%), breast tenderness (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (1%; combination therapy 2%), rhinitis (1%; combination therapy 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Breast cancer (males), depression, hypersensitivity (pruritus, rash, urticaria, swelling of face/lips), male infertility (temporary), mental impairment, penile curvature decreased, penile size decreased, prostate cancer (high grade), prostatitis, sexual dysfunction (may not be reversible with discontinuation), testicular pain, testicular size decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F171283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to finasteride or any component of the formulation; women of childbearing potential",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F171266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer: Rare reports of male breast cancer have been observed with finasteride use.  Patients should promptly report any breast changes, including breast enlargement, lumps, tenderness, pain, or nipple discharge to their healthcare provider.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diminished urinary flow: Carefully monitor patients with a large residual urinary volume or severely diminished urinary flow for obstructive uropathy; these patients may not be candidates for finasteride therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; finasteride is extensively metabolized in the liver.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostate cancer: When compared to placebo, 5-alpha-reductase inhibitors (5-ARIs) have been shown to reduce the overall incidence of prostate cancer, although an increase in the incidence of high-grade prostate cancers has been observed; 5-ARIs are not approved in the U.S. or Canada for the prevention of prostate cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Women/pregnancy: Active ingredient of crushed or broken tablets can be absorbed through the skin; unbroken tablets are coated which prevents contact with the active ingredient during normal handling. Women should avoid contact with crushed or broken tablets and the semen from a male partner exposed to finasteride; finasteride may negatively impact fetal development.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Other urological diseases (including prostate cancer) should be ruled out before initiating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Duration of therapy: For BPH, a minimum of 6 months of treatment may be necessary to determine whether an individual will respond to finasteride; for male pattern hair loss, daily use for 3 months or longer may be required before benefit is observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; PSA monitoring: Reduces prostate specific antigen (PSA) by ~50%; in patients treated for &ge;6 months the PSA value should be doubled when comparing to normal ranges in untreated patients (for interpretation of serial PSAs, a new PSA baseline should be established &ge;6 months after treatment initiation and PSA monitored periodically thereafter). Failure to demonstrate a meaningful PSA decrease (&lt;50%) or a PSA increase while on this medication may be associated with an increased risk for prostate cancer (NCCN prostate cancer early detection guidelines, v.1.2011). Patients on a 5-ARI with any increase in PSA levels, even if within normal limits, should be evaluated; may indicate presence of prostate cancer.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F171339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F171270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F171299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Herb/Nutraceutical: St John's wort may decrease finasteride levels. Avoid saw palmetto (concurrent use has not been adequately studied).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F171272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F171286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Abnormalities of external male genitalia were reported in animal reproduction studies. Use is not indicated in women. Pregnant women are advised to avoid contact with crushed or broken tablets and the semen from a male partner exposed to finasteride.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F171313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated in women of childbearing potential",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F171287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if finasteride is excreted in breast milk. Use is contraindicated in women of childbearing potential.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F10534884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F171285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Finasteride Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (30): $81.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (30): $93.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Propecia Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (30): $90.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Proscar Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (30): $129.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F171274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Objective and subjective signs of relief of benign prostatic hyperplasia, including improvement in urinary flow, reduction in symptoms of urgency, and relief of difficulty in micturition; for interpretation of serial PSAs, establish a new PSA baseline &ge;6 months after treatment initiation and monitor PSA periodically thereafter. Finasteride does not interfere with free PSA levels.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F171288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alofecid (KP);",
"     </li>",
"     <li>",
"      Aprodil (EC);",
"     </li>",
"     <li>",
"      Atepros (PH);",
"     </li>",
"     <li>",
"      Bearfina (KP);",
"     </li>",
"     <li>",
"      Chibro-Proscar (FR);",
"     </li>",
"     <li>",
"      Damopecia (KP);",
"     </li>",
"     <li>",
"      Finarid (PH);",
"     </li>",
"     <li>",
"      Finas (SG);",
"     </li>",
"     <li>",
"      Finaspro (TW);",
"     </li>",
"     <li>",
"      Finaspros (CO);",
"     </li>",
"     <li>",
"      Finastid (HR);",
"     </li>",
"     <li>",
"      Finatra (CL);",
"     </li>",
"     <li>",
"      Fincar (HK, IN, KP);",
"     </li>",
"     <li>",
"      Finpro (ID, ZA);",
"     </li>",
"     <li>",
"      Firide (TH);",
"     </li>",
"     <li>",
"      Fistrin (CO);",
"     </li>",
"     <li>",
"      Fynasid (TW);",
"     </li>",
"     <li>",
"      Harifin (TH);",
"     </li>",
"     <li>",
"      Jun Neng (CL);",
"     </li>",
"     <li>",
"      Monastar (KP);",
"     </li>",
"     <li>",
"      New Hair (EC);",
"     </li>",
"     <li>",
"      Pro-Cure (IL);",
"     </li>",
"     <li>",
"      Pronax (PH);",
"     </li>",
"     <li>",
"      Propecia (AR, AU, BB, BR, BS, BZ, CL, CO, DO, ES, GT, HK, HN, IL, JM, MY, NI, NL, NZ, PA, PE, PH, SE, SG, SV, TH, TT, TW);",
"     </li>",
"     <li>",
"      Propeshia (MX);",
"     </li>",
"     <li>",
"      Proscar (AR, AT, AU, BE, BG, BM, BO, BR, CH, CL, CN, CR, CZ, DE, DK, DO, EE, ES, FI, GB, GR, GT, GY, HK, HN, HR, HU, ID, IE, IT, KP, LU, MT, MX, MY, NI, NO, NZ, PA, PE, PH, PK, PL, PR, PT, RU, SE, SG, SK, SR, TH, TR, TW, VE);",
"     </li>",
"     <li>",
"      Prostanus (PH);",
"     </li>",
"     <li>",
"      Prosterid (HU);",
"     </li>",
"     <li>",
"      Prosteride (HK, PH, TH);",
"     </li>",
"     <li>",
"      Prostide (ID);",
"     </li>",
"     <li>",
"      Prostop (UY);",
"     </li>",
"     <li>",
"      Reprostom (ID);",
"     </li>",
"     <li>",
"      Tensen (TW);",
"     </li>",
"     <li>",
"      Uromedin (PY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F171265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Finasteride is a competitive inhibitor of both tissue and hepatic 5-alpha reductase. This results in inhibition of the conversion of testosterone to dihydrotestosterone and markedly suppresses serum dihydrotestosterone levels",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F171282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: BPH: 6 months; Male pattern hair loss: &ge;3 months of daily use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     After a single oral dose as small as 0.5 mg: 65% depression of plasma dihydrotestosterone levels persists 5-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     After 6 months of treatment with 5 mg/day: Circulating dihydrotestosterone levels are reduced to castrate levels without significant effects on circulating testosterone; levels return to normal within 14 days of discontinuation of treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 76 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4; two active metabolites (&lt;20% activity of finasteride)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Mean: 65%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination, serum: 6 hours (range: 3-16 hours); Elderly: 8 hours (range: 6-15 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (57%) and urine (39%) as metabolites",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Irwig MS, \"Persistent Sexual Side Effects of Finasteride: Could They Be Permanent?\"",
"      <i>",
"       J Sex Med",
"      </i>",
"      , 2012.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/24/39301/abstract-text/22789024/pubmed\" id=\"22789024\" target=\"_blank\">",
"        22789024",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kramer BS, Hagerty KL, Justman S, et al, &ldquo;Use of 5-&alpha;-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(9):1502-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/24/39301/abstract-text/19252137/pubmed\" id=\"19252137\" target=\"_blank\">",
"        19252137",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lepor H, Williford WO, Barry MJ, et al, &ldquo;The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 335(8):533-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/24/39301/abstract-text/8684407/pubmed\" id=\"8684407\" target=\"_blank\">",
"        8684407",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McConnell JD, Roehrborn CG, Bautista OM, et al, &ldquo;The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 349(25):2387-98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/24/39301/abstract-text/14681504/pubmed\" id=\"14681504\" target=\"_blank\">",
"        14681504",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moghetti  P, Tosi F, Tosti A, et al, &ldquo;Comparison of Spironolactone, Flutamide, and Finasteride Efficacy in the Treatment of Hirsutism: A Randomized, Double Blind, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2000, 85(1):89-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/24/39301/abstract-text/10634370/pubmed\" id=\"10634370\" target=\"_blank\">",
"        10634370",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Prostate Cancer Early Detection,&rdquo; Version 1.2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/prostate_detection.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pole M and Koren G, &ldquo;Finasteride. Does It Affect Spermatogenesis and Pregnancy,&rdquo;",
"      <i>",
"       Can Fam Physician",
"      </i>",
"      , 2001, 47:2469-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/24/39301/abstract-text/11785276/pubmed\" id=\"11785276\" target=\"_blank\">",
"        11785276",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thompson IM, Goodman PJ, Tangen CM, et al, &ldquo;The Influence of Finasteride on the Development of Prostate Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, Jul 349(3):215-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/24/39301/abstract-text/12824459/pubmed\" id=\"12824459\" target=\"_blank\">",
"        12824459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8447 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-3636CB1C0C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_24_39301=[""].join("\n");
var outline_f38_24_39301=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171302\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171303\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171346\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171305\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171306\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171307\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171308\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171276\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171262\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171280\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171279\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171342\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171352\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171344\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171283\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171266\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171339\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171270\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171299\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171272\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171286\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171313\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171287\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10534884\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171285\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171274\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171288\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171265\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171282\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8447\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8447|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/44/12996?source=related_link\">",
"      Finasteride: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_24_39302="Severe eczema hyper IgE";
var content_f38_24_39302=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F61049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F61049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe eczema in an infant with hyperimmunoglobulin E syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 583px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_24_39302=[""].join("\n");
var outline_f38_24_39302=null;
var title_f38_24_39303="Adalimumab: Drug information";
var content_f38_24_39303=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Adalimumab: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/61/3030?source=see_link\">",
"    see \"Adalimumab: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/53/20311?source=see_link\">",
"    see \"Adalimumab: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F130499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Humira&reg;;",
"     </li>",
"     <li>",
"      Humira&reg; Pen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Humira&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F130514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antirheumatic, Disease Modifying;",
"     </li>",
"     <li>",
"      Gastrointestinal Agent, Miscellaneous;",
"     </li>",
"     <li>",
"      Monoclonal Antibody;",
"     </li>",
"     <li>",
"      Tumor Necrosis Factor (TNF) Blocking Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F130502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Ankylosing spondylitis:",
"     </b>",
"     SubQ: 40 mg every other week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Crohn&rsquo;s disease:",
"     </b>",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial: 160 mg (given as 4 injections on day 1 or as 2 injections daily over 2 consecutive days), then 80 mg 2 weeks later (day 15)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance: 40 mg every other week beginning day 29.",
"     <b>",
"      Note:",
"     </b>",
"     Some patients may require 40 mg every week as maintenance therapy (Lichtenstein, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Plaque psoriasis:",
"     </b>",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial: 80 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance: 40 mg every other week beginning 1 week after initial dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Psoriatic arthritis:",
"     </b>",
"     SubQ: 40 mg every other week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Rheumatoid arthritis:",
"     </b>",
"     SubQ: 40 mg every other week; patients not taking methotrexate may increase dose to 40 mg every week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Ulcerative colitis:",
"     </b>",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial: 160 mg (given as 4 injections on day 1 or as 2 injections daily over 2 consecutive days), then 80 mg 2 weeks later (day 15)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance: 40 mg every other week beginning day 29.",
"     <b>",
"      Note:",
"     </b>",
"     Only continue maintenance dose in patients demonstrating clinical remission by 8 weeks (day 57) of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F5737985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/53/20311?source=see_link\">",
"      see \"Adalimumab: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Juvenile idiopathic arthritis (JIA):",
"     </b>",
"     Children &ge;4 years: SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     15 kg to &lt;30 kg: 20 mg every other week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &ge;30 kg: 40 mg every other week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     24 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (maximum dose: 40 mg) every other week",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2523799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15671304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15671305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F130481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Humira&reg;: 40 mg/0.8 mL (0.8 mL) [contains natural rubber/natural latex in packaging, polysorbate 80; prefilled syringe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Humira&reg; Pen: 40 mg/0.8 mL (0.8 mL) [contains natural rubber/natural latex in packaging, polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [pediatric, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Humira&reg;: 20 mg/0.4 mL (0.4 mL) [contains natural rubber/natural latex in packaging, polysorbate 80; prefilled syringe]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F15897527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [pediatric, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Humira&reg;: 40 mg/0.8 mL (0.8 mL) [vial]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F130468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088611.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088611.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F130483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For SubQ injection (into thigh or lower abdomen, avoiding areas within 2 inches of navel); rotate injection sites. Do not use if solution is discolored. Do not administer to skin which is red, tender, bruised, or hard. Needle cap of the prefilled syringe may contain latex.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F130482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treatment of active rheumatoid arthritis (moderate-to-severe) and active psoriatic arthritis; may be used alone or in combination with other nonbiologic disease-modifying antirheumatic drugs (DMARDs)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treatment of ankylosing spondylitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treatment of moderately- to severely-active Crohn&rsquo;s disease in patients with inadequate response to conventional treatment, or patients who have lost response to or are intolerant of infliximab",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treatment of moderately- to severely-active ulcerative colitis in patients unresponsive to immunosuppressants (",
"     <b>",
"      Note:",
"     </b>",
"     Efficacy in patients that are intolerant or no longer responsive to other TNF blockers has not been established.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treatment of moderate-to-severe plaque psoriasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treatment of moderately- to severely-active juvenile idiopathic arthritis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F130521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Humira&reg; may be confused with Humulin&reg;, Humalog&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Humira&reg; Pen may be confused with HumaPen&reg; Memoir&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F130512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (6% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (12% to 20%; includes erythema, itching, hemorrhage, pain, swelling)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: CPK increased (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (17%), sinusitis (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Serious infection (adults 1.4-6.7 events/100 person years, children 2 events/100 person years [Burmester, 2012]), antibodies to adalimumab (3% to 26%; significance unknown), positive ANA (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     5% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperlipidemia (7%), hypercholesterolemia (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (9%), abdominal pain (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (8%; other than erythema, itching, hemorrhage, pain, swelling)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Hematuria (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Accidental injury (10%), flu-like syndrome (7%), hypersensitivity reactions (children 6%; adults &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 5%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, atrial fibrillation, chest pain, CHF, coronary artery disorder, deep vein thrombosis, heart arrest, MI, palpitation, pericardial effusion, pericarditis, peripheral edema, syncope, tachycardia, vascular disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Confusion, fever, hypertensive encephalopathy, multiple sclerosis, subdural hematoma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia, cellulitis, erysipelas",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration, menstrual disorder, parathyroid disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diverticulitis, esophagitis, gastroenteritis, gastrointestinal hemorrhage, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Cystitis, pelvic pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, granulocytopenia, leukopenia, pancytopenia, paraproteinemia, polycythemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Cholecystitis, cholelithiasis, hepatic necrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, arthritis, bone fracture, bone necrosis, joint disorder, muscle cramps, myasthenia, pain in extremity, paresthesia, pyogenic arthritis, synovitis, tendon disorder, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Cataract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Kidney calculus, pyelonephritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Asthma, bronchospasm, dyspnea, lung function decreased, pleural effusion, pneumonia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Adenoma, allergic reactions (1%), carcinoma (including breast, gastrointestinal, skin, urogenital), healing abnormality, herpes zoster, ketosis, lupus erythematosus syndrome, lymphoma, melanoma, postsurgical infection, sepsis, tuberculosis (reactivation of latent infection; miliary, lymphatic, peritoneal and pulmonary)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abscess (limb, perianal), anal fistula, anaphylactoid reaction, anaphylaxis, angioedema, aplastic anemia, appendicitis, basal cell carcinoma, cerebrovascular accident, cervical dysplasia, circulatory collapse, cutaneous vasculitis, cytopenia, endometrial hyperplasia, erythema multiforme, fixed drug eruption, granuloma annulare (children and adolescents), Guillain-Barr&eacute; syndrome, HBV reactivation, hepatic failure, herpes virus infection, histoplasmosis, infections (bacterial, viral, fungal and protozoal), interstitial lung disease (eg, pulmonary fibrosis), intestinal obstruction, intestinal perforation, leukemias, liver metastases, lupus-like syndrome, lymphadenopathy, lymphocytosis, mycobacterium avium complex infection, myositis (children and adolescents), necrotizing fasciitis, neutropenia, optic neuritis, ovarian cancer, pancreatitis, pharyngitis (children and adolescents), psoriasis (including new onset, palmoplantar, pustular, or exacerbation), pulmonary embolism, respiratory failure, sarcoidosis, septic arthritis, septic shock, skin ulceration, Stevens-Johnson syndrome, streptococcal pharyngitis (children and adolescents), systemic vasculitis, testicular cancer, thrombocytopenia, transaminases increased, viral meningitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F130486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the FDA-approved labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to adalimumab or any component of the formulation; severe infection (eg, sepsis, tuberculosis, opportunistic infection); moderate-to-severe heart failure (NYHA class III/IV)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F130471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/hypersensitivity reactions: May rarely cause hypersensitivity, anaphylaxis, anaphylactoid reactions, or angioedema; medications for the treatment of hypersensitivity reactions should be available for immediate use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Autoimmune disorder: Positive antinuclear antibody titers have been detected in patients (with negative baselines). Rare cases of autoimmune disorder, including lupus-like syndrome, have been reported; monitor and discontinue if symptoms develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatitis B: Rare reactivation of hepatitis B (HBV) has occurred in chronic carriers of the virus, usually in patients receiving concomitant immunosuppressants; evaluate for HBV prior to initiation in all patients.  Monitor during and for several months following discontinuation of treatment in HBV carriers; interrupt therapy if reactivation occurs and treat appropriately with antiviral therapy; if resumption of therapy is deemed necessary, exercise caution and monitor patient closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infections:",
"     <b>",
"      [U.S. Boxed Warning]: Patients receiving adalimumab are at increased risk for serious infections which may result in hospitalization and/or fatality; infections usually developed in patients receiving concomitant immunosuppressive agents (eg, methotrexate or corticosteroids) and may present as disseminated (rather than local) disease. Active tuberculosis (or reactivation of latent tuberculosis), invasive fungal (including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, and pneumocystosis) and bacterial, viral or other opportunistic infections (including legionellosis and listeriosis) have been reported in patients receiving TNF-blocking agents, including adalimumab. Monitor closely for signs/symptoms of infection. Discontinue for serious infection or sepsis. Consider risks versus benefits prior to use in patients with a history of chronic or recurrent infection. Consider empiric antifungal therapy in patients who are at risk for invasive fungal infection and develop severe systemic illness.",
"     </b>",
"     Caution should be exercised when considering use in the elderly or in patients with conditions that predispose them to infections (eg, diabetes) or residence/travel from areas of endemic mycoses (blastomycosis, coccidioidomycosis, histoplasmosis), or with latent or localized infections. Do not initiate adalimumab therapy with clinically important active infection. Patients who develop a new infection while undergoing treatment should be monitored closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Malignancy:",
"     <b>",
"      [U.S. Boxed Warning]: Lymphoma and other malignancies have been reported in children and adolescent patients receiving other TNF-blocking agents.",
"     </b>",
"     Half the cases are lymphomas (Hodgkin&rsquo;s and non-Hodgkin&rsquo;s) and the other cases are varied, but include malignancies not typically observed in this population. Most patients were receiving concomitant immunosuppressants.",
"     <b>",
"      [U.S. Boxed Warning]: Hepatosplenic T-cell lymphoma (HSTCL), a rare T-cell lymphoma, has also been reported primarily in patients with Crohn&rsquo;s disease or ulcerative colitis treated with adalimumab and who received concomitant azathioprine or mercaptopurine; reports occurred predominantly  in adolescent and young adult males.",
"     </b>",
"     Use may affect defenses against malignancies; impact on the development and course of malignancies is not fully defined. As compared to the general population, an increased risk of lymphoma has been noted in clinical trials; however, rheumatoid arthritis has been previously associated with an increased rate of lymphoma. A higher incidence of nonmelanoma skin cancers was noted in adalimumab-treated patients (0.7/100 patient years), when compared to the control group (0.2/100 patient years). Hepatosplenic T-cell lymphoma (HSTCL), a rare T-cell lymphoma, has also been associated with TNF-blocking agents, primarily reported in adolescent and young adult males with Crohn&rsquo;s disease or ulcerative colitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancytopenia: Rare cases of pancytopenia (including aplastic anemia) have been reported with TNF-blocking agents; with significant hematologic abnormalities, consider discontinuing therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tuberculosis: Tuberculosis (disseminated or extrapulmonary) has been reactivated while on adalimumab; most cases have been reported within the first 8 months of treatment. Doses higher than recommended are associated with an increased risk for tuberculosis reactivation.",
"     <b>",
"      [U.S. Boxed Warnings]: Patients should be evaluated for latent tuberculosis infection with a tuberculin skin test prior to therapy. Treatment of latent tuberculosis should be initiated before use. Patients with initial negative tuberculin skin tests should receive continued monitoring for tuberculosis throughout treatment;",
"     </b>",
"     active tuberculosis has developed in this population during treatment. Use with caution in patients who have resided in regions where tuberculosis is endemic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Demyelinating disease: Use with caution in patients with pre-existing or recent onset central or peripheral nervous system demyelinating disorders; rare cases of new-onset or exacerbation of demyelinating disorders (eg, multiple sclerosis, optic neuritis, Guillain-Barr&eacute; syndrome) have been reported.  Consider discontinuing use in patients who develop peripheral or central nervous system demyelinating disorders during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use with caution in patients with HF or decreased left ventricular function; worsening and new-onset HF has been reported. Canadian labeling contraindicates use in heart failure (NYHA class III/IV).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abatacept: Serious infections were reported when abatacept was used with TNF-blocking agents; therefore, concurrent use of adalimumab and abatacept is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anakinra: Serious infections were reported when anakinra was used with TNF-blocking agents; therefore, concurrent use of adalimumab and anakinra is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Infection and malignancy has been reported at a higher incidence in elderly patients compared to younger adults; use caution in elderly patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Malignancies have been reported among children and adolescents receiving TNF-blocking agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgery patients: Limited experience with patients undergoing surgical procedures while on therapy; consider long half-life with planned procedures. Monitor closely for infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage form specific issues:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Latex: The packaging (needle cover of prefilled syringe) may contain latex.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polysorbate 80: Product may contain polysorbate 80.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunizations: Patients should be brought up to date with all immunizations before initiating therapy; live vaccines should not be given concurrently. There is no data available concerning the effects of therapy on vaccination or secondary transmission of live vaccines in patients receiving therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F130475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abciximab: May enhance the potential for allergic or hypersensitivity reactions to Monoclonal Antibodies. Also may cause thrombocytopenia or diminished therapeutic effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Certolizumab Pegol: Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab Pegol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Adalimumab may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Adalimumab may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May enhance the immunosuppressive effect of Anti-TNF Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Anti-TNF Agents may enhance the adverse/toxic effect of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Adalimumab may decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F3149966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Herb/nutraceutical: Echinacea may decrease the therapeutic effects of adalimumab; avoid concurrent use.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F130477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F130488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies, however, there are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed. A pregnancy registry has been established to monitor outcomes of women exposed to adalimumab during pregnancy (877-311-8972).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F130504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4007130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known whether adalimumab is secreted in human milk. Because many immunoglobulins are secreted in milk and the potential for serious adverse reactions exists, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F130487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Humira Pen Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/0.8 mL (1): $1313.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Humira Pen-Crohns Starter Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/0.8 mL (1): $1313.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Humira Pen-Psoriasis Starter Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/0.8 mL (1): $1313.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Humira Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/0.4 mL (1): $1313.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/0.8 mL (1): $1313.98",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F130479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor improvement of symptoms and physical function assessments. Latent TB screening prior to initiating and during therapy; signs/symptoms of infection (prior to, during, and following therapy); CBC with differential; signs/symptoms/worsening of heart failure; HBV screening prior to initiating (all patients), HBV carriers (during and for several months following therapy); signs and symptoms of hypersensitivity reaction; symptoms of lupus-like syndrome; signs/symptoms of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F130489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Humira (AE, AR, AT, AU, BE, BG, BH, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EC, EE, EG, FI, FR, GB, GR, HK, HN, IE, IL, IQ, IR, IT, JO, KP, KW, LB, LY, MT, MX, MY, NL, NO, NZ, OM, PE, PL, PT, PY, QA, RU, SA, SE, SG, SK, SY, TR, TW, UY, VE, YE);",
"     </li>",
"     <li>",
"      Trudexa (AT, BE, BG, CH, CZ, DE, DK, EE, FI, FR, GB, GR, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F130470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adalimumab is a recombinant monoclonal antibody that binds to human tumor necrosis factor alpha (TNF-alpha), thereby interfering with binding to TNF&alpha; receptor sites and subsequent cytokine-driven inflammatory processes. Elevated TNF levels in the synovial fluid are involved in the pathologic pain and joint destruction in immune-mediated arthritis. Adalimumab decreases signs and symptoms of psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis. It inhibits progression of structural damage of rheumatoid and psoriatic arthritis. Reduces signs and symptoms and maintains clinical remission in Crohn&rsquo;s disease and ulcerative colitis; reduces epidermal thickness and inflammatory cell infiltration in plaque psoriasis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F130485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 4.7-6 L; Synovial fluid concentrations: 31% to 96% of serum",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Absolute: 64%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: ~2 weeks (range: 10-20 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: SubQ: 131 &plusmn; 56 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Clearance increased in the presence of antiadalimumab antibodies; decreased in patients &ge;40 years of age",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Burmester GR, Panaccione R, Gordon KB, et al, \"Adalimumab: Long-Term Safety in 23 458 Patients From Global Clinical Trials in Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis and Crohn's Disease,\"",
"      <i>",
"       Ann Rheum Dis",
"      </i>",
"      , 2012.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/24/39303/abstract-text/22562972/pubmed\" id=\"22562972\" target=\"_blank\">",
"        22562972",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dommasch E and Gelfand JM, &ldquo;Is There Truly a Risk of Lymphoma From Biologic Therapies?&rdquo;",
"      <i>",
"       Dermatol Ther",
"      </i>",
"      , 2009, 22 (5):418-30.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gordon KB, Langley RG, Leonardi C, et al, &ldquo;Clinical Response to Adalimumab Treatment in Patients With Moderate to Severe Psoriasis: Double-Blind, Randomized Controlled Trial and Open-Label Extension Study,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2006, 55(4):598-606.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/24/39303/abstract-text/17010738/pubmed\" id=\"17010738\" target=\"_blank\">",
"        17010738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keystone EC, Kavanaugh AF, Sharp JYT, et al, &ldquo;Radiographic, Clinical, and Functional Outcomes of Treatment With Adalimumab (A Human Anti-Tumor Necrosis Factor Monoclonal Antibody) in Patients With Active Rheumatoid Arthritis Receiving Concomitant Methotrexate Therapy: A Randomized, Placebo-Controlled, 52-Week Trial,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2004, 50(5):1400-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/24/39303/abstract-text/15146409/pubmed\" id=\"15146409\" target=\"_blank\">",
"        15146409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lichtenstein GR, Hanauer SB, and Sandborn WJ, &ldquo;Management of Crohn's Disease in Adults,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2009, 104(2):465-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/24/39303/abstract-text/19174807/pubmed\" id=\"19174807\" target=\"_blank\">",
"        19174807",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lopez-Oilvo MA, Tayar JH, Martinez-Lopez JA, et al, &ldquo;Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy: A Meta-Analysis,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2012, 308(9): 898-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/24/39303/abstract-text/22948700/pubmed\" id=\"22948700\" target=\"_blank\">",
"        22948700",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parakkal D, Sifuentes H, Semer R, et al, &ldquo;Hepatosplenic T-Cell Lymphoma in Patients Receiving TNF-&alpha; Inhibitor Therapy: Expanding the Groups at Risk,&rdquo;",
"      <i>",
"       Eur J Gastroenterol Hepatol",
"      </i>",
"      , 2011, 23(12):1150-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/24/39303/abstract-text/21941193/pubmed\" id=\"21941193\" target=\"_blank\">",
"        21941193",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sandborn WJ, Rutgeerts P, Enns R, et al, \"Adalimumab Induction Therapy for Crohn Disease Previously Treated With Infliximab: A Randomized Trial.,\"",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2007, 146(12):829-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/24/39303/abstract-text/17470824/pubmed\" id=\"17470824\" target=\"_blank\">",
"        17470824",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh JA, Furst DE, Bharat A, et al, &ldquo;2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(5):625-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/24/39303/abstract-text/22473917/pubmed\" id=\"22473917\" target=\"_blank\">",
"        22473917",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van der Heijde D, Kivitz A, Schiff MH, et al, &ldquo;Efficacy and Safety of Adalimumab in Patients With Ankylosing Spondylitis: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2006, 54(7):2136-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/24/39303/abstract-text/16802350/pubmed\" id=\"16802350\" target=\"_blank\">",
"        16802350",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8583 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-1D72A0B336-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_24_39303=[""].join("\n");
var outline_f38_24_39303=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708607\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130499\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855045\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130514\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130502\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5737985\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2523799\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671304\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671305\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130481\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897527\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130468\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874545\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130483\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130482\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130521\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130512\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130486\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130471\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298685\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130475\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3149966\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130477\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130488\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130504\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4007130\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130487\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130479\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130489\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130470\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130485\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8583\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8583|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/61/3030?source=related_link\">",
"      Adalimumab: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/53/20311?source=related_link\">",
"      Adalimumab: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_24_39304="Evaluation of fever in the returning traveler";
var content_f38_24_39304=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of fever in the returning traveler",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/24/39304/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/24/39304/contributors\">",
"     Mary Elizabeth Wilson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/24/39304/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/24/39304/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/24/39304/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/24/39304/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/24/39304/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 21, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many travelers return home with fever with or without other accompanying symptoms. Up to 8 percent of travelers to developing countries are ill enough to seek health care while abroad or after returning home [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Fever in the returned traveler can be a manifestation of a minor, self-limited process or can herald a progressive, life-threatening illness. It may be difficult to distinguish between trivial and serious infections based on initial findings.",
"   </p>",
"   <p>",
"    The assessment of these patients is often hampered by the clinician's lack of familiarity with the types of infections that the patient may have encountered while traveling. A systematic approach to the evaluation of these patients is vital and should include basic information about the geographic distribution of infections in the locations where the person has lived and traveled (including even brief stays and airport transfers), as well as any activities that were undertaken [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ]. The tempo and intensity of the initial work-up will be influenced by both the clinical findings and by the types of infections that are possible.",
"   </p>",
"   <p>",
"    The evaluation of such patients should focus on three basic questions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What infections are possible given where the patient has lived or traveled and the time when exposures may have occurred?",
"     </li>",
"     <li>",
"      Which of these infections is more probable given the patient's clinical findings, pretravel measures, and potential exposures?",
"     </li>",
"     <li>",
"      Which of these infections is treatable or transmissible or both?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The epidemiology, etiology, and evaluation of fever in the returning traveler will be reviewed here. Skin lesions acquired during travel are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/43/20152?source=see_link\">",
"     \"Skin lesions in the returning traveler\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Illness after travel is common and is self-reported by 22 to 64 percent of travelers to developing countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/6\">",
"     6",
"    </a>",
"    ]. Published series can provide a general framework for assessing which infections in returned travelers are more common. A number of studies have evaluated the epidemiology of fever in the traveler returning from a visit to a developing country [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/1-4,7-14\">",
"     1-4,7-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest contemporary experience in illness related to travel to developing countries comes from GeoSentinel, the global surveillance network of the International Society of Travel Medicine and the Centers for Disease Control and Prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. Sentinel data on ill travelers are collected at more than 40 GeoSentinel sites on six continents.",
"   </p>",
"   <p>",
"    A 2006 report from 30 GeoSentinel sites in developed countries provided clinical-based surveillance information on 17,353 ill travelers who returned from travel in developing countries and were seen between June 1996 and August 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/1\">",
"     1",
"    </a>",
"    ]. The primary manifestations for approximately two-thirds of the returned travelers fell into five major syndrome categories: systemic febrile illness without localizing findings, acute diarrhea, dermatologic disorders, chronic diarrhea, and nondiarrheal gastrointestinal disorders. The causes of these disorders in particular regions are discussed separately on the appropriate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/5/3161?source=see_link\">",
"     \"Diseases potentially acquired by travel to Central and South America\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/17/12568?source=see_link\">",
"     \"Diseases potentially acquired by travel to Southeast Asia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/0/13319?source=see_link\">",
"     \"Diseases potentially acquired by travel to East Asia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40121?source=see_link\">",
"     \"Diseases potentially acquired by travel to sub-Saharan Africa\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A later report from GeoSentinel specifically evaluated fever, which was a chief reason for seeking care in 28 percent of almost 25,000 ill returned travelers seen between 1997 and 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/4\">",
"     4",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common specific diagnoses among patients with fever were malaria and dengue fever (21 and 6 percent of cases, respectively); 22 percent of patients had an unspecified febrile illness. Since the clinical manifestations of dengue in many patients are mild and nonspecific, the frequency of diagnosis may be falsely low since many patients with dengue may not seek evaluation. The World Health Organization estimates there may be 50 million dengue infections worldwide yearly. In 2007 alone, there were more than 890,000 reported cases of dengue in the Americas. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/34/18985?source=see_link\">",
"       \"Clinical presentation and diagnosis of dengue virus infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Febrile diarrheal disease occurred in 15 percent of patients; fever and respiratory infection in 14 percent of patients.",
"     </li>",
"     <li>",
"      More than 17 percent had a disease preventable by vaccine (eg, Salmonella typhi infection, hepatitis A, influenza) or chemoprophylaxis (falciparum malaria).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Almost 70 percent of ill returned travelers seen at GeoSentinel sites had visited sub-Saharan Africa, Southeast Asia, the Caribbean, and Central and South America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/4\">",
"     4",
"    </a>",
"    ]. The following were the major causes of fever at these sites:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sub-Saharan Africa &mdash; A systemic febrile illness was present in 49 percent of patients (malaria in 42 percent, respiratory illness in 10 percent, diarrheal illness in 10 percent, and no diagnosis in 19 percent). In addition, most rickettsial infections were acquired in this region and were usually tickborne [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40121?source=see_link\">",
"       \"Diseases potentially acquired by travel to sub-Saharan Africa\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Southeast Asia &mdash; A systemic febrile illness was present in 34 percent of patients (dengue fever in 18 percent, malaria in 7 percent, respiratory illness in 17 percent, diarrheal illness in 17 percent, and no diagnosis in 22 percent). More than 70 percent of cases of enteric fever (typhoid and paratyphoid) were acquired in south-central or Southeast Asia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/17/12568?source=see_link\">",
"       \"Diseases potentially acquired by travel to Southeast Asia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Caribbean and Central and South America &mdash; A systemic febrile illness was present in 25 percent (dengue fever in 9 percent, malaria in 8 percent, respiratory illness in 13 percent, diarrheal illness in 15 percent, and no diagnosis in 26 percent). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/5/3161?source=see_link\">",
"       \"Diseases potentially acquired by travel to Central and South America\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among these patients presenting to GeoSentinel clinics (specialized",
"    <span class=\"nowrap\">",
"     travel/tropical",
"    </span>",
"    centers), almost 26 percent of febrile patients and 46 percent of those with a systemic febrile illness required hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical history should establish the geographic region of travel, dates of travel, duration of stay, types of accommodations, activities and exposures, and information about the host, including preparation for travel and any predispositions to infection (",
"    <a class=\"graphic graphic_table graphicRef54195 \" href=\"mobipreview.htm?12/24/12684\">",
"     table 1",
"    </a>",
"    ). The clinical history should also include careful documentation of the time of onset and nature of various signs and symptoms. It should also establish whether the person has visited malarious areas during the past 12 months.",
"   </p>",
"   <p>",
"    The type of transportation, layovers, and intermediate stops are also relevant, as infections can be acquired en route. Transmission of a wide range of infections has been traced to airplanes, cruise ships, buses, and trains. These include influenza, tuberculosis, Legionnaires' disease, cholera, norovirus, measles, SARS, shigellosis, rubella, and salmonellosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/15-18\">",
"     15-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Good resources that provide current information about what infections occur in different geographic areas are essential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. The Centers for Disease Control and Prevention (CDC) website includes an online version of Health Information for International Travel under Travelers' Health and updates on travel-related infections (",
"    <a class=\"external\" href=\"file://www.cdc.gov/\">",
"     www.cdc.gov",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/19\">",
"     19",
"    </a>",
"    ]. The WHO website also has regularly updated information about outbreaks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Timing of exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Understanding the timeline of the clinical history and exposures is important for refining and limiting the differential diagnosis. Knowing when potential exposures occurred allows the determination of an incubation period. Most of the severe, rapidly progressive infections (such as falciparum malaria and hemorrhagic fevers) acquired in tropical or developing countries usually become apparent within one to two months after return. In a large study from Belgium, for example, 78 percent of febrile returning travelers had onset of fever during travel or within one month of return [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/8\">",
"     8",
"    </a>",
"    ]. If more than one month has lapsed since tropical travel, many infections can be excluded. The table lists the causes of fever after travel by the interval since exposure (",
"    <a class=\"graphic graphic_table graphicRef55035 \" href=\"mobipreview.htm?2/5/2142\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The duration of stay is also relevant. Infections that can be transmitted by inhalation, by a single arthropod bite, or by ingestion of contaminated food or water can follow even a brief sojourn in an area, although the probability of infection increases with the length of stay. As an example, among British travelers to West Africa, the relative risk of malaria was more than 80 times greater for stays of 6 to 12 months compared with stays of one week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial history should focus on the preceding year. It is distinctly uncommon for a pathogen to cause an acute febrile illness if the travel occurred more than one year earlier, especially if the duration of the trip was short. Illnesses that turn out to be diagnostic puzzles will require probing for more remote history and consideration of pathogens that can persist and cause symptoms following a long latent or asymptomatic period, such as tuberculosis or visceral leishmaniasis.",
"   </p>",
"   <p>",
"    Some infections, including many filarial infections such as lymphatic filariasis, onchocerciasis, and loiasis, develop primarily in persons who were born and raised in endemic areas or who have spent prolonged periods in tropical areas, though infections occasionally follow stays of &lt;30 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/23\">",
"     23",
"    </a>",
"    ]. Clinical presentation often does not include fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Timing of presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is helpful to know when symptoms are most likely to develop from an infection acquired during tropical travel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/4,24\">",
"     4,24",
"    </a>",
"    ]. The largest experience comes from GeoSentinel, which found that the interval varied widely by diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      66 percent of patients with dengue were seen within one week of return",
"     </li>",
"     <li>",
"      65 percent of patients with falciparum malaria were seen within two weeks of return; only 27 percent of patients with vivax malaria were seen within two weeks, while 54 percent were seen more than six weeks after return.",
"     </li>",
"     <li>",
"      34 percent of patients with hepatitis (mostly hepatitis A or nonspecified hepatitis) were seen more than six weeks after return.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings were noted in a review of malaria cases in the United States in 2007 from the Centers for Disease Control and Prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/25\">",
"     25",
"    </a>",
"    ]. Approximately 80 percent of patients with P. falciparum malaria developed symptoms within one month of returning from travel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/25\">",
"     25",
"    </a>",
"    ]. In contrast, only 36 percent of patients with P. vivax infection presented for medical care during the first month after return, about 20 percent were first seen more than six months after return, and 3 percent &gt;1 year. Overall, 1.6 percent of all malaria cases reported in the United States in 2007 was diagnosed more than one year after the travelers returned from malarious regions.",
"   </p>",
"   <p>",
"    Acute schistosomiasis, which can cause high, persistent fevers, has a longer incubation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Among travelers with acute schistosomiasis acquired during freshwater swimming in Mali, the median incubation period was 40 days (range 14 to 63 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9671561\">",
"    <span class=\"h2\">",
"     Vaccines and chemoprophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history of vaccination prior to travel and use of chemoprophylactic agents during the trip influences the likelihood of acquiring infections for which effective vaccines or chemoprophylaxis exist. These interventions vary in efficacy. The yellow fever and hepatitis A vaccines are highly efficacious, making infection unlikely in persons who have received the vaccines. The protective efficacy with the parenteral Vi capsular polysaccharide",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/7/25718?source=see_link\">",
"     typhoid vaccine",
"    </a>",
"    is estimated to be 60 to 72 percent in field trials in endemic regions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, some travelers lack immunity to measles, rubella, and diphtheria because of gaps in immunization. During travel they may be exposed to these infections, which still circulate in some parts of world. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/48/8967?source=see_link\">",
"     \"Travel advice\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=see_link\">",
"     \"Immunizations for travel\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of various malaria chemoprophylactic regimens varies with the geographic region and also changes over time. As an example, travelers taking agents that were effective for malaria prophylaxis in the past may experience higher failure rates especially with travel to areas where resistance of malaria parasites is prevalent. Even in areas where no resistance has been reported, malaria chemoprophylaxis is not 100 percent effective. Clinicians should inquire as to the type of medication, the dose administered, the intervals between doses, and the duration of therapy prior to and leaving the endemic area. Commonly used chemoprophylactic drugs do not prevent relapse of vivax malaria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/30\">",
"     30",
"    </a>",
"    ]. Use of chemoprophylaxis also may delay the onset of symptoms of malaria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/3/13370?source=see_link\">",
"     \"Prevention of malaria infection in travelers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Sex and travel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual contact with new partners is common during travel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. In a study of 782 travelers in 1991 and 1992, 19 percent reported a new sexual partner on their most recent trip abroad, and 6 percent acquired a sexually transmitted infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/35\">",
"     35",
"    </a>",
"    ]. An active industry has developed around sexual tourism, aimed at providing new sexual partners as a primary reason for travel.",
"   </p>",
"   <p>",
"    Many studies have documented high rates of sexual contact with new partners in expatriates, backpackers, volunteers, and military personnel, among others. Barrier protection is frequently absent or inadequate. In one study of Peace Corps volunteers, only 32 percent reported always using condoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/36\">",
"     36",
"    </a>",
"    ]. In a study of international travelers, 15 percent reported having sex with a new partner or a potential exposure to blood and body fluids (eg, through injections, tattoos, dental work, and other skin perforating procedures) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several sexually transmitted infections can manifest with fever and systemic symptoms in the absence of genital lesions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/20/38217?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of Neisseria gonorrhoeae infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/55/12150?source=see_link\">",
"     \"Pathophysiology, transmission, and natural history of syphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18151?source=see_link\">",
"     \"Acute and early HIV infection: Pathogenesis and epidemiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial history should include a sexual history, including number of partners, types of sexual activities, and whether barrier protection was used. Patients typically will not offer this information and may be unaware that it has any relevance. The table below lists sexually transmitted infections that may cause fever (",
"    <a class=\"graphic graphic_table graphicRef57915 \" href=\"mobipreview.htm?1/40/1675\">",
"     table 3",
"    </a>",
"    ). The complete physical examination should include a careful genital examination in persons who have had sexual contact while traveling. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10696?source=see_link\">",
"     \"Chancroid\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9671678\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should include evaluation for skin lesions, lymphadenopathy, retinal or conjunctival changes, enlargement of liver or spleen, genital lesions, and neurologic findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9672662\">",
"    <span class=\"h3\">",
"     Signs requiring urgent intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings that should prompt urgent intervention include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemorrhagic manifestations",
"     </li>",
"     <li>",
"      Respiratory distress",
"     </li>",
"     <li>",
"      Hypotension or hemodynamic instability",
"     </li>",
"     <li>",
"      Confusion, lethargy, stiff neck, or focal neurologic findings.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many infections can be associated with hemorrhage, including viral hemorrhagic fevers, meningococcemia, leptospirosis, plague, rickettsial infections, and vibrio infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/39\">",
"     39",
"    </a>",
"    ]. (See related topics.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial work-up in febrile patients who have had tropical exposures should include the following: complete blood count (CBC) and differential, liver enzymes, blood cultures, blood smears for malaria, and chest radiograph. Additional studies depend upon exposures and other factors (",
"    <a class=\"graphic graphic_table graphicRef70923 \" href=\"mobipreview.htm?28/24/29067\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Tests for malaria should be carried out urgently (same day) in persons who may have falciparum malaria. Because parasites may be sequestered in the deep vasculature in patients with falciparum malaria, few parasites may be visible on a peripheral smear even in severe infection. Blood smears should be repeated if the initial smears are negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/0/10248?source=see_link\">",
"     \"Diagnosis of malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine causes of febrile illness should be considered together with tropical infections. Patients may have been incubating an infection prior to departure or have become ill after their return. To focus solely on unusual infections may lead to missing important treatable causes of fever. Some routine infections that may occur more commonly after travel include staphylococcal skin infections, meningococcemia, and urinary tract infections. In addition, there may be unusual antibiotic resistance patterns if the pathogens were acquired overseas. The differential diagnosis for travel-related infections should include those with a worldwide distribution, such as influenza [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/42\">",
"     42",
"    </a>",
"    ], including those that occur more commonly in developing countries, and unusual infections such as malaria and dengue fever with focal geographic distributions (",
"    <a class=\"graphic graphic_table graphicRef75701 \" href=\"mobipreview.htm?28/19/28987\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Returned travelers often present with an acute fever, few or no remarkable findings on physical examination, normal or low white blood cell count (WBC), and normal or low platelets. Patients may not appear to be severely ill. Although some of these patients may have self-limited illness, several infections that can be severe or life-threatening also produce this same constellation of findings.",
"   </p>",
"   <p>",
"    GeoSentinel data has demonstrated that among patients with systemic febrile illness, the most common specific diagnoses are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Malaria",
"     </li>",
"     <li>",
"      Dengue fever",
"     </li>",
"     <li>",
"      Mononucleosis (due to EBV or CMV)",
"     </li>",
"     <li>",
"      Rickettsial infection",
"     </li>",
"     <li>",
"      Typhoid or paratyphoid fever (enteric fever) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is also important to consider causes of infection that may be acquired domestically. Geographically focal infections in the United States that can be acquired during travel include plague, babesiosis, Lyme disease, coccidioidomycosis, ehrlichiosis, relapsing fever, Colorado tick fever, rickettsial infections, tularemia, and hantavirus pulmonary syndrome. In focal areas of Europe, infections include visceral leishmaniasis, hemorrhagic fever with renal syndrome, sandfly fever, and tick borne encephalitis.",
"   </p>",
"   <p>",
"    Many noninfectious diseases also cause fever and should be considered if the initial evaluation does not yield a diagnosis. For example, in one study, noninfectious causes accounted for 2.2 percent of the fevers in patients seen after tropical travel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/8\">",
"     8",
"    </a>",
"    ]. Some of these may be directly related to the process of travel, eg, thrombophlebitis and pulmonary emboli, or drug fever due to pharmacologic agents taken for prophylaxis or empiric therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any patient who has spent time in a malarious region and who gives a history of fever should be tested for malaria, even if afebrile at the time of evaluation. Fevers in malaria wax and wane; &ge;40 percent of patients may not have fever at the time of the initial evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/44\">",
"     44",
"    </a>",
"    ]. Physical examination can be completely normal in a patient with acute falciparum malaria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/26/5543?source=see_link\">",
"     \"Clinical manifestations of malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Dengue fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although dengue fever does not respond to currently available antivirals, supportive therapy is sometimes needed and can be lifesaving in patients with complicated dengue, eg, dengue hemorrhagic fever and dengue shock syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/50/808?source=see_link\">",
"     \"Prevention and treatment of dengue virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Viral hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis E is being recognized more frequently as a cause of hepatitis and jaundice in travelers, now that many travelers are protected against hepatitis A and hepatitis B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/11/33976?source=see_link\">",
"     \"Hepatitis E virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other infections that are uncommon or rare in travelers but important to recognize include African trypanosomiasis (sleeping sickness), which has increased recently in Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/50-52\">",
"     50-52",
"    </a>",
"    ], amoebic liver abscess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/53\">",
"     53",
"    </a>",
"    ], anthrax, diphtheria, melioidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/54,55\">",
"     54,55",
"    </a>",
"    ], Q fever, rabies, relapsing fever, and visceral, cutaneous, or mucocutaneous leishmaniasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/56\">",
"     56",
"    </a>",
"    ]. (See related topic reviews).",
"   </p>",
"   <p>",
"    Another emerging infection is chikungunya fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/57\">",
"     57",
"    </a>",
"    ]. Chikungunya is an alphavirus that is transmitted to humans via the bite of an infected Aedes mosquito [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/58\">",
"     58",
"    </a>",
"    ]. Infection is characterized by a febrile illness with prominent polyarthralgia, which may be severe and persistent; skin rash occurs in about half of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15576?source=see_link\">",
"     \"Chikungunya fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Leptospirosis may be more common than recognized in travelers returning from tropical areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. In one report, 32 cases were recognized in Dutch travelers over a five-year period; the infection was acquired in Thailand or other countries in Southeast Asia from contact with surface water [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43879?source=see_link\">",
"     \"Microbiology, epidemiology, clinical manifestations, and diagnosis of leptospirosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fungal infections such as histoplasmosis and coccidioidomycosis have caused outbreaks in travelers to Latin America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39304/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. Risk factors have included exploration of caves and proximity to excavation or construction sites. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21881?source=see_link\">",
"     \"Diagnosis and treatment of pulmonary histoplasmosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/425?source=see_link\">",
"     \"Primary coccidioidal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/44/21187?source=see_link\">",
"       \"Patient information: Vaccines for travel (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/31/36338?source=see_link\">",
"       \"Patient information: When to worry about a fever (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/2/16421?source=see_link\">",
"       \"Patient information: General travel advice (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9672990\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary manifestations for a majority of returned travelers fall into five major syndrome categories: systemic febrile illness without localizing findings, acute diarrhea, dermatologic disorders, chronic diarrhea, and nondiarrheal gastrointestinal disorders. The most common specific diagnoses among patients with fever are malaria and dengue. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical history should establish the geographic region of travel, dates of travel, duration of stay, types of accommodations, activities and exposures, and information about the host, including preparation for travel and any predispositions to infection (",
"      <a class=\"graphic graphic_table graphicRef54195 \" href=\"mobipreview.htm?12/24/12684\">",
"       table 1",
"      </a>",
"      ). The clinical history should also include careful documentation of the time of onset and nature of various signs and symptoms. The history should establish whether the person has visited malarious areas during the past 12 months. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Good resources that provide current information about what infections occur in different geographic areas are essential. The Centers for Disease Control and Prevention (CDC) website includes an online version of Health Information for International Travel under Travelers' Health and updates on travel-related infections (",
"      <a class=\"external\" href=\"file://www.cdc.gov/\">",
"       www.cdc.gov",
"      </a>",
"      ). The WHO website also has regularly updated information about outbreaks. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Knowing when potential exposures occurred allows the determination of an incubation period. Most of the severe, rapidly progressive infections (such as falciparum malaria and hemorrhagic fevers) acquired in tropical or developing countries become apparent within one to two months after return. The table lists the causes of fever after travel by the interval since exposure (",
"      <a class=\"graphic graphic_table graphicRef55035 \" href=\"mobipreview.htm?2/5/2142\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Timing of exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physical examination should include evaluation for skin lesions, lymphadenopathy, retinal or conjunctival changes, enlargement of liver or spleen, genital lesions, and neurologic findings. The initial work-up in febrile patients who have had tropical exposures should include the following: complete blood count (CBC) and differential, liver enzymes, blood cultures, rapid diagnostic tests (RDT), and blood smears for malaria, and chest radiograph. Additional studies depend upon exposures and other factors (",
"      <a class=\"graphic graphic_table graphicRef70923 \" href=\"mobipreview.htm?28/24/29067\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Initial evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine causes of febrile illness should be considered first; subsequently the differential diagnosis should be expanded to include infections related to travel (",
"      <a class=\"graphic graphic_table graphicRef75701 \" href=\"mobipreview.htm?28/19/28987\">",
"       table 5",
"      </a>",
"      ). Among patients with systemic febrile illness, the most common specific diagnoses are malaria, dengue fever, mononucleosis, rickettsial infection, and enteric fever (typhoid or paratyphoid fever). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/1\">",
"      Freedman DO, Weld LH, Kozarsky PE, et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med 2006; 354:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/2\">",
"      Steffen R, Rickenbach M, Wilhelm U, et al. Health problems after travel to developing countries. J Infect Dis 1987; 156:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/3\">",
"      Hill DR. Health problems in a large cohort of Americans traveling to developing countries. J Travel Med 2000; 7:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/4\">",
"      Wilson ME, Weld LH, Boggild A, et al. Fever in returned travelers: results from the GeoSentinel Surveillance Network. Clin Infect Dis 2007; 44:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/5\">",
"      Ryan ET, Wilson ME, Kain KC. Illness after international travel. N Engl J Med 2002; 347:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/6\">",
"      Steffen R, deBernardis C, Ba&ntilde;os A. Travel epidemiology--a global perspective. Int J Antimicrob Agents 2003; 21:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/7\">",
"      O'Brien D, Tobin S, Brown GV, Torresi J. Fever in returned travelers: review of hospital admissions for a 3-year period. Clin Infect Dis 2001; 33:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/8\">",
"      Bottieau E, Clerinx J, Schrooten W, et al. Etiology and outcome of fever after a stay in the tropics. Arch Intern Med 2006; 166:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/9\">",
"      Bottieau E, Clerinx J, Van den Enden E, et al. Infectious mononucleosis-like syndromes in febrile travelers returning from the tropics. J Travel Med 2006; 13:191.",
"     </a>",
"    </li>",
"    <li>",
"     MacLean, J, Lalonde, R, Ward, B. Fever from the tropics. Travel Medicine Advisor 1994; (sec 5:27:1-27.14).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/11\">",
"      Emond RT, Smith H, Welsby PD. Assessment of patients with suspected viral haemorrhagic fever. Br Med J 1978; 1:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/12\">",
"      Schwartz E, Mendelson E, Sidi Y. Dengue fever among travelers. Am J Med 1996; 101:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/13\">",
"      Jensenius M, Fournier PE, Vene S, et al. African tick bite fever in travelers to rural sub-Equatorial Africa. Clin Infect Dis 2003; 36:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/14\">",
"      Raoult D, Fournier PE, Fenollar F, et al. Rickettsia africae, a tick-borne pathogen in travelers to sub-Saharan Africa. N Engl J Med 2001; 344:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/15\">",
"      Moser MR, Bender TR, Margolis HS, et al. An outbreak of influenza aboard a commercial airliner. Am J Epidemiol 1979; 110:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/16\">",
"      Driver CR, Valway SE, Morgan WM, et al. Transmission of Mycobacterium tuberculosis associated with air travel. JAMA 1994; 272:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/17\">",
"      Jernigan DB, Hofmann J, Cetron MS, et al. Outbreak of Legionnaires' disease among cruise ship passengers exposed to a contaminated whirlpool spa. Lancet 1996; 347:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/18\">",
"      Olsen SJ, Chang HL, Cheung TY, et al. Transmission of the severe acute respiratory syndrome on aircraft. N Engl J Med 2003; 349:2416.",
"     </a>",
"    </li>",
"    <li>",
"     CDC. Health information for international travel 2011-2012. DHHS, Atlanta, GA 2011.",
"    </li>",
"    <li>",
"     World Health Organization. International Travel and Health: Vaccination Requirements and Health Advice, Geneva: World Health Organization (Updated and published annually).",
"    </li>",
"    <li>",
"     Wilson, ME. A world guide to infections: Diseases, distribution, diagnosis, Oxford University Press, New York 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/22\">",
"      Phillips-Howard PA, Radalowicz A, Mitchell J, Bradley DJ. Risk of malaria in British residents returning from malarious areas. BMJ 1990; 300:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/23\">",
"      Lipner EM, Law MA, Barnett E, et al. Filariasis in travelers presenting to the GeoSentinel Surveillance Network. PLoS Negl Trop Dis 2007; 1:e88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/24\">",
"      Shah S, Filler S, Causer LM, et al. Malaria surveillance--United States, 2002. MMWR Surveill Summ 2004; 53:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/25\">",
"      Mali, S, Steele, S, Slutsker, L, Arguin, PM. Malaria Surveillance --- United States, 2007. MMWR Surveill Summ 2009; 58(SS-02):1-16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/26\">",
"      Meltzer E, Artom G, Marva E, et al. Schistosomiasis among travelers: new aspects of an old disease. Emerg Infect Dis 2006; 12:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/27\">",
"      Visser LG, Polderman AM, Stuiver PC. Outbreak of schistosomiasis among travelers returning from Mali, West Africa. Clin Infect Dis 1995; 20:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/28\">",
"      Ross AG, Vickers D, Olds GR, et al. Katayama syndrome. Lancet Infect Dis 2007; 7:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/29\">",
"      Levine MM, Ferreccio C, Cryz S, Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet 1990; 336:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/30\">",
"      Chen LH, Wilson ME, Schlagenhauf P. Controversies and misconceptions in malaria chemoprophylaxis for travelers. JAMA 2007; 297:2251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/31\">",
"      Reyburn H, Behrens RH, Warhurst D, Bradley D. The effect of chemoprophylaxis on the timing of onset of falciparum malaria. Trop Med Int Health 1998; 3:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/32\">",
"      Mulhall BP. Sexually transmissible diseases and travel. Br Med Bull 1993; 49:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/33\">",
"      Matteelli A, Carosi G. Sexually transmitted diseases in travelers. Clin Infect Dis 2001; 32:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/34\">",
"      Rogstad KE. Sex, sun, sea, and STIs: sexually transmitted infections acquired on holiday. BMJ 2004; 329:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/35\">",
"      Hawkes S, Hart GJ, Johnson AM, et al. Risk behaviour and HIV prevalence in international travellers. AIDS 1994; 8:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/36\">",
"      Moore J, Beeker C, Harrison JS, et al. HIV risk behavior among Peace Corps Volunteers. AIDS 1995; 9:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/37\">",
"      Correia JD, Shafer RT, Patel V, et al. Blood and body fluid exposure as a health risk for international travelers. J Travel Med 2001; 8:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/38\">",
"      Centers for Disease Control and Prevention (CDC). Update: management of patients with suspected viral hemorrhagic fever--United States. MMWR Morb Mortal Wkly Rep 1995; 44:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/39\">",
"      Monsuez JJ, Kidouche R, Le Gueno B, Postic D. Leptospirosis presenting as haemorrhagic fever in visitor to Africa. Lancet 1997; 349:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/40\">",
"      Winters RA, Murray HW. Malaria--the mime revisited: fifteen more years of experience at a New York City teaching hospital. Am J Med 1992; 93:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/41\">",
"      Svenson JE, MacLean JD, Gyorkos TW, Keystone J. Imported malaria. Clinical presentation and examination of symptomatic travelers. Arch Intern Med 1995; 155:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/42\">",
"      Mutsch M, Tavernini M, Marx A, et al. Influenza virus infection in travelers to tropical and subtropical countries. Clin Infect Dis 2005; 40:1282.",
"     </a>",
"    </li>",
"    <li>",
"     Connor, EA, Schwartz, E. Typhoid and paratyphoid fevers in travelers. Lancet Infect Dis 2005; 6:623.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/44\">",
"      Dorsey G, Gandhi M, Oyugi JH, Rosenthal PJ. Difficulties in the prevention, diagnosis, and treatment of imported malaria. Arch Intern Med 2000; 160:2505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/45\">",
"      Newman RD, Parise ME, Barber AM, Steketee RW. Malaria-related deaths among U.S. travelers, 1963-2001. Ann Intern Med 2004; 141:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/46\">",
"      Christen D, Steffen R, Schlagenhauf P. Deaths caused by malaria in Switzerland 1988-2002. Am J Trop Med Hyg 2006; 75:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/47\">",
"      Wichmann O, Gascon J, Schunk M, et al. Severe dengue virus infection in travelers: risk factors and laboratory indicators. J Infect Dis 2007; 195:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/48\">",
"      Mohammed HP, Ramos MM, Rivera A, et al. Travel-associated dengue infections in the United States, 1996 to 2005. J Travel Med 2010; 17:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/49\">",
"      Piper-Jenks N, Horowitz HW, Schwartz E. Risk of hepatitis E infection to travelers. J Travel Med 2000; 7:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/50\">",
"      Chretien JP, Smoak BL. African Trypanosomiasis: Changing Epidemiology and Consequences. Curr Infect Dis Rep 2005; 7:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/51\">",
"      Sinha A, Grace C, Alston WK, et al. African trypanosomiasis in two travelers from the United States. Clin Infect Dis 1999; 29:840.",
"     </a>",
"    </li>",
"    <li>",
"     Jelinek T, Bisoffi Z, Bonazzi L, et al. Cluster of African trypanosomiasis in travelers to Tanzanian national parks.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/53\">",
"      Hughes MA, Petri WA Jr. Amebic liver abscess. Infect Dis Clin North Am 2000; 14:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/54\">",
"      Wilks D, Jacobson SK, Lever AM, Farrington M. Fatal melioidosis in a tourist returning from Thailand. J Infect 1994; 29:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/55\">",
"      Dance DA, Smith MD, Aucken HM, Pitt TL. Imported melioidosis in England and Wales. Lancet 1999; 353:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/56\">",
"      Schwartz E, Hatz C, Blum J. New world cutaneous leishmaniasis in travellers. Lancet Infect Dis 2006; 6:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/57\">",
"      Borgherini G, Poubeau P, Staikowsky F, et al. Outbreak of chikungunya on Reunion Island: early clinical and laboratory features in 157 adult patients. Clin Infect Dis 2007; 44:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/58\">",
"      Lakshmi V, Neeraja M, Subbalaxmi MV, et al. Clinical features and molecular diagnosis of Chikungunya fever from South India. Clin Infect Dis 2008; 46:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/59\">",
"      Centers for Disease Control and Prevention (CDC). Malaria--Great Exuma, Bahamas, May-June 2006. MMWR Morb Mortal Wkly Rep 2006; 55:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/60\">",
"      Hochedez P, Canestri A, Guihot A, et al. Management of travelers with fever and exanthema, notably dengue and chikungunya infections. Am J Trop Med Hyg 2008; 78:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/61\">",
"      van Crevel R, Speelman P, Gravekamp C, Terpstra WJ. Leptospirosis in travelers. Clin Infect Dis 1994; 19:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/62\">",
"      Centers for Disease Control and Prevention (CDC). Update: outbreak of acute febrile illness among athletes participating in Eco-Challenge-Sabah 2000--Borneo, Malaysia, 2000. MMWR Morb Mortal Wkly Rep 2001; 50:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/63\">",
"      Panackal AA, Hajjeh RA, Cetron MS, Warnock DW. Fungal infections among returning travelers. Clin Infect Dis 2002; 35:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/64\">",
"      Cairns L, Blythe D, Kao A, et al. Outbreak of coccidioidomycosis in Washington state residents returning from Mexico. Clin Infect Dis 2000; 30:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39304/abstract/65\">",
"      Salomon J, Flament Saillour M, De Truchis P, et al. An outbreak of acute pulmonary histoplasmosis in members of a trekking trip in Martinique, French West Indies. J Travel Med 2003; 10:87.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3888 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-F93BED5DA7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_24_39304=[""].join("\n");
var outline_f38_24_39304=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9672990\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Timing of exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Timing of presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9671561\">",
"      Vaccines and chemoprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Sex and travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9671678\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9672662\">",
"      - Signs requiring urgent intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Malaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Dengue fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Viral hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9672990\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3888\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3888|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/24/12684\" title=\"table 1\">",
"      Clinical history in returning travelers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/5/2142\" title=\"table 2\">",
"      Incubation of infection in travelers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/40/1675\" title=\"table 3\">",
"      Sexually transmitted diseases and travel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/24/29067\" title=\"table 4\">",
"      Labs for fever in travelers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/19/28987\" title=\"table 5\">",
"      Concepts regarding evaluation of fever after travel",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18151?source=related_link\">",
"      Acute and early HIV infection: Pathogenesis and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10696?source=related_link\">",
"      Chancroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15576?source=related_link\">",
"      Chikungunya fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/26/5543?source=related_link\">",
"      Clinical manifestations of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/34/18985?source=related_link\">",
"      Clinical presentation and diagnosis of dengue virus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21881?source=related_link\">",
"      Diagnosis and treatment of pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/0/10248?source=related_link\">",
"      Diagnosis of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/5/3161?source=related_link\">",
"      Diseases potentially acquired by travel to Central and South America",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/0/13319?source=related_link\">",
"      Diseases potentially acquired by travel to East Asia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/17/12568?source=related_link\">",
"      Diseases potentially acquired by travel to Southeast Asia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40121?source=related_link\">",
"      Diseases potentially acquired by travel to sub-Saharan Africa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/20/38217?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of Neisseria gonorrhoeae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/11/33976?source=related_link\">",
"      Hepatitis E virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=related_link\">",
"      Immunizations for travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43879?source=related_link\">",
"      Microbiology, epidemiology, clinical manifestations, and diagnosis of leptospirosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/55/12150?source=related_link\">",
"      Pathophysiology, transmission, and natural history of syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/2/16421?source=related_link\">",
"      Patient information: General travel advice (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/44/21187?source=related_link\">",
"      Patient information: Vaccines for travel (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/31/36338?source=related_link\">",
"      Patient information: When to worry about a fever (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/50/808?source=related_link\">",
"      Prevention and treatment of dengue virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/3/13370?source=related_link\">",
"      Prevention of malaria infection in travelers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/425?source=related_link\">",
"      Primary coccidioidal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/43/20152?source=related_link\">",
"      Skin lesions in the returning traveler",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/48/8967?source=related_link\">",
"      Travel advice",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_24_39305="Management of benign esophageal strictures";
var content_f38_24_39305=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of benign esophageal strictures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/24/39305/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/24/39305/contributors\">",
"     Moises Guelrud, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/24/39305/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/24/39305/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/24/39305/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/24/39305/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/24/39305/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of benign esophageal strictures result from long-standing gastroesophageal reflux [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Treatment usually involves dilation combined with acid-suppressive therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19253?source=see_link\">",
"     \"Complications of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 25 percent of cases of benign esophageal strictures are unrelated to gastroesophageal reflux, and treatment in these cases may be more difficult. Examples include strictures secondary to external beam radiation, esophageal sclerotherapy, caustic ingestions (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/38/40551?source=see_link\">",
"     \"Caustic esophageal injury in adults\"",
"    </a>",
"    ), surgical anastomosis, and rare dermatologic diseases (eg, epidermolysis bullosa dystrophica). Strictures may also result from external compression of the esophagus due to mediastinal fibrosis induced by tuberculosis or idiopathic fibrosing mediastinitis. These conditions result in long and narrow strictures that are difficult to dilate, and in which dilation may be associated with a higher rate of complications. Eosinophilic esophagitis is a more commonly recognized cause of esophageal strictures, particularly in young men. Its recognition is important since dilation can be associated with mucosal tearing and perforation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The goals of therapy for benign esophageal strictures are the relief of dysphagia and the prevention of stricture recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/3\">",
"     3",
"    </a>",
"    ]. In the majority of patients, this can be accomplished with esophageal dilation, though in cases of refractory strictures, additional therapy may be required.",
"   </p>",
"   <p>",
"    This topic will review the management of benign esophageal strictures, including patient selection, methods of dilation, and treatment of refractory esophageal strictures. Complications of dilation, pneumatic dilation of the lower esophageal sphincter for achalasia, dilation of esophageal rings and webs, and management of malignant esophageal obstruction are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/57/10137?source=see_link\">",
"     \"Complications of endoscopic esophageal stricture dilation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/32/12810?source=see_link&amp;anchor=H2#H2\">",
"     \"Pneumatic dilation and botulinum toxin injection for achalasia\", section on 'Pneumatic dilation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/34/12838?source=see_link&amp;anchor=H4#H4\">",
"     \"Esophageal webs and rings\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/41/6809?source=see_link\">",
"     \"Expandable stents in the treatment of esophageal obstruction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42006?source=see_link\">",
"     \"Endoscopic palliation of esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVALUATION PRIOR TO DILATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardinal feature of an esophageal stricture is dysphagia. However, dysphagia may be caused by conditions other than an esophageal stricture, such as gastroesophageal reflux disease, motility disturbances, infection, malignancy, and esophageal webs or rings. Although treatment of some of these conditions may involve esophageal dilation, the specific techniques used differ. Therefore, endoscopic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiographic evaluation of the stricture is required prior to determining a course of therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/17/12569?source=see_link\">",
"     \"Evaluation of dysphagia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Barium studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow is not needed prior to endoscopy in most patients with a suspected esophageal stricture. However, it is typically performed in patients in whom there is concern that a complex esophageal stricture may be present (such as from radiation therapy or after caustic ingestion). The goals are to establish the location, length, and number of strictures, determine the diameter of the esophageal lumen, and look for associated pathology such as esophageal diverticula or a hiatal hernia. This information is used to select the dilating technique, to determine the number of sessions that will be required to relieve symptoms, and to counsel the patient about the expected risks of dilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    studies raise suspicion for a malignant cause, a diagnostic endoscopy may be required prior to dilation. However, endoscopy and dilation are more often performed together during the initial session.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS TO DILATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific features of the esophageal stricture as well as comorbid illnesses can increase the risk of esophageal dilation. Dilation should be avoided or performed with caution in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dilation should not be attempted in the setting of an acute or incompletely healed esophageal perforation",
"     </li>",
"     <li>",
"      In the case of a potentially malignant stricture, dilation should be postponed until the stricture has been confirmed to be benign",
"     </li>",
"     <li>",
"      The benefit of esophageal dilation should be weighed against the risk of the procedure in patients with bleeding disorders or severe pulmonary or cardiovascular disease as such patients may not tolerate endoscopy with or without dilation",
"     </li>",
"     <li>",
"      Dilation should be performed cautiously in patients with a pharyngeal or cervical deformity, recent surgery, a large thoracic aneurysm, or an impacted food bolus",
"     </li>",
"     <li>",
"      Dilation should be carried out with extreme care in patients with eosinophilic esophagitis, due to an increased risk of esophageal perforation (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/16/44297?source=see_link\">",
"       \"Treatment of eosinophilic esophagitis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TYPES OF ESOPHAGEAL DILATORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal dilators fall into two main categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mechanical (push-type or Bougie) dilators",
"     </li>",
"     <li>",
"      Balloon dilators",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies comparing mechanical (Bougie) dilation to balloon dilation have shown variable results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. The success of one technique versus another depends largely upon the endoscopist&rsquo;s experience and familiarity with a particular system.",
"   </p>",
"   <p>",
"    The exact mechanism leading to an increase in esophageal lumen size during dilation is unknown. It is probably due to either circumferential stretching or splitting of the stricture. Mechanical and balloon dilators differ in how they accomplish this goal. Mechanical dilators exert a longitudinal and radial force and dilate progressively from the proximal to the distal extent of the stricture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/8\">",
"     8",
"    </a>",
"    ]. By contrast, balloon dilators simultaneously deliver the entire dilating force radially over the entire length of the stricture, significantly reducing shear stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Mechanical dilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical dilators can be divided into those which are passed freely and those that are inserted over a guidewire.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Maloney dilator (Medovations, Germantown, WI) is the most commonly used dilator that does not require passage over a guidewire. Maloney dilators have a tapered tip and come in multiple sizes. Another freely passed dilator (Hurst) has a rounded tip that may be more difficult to pass and is rarely used. Both Maloney and Hurst dilators were traditionally filled with mercury, which provided flexibility and weight. Because of concerns over leakage and disposal of mercury, both are also available with tungsten filling, which simulates the weight and feel of mercury.",
"     </li>",
"     <li>",
"      Several versions of guidewire assisted dilators are available, but the Savary-Gilliard (Cook Medical, Bloomington, IL) is probably the most commonly used. This dilator is made from plastic, has a tapered tip, and comes in multiple sizes. Another similar system is the American Dilatation System (Bard Interventional Products, Tewksbury, MA). An older system, the Eder-Puestow olive dilators (Eder Instruments Co., Chicago, IL), uses progressively larger elliptical metal dilators passed over a guidewire. Because Savary dilators are flexible and easy to use, they have generally supplanted the use of the metal olive dilators [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A flexible, transparent bougie has been developed that fits over a standard endoscope and has three dilating steps, thereby allowing for sequential dilation under direct visualization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/12\">",
"       12",
"      </a>",
"      ]. Experience with this dilator is limited.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Balloon dilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two types of balloon dilators: through-the-scope (TTS) dilators (multiple manufacturers), which are passed directly through the biopsy channel of the endoscope, and an over-the-guidewire (OTW) balloon dilator (multiple manufacturers). Compared with their predecessors, newer balloons are capable of exerting a greater radial force and more predictably retain their maximum diameter. Balloon dilators were available initially in sizes that increased by 2 mm increments, which made them unfavorable compared with the gradual dilation provided by the Maloney and Savary systems. Improvements in the TTS balloons allow them to expand to three different diameters at 1.0 to 1.5 mm increments (depending upon the TTS balloon being used) without having to change balloons (",
"    <a class=\"graphic graphic_picture graphicRef66533 \" href=\"mobipreview.htm?24/43/25279\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     THERAPEUTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to a patient with an esophageal stricture depends upon characteristics of the stricture and the endoscopist&rsquo;s familiarity with the available systems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Simple strictures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple esophageal strictures are typically related to prolonged reflux esophagitis (peptic strictures). They are smooth surfaced, short, straight, located in the distal esophagus, and can be traversed with the endoscope (ie, &gt;10 mm in diameter). In such cases, passage of Maloney dilators can lead to effective and safe dilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. However, many endoscopists will treat the stricture with either a balloon dilator or a mechanical dilator passed over a guidewire based upon personal preferences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Complex strictures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complex esophageal strictures have one or more characteristics that require special attention during dilation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the use of specific dilation systems. Examples include strictures that are long, narrow, or tortuous, or strictures associated with large hiatal hernias, esophageal diverticula (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57582 \" href=\"mobipreview.htm?4/11/4286\">",
"     image 1",
"    </a>",
"    ), or a tracheoesophageal fistula. In such cases, the tips of freely passed dilators may not enter the stomach and can perforate the esophagus. To avoid this complication, complex strictures require the use of a guidewire-based system or a balloon dilator [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some cases, the patient may be managed using a combination of dilators. As an example, a patient with a narrow distal esophageal stricture that cannot be traversed with the endoscope may undergo initial dilation using a guidewire or balloon dilator. Once the lumen is sufficiently patent (and if there are no other complex features), Maloney dilators may be used for further dilating sessions.",
"   </p>",
"   <p>",
"    Patients with proximal esophageal strictures may benefit from a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow prior to dilation to define the location and extent of the stricture. Strictures in the upper esophagus are typically treated using a dilator that is passed over a guidewire (eg, a Savary dilator), sometimes under fluoroscopic guidance. Through-the-scope balloon dilators generally cannot be used in patients with proximal strictures because to do so requires that the endoscope be maintained in the oropharynx during the dilation.",
"   </p>",
"   <p>",
"    Dilatation in eosinophilic esophagitis (EoE) should be used primarily as an adjunctive therapy when medical treatment fails. When it is required, it should be performed carefully since dilation of EoE has been associated with an increased risk of esophageal tearing and perforation. Dilatation has been performed with both mechanical (Savary and Maloney) dilators and balloons; neither has been shown to be superior. The maximum diameter to be achieved should be the one that produces symptomatic relief, usually 13 to 14 mm. Mucosal tearing occurs frequently, often down to the muscularis, as can be seen if endoscopy is performed after the dilatation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/16/44297?source=see_link\">",
"     \"Treatment of eosinophilic esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A systematic review looked at 18 papers that evaluated the risk of perforation in eosinophilic esophagitis. In a total of 671 dilations in 468 patients, the relative perforation risk overall was 0.1 percent, which is similar to the rate seen with strictured dilations for indications other than EoE. They suggest that this risk may have been overrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal dilation is typically performed as an ambulatory procedure using conscious sedation and topical pharyngeal anesthesia. Patients requiring multiple dilations may tolerate the procedure well without sedation. Motivated patients requiring frequent dilations may even use Maloney dilators to perform self-dilation at home.",
"   </p>",
"   <p>",
"    Prior to dilation, patients are kept fasting to assure a clear view of the esophageal lumen and avoid aspiration. Most patients are instructed to avoid antiplatelet agents and anticoagulants for five to seven days prior to the procedure. While recommended in the past, the American Heart Association and the American Society of Gastrointestinal Endoscopy no longer recommend antibiotic prophylaxis for esophageal dilations, even in patients at high risk for bacterial endocarditis (",
"    <a class=\"graphic graphic_table graphicRef51133 \" href=\"mobipreview.htm?30/19/31037\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41367?source=see_link&amp;anchor=H3#H3\">",
"     \"Antibiotic prophylaxis for gastrointestinal endoscopic procedures\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5702?source=see_link\">",
"     \"Management of antiplatelet agents in patients undergoing endoscopic procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21014?source=see_link\">",
"     \"Management of anticoagulants in patients undergoing endoscopic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Proper positioning of the patient and assistance from an endoscopy nurse help assure the safe passage of the dilators. Dilation is usually performed in the left lateral decubitus position, although Maloney dilators can be safely passed with the patient seated.",
"   </p>",
"   <p>",
"    The choice of the initial dilator size is based upon the stricture diameter, which can be estimated during radiography or by comparing the stricture to the outer diameter of the endoscope. When using mechanical dilators, the diameter of the initial dilator should be approximately the same width as the stricture. Similarly, for balloon dilators, the initial balloon size corresponds to the estimated stricture diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7991840\">",
"    <span class=\"h2\">",
"     Mechanical dilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the case of dilation with a Maloney dilator, once the dilator has been chosen based upon the size of the stricture, the endoscope is removed, and the dilator is passed blindly. The endoscopist should assess for resistance to passage of the dilator and look for blood on the dilator. If these signs are not present, it suggests that the size of the chosen dilator was too small, and a larger dilator should be used. Typically, multiple dilators are passed during one session. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Number of dilations per session'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If the dilator is being passed over a guidewire, the guidewire is fed through the accessory channel of the endoscope into to the stomach. Once the guidewire is in place, the scope is withdrawn, taking care to maintain the position of the guidewire. The dilator is then passed over the guidewire and the stricture is dilated. As with dilation using a Maloney dilator, the endoscopist feels and looks for signs that the stricture is being successfully dilated.",
"   </p>",
"   <p>",
"    Dilation can be performed without endoscopy, during endoscopy with or without fluoroscopy, or under fluoroscopy alone, depending upon the clinical circumstances and preference of the endoscopist. As an example, some endoscopists routinely use fluoroscopy when passing a guidewire through a narrow stricture. Others will pass a guidewire through the stricture during endoscopy without fluoroscopy if the passage into the stomach is clearly visible or if the patient has undergone prior endoscopy (assuring that there is no unexpected pathology or anatomical variant distal to the view of the endoscope) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether or not fluoroscopy improves the effectiveness of dilation is uncertain. One study randomly assigned 83 patients with benign esophageal strictures to Maloney dilation with or without fluoroscopic guidance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/19\">",
"     19",
"    </a>",
"    ]. Patients who underwent dilation with fluoroscopy more often tolerated passage of a 12.5 mm",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    pill after dilation (62 versus 42 percent) and more often had significant improvements in dysphagia scores (93 versus 69 percent). In another study, however, the experience of the endoscopist rather than the use of fluoroscopy correlated with the success of dilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7991997\">",
"    <span class=\"h2\">",
"     TTS balloon dilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many endoscopists have not received as much training in the use of balloon dilating systems compared with mechanical dilators. This may in part reflect the ease and relative safety of mechanical dilating systems compared with early balloon systems. However, prospective comparisons of TTS balloon dilators with mechanical dilators suggest that they are equally safe for dilating esophageal strictures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, one study suggested that stricture recurrence may be less during the second year following TTS compared with mechanical dilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TTS balloons dilators are passed through the channel of the endoscope into the stricture under direct visualization or during fluoroscopy (",
"    <a class=\"graphic graphic_picture graphicRef66533 \" href=\"mobipreview.htm?24/43/25279\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef71653 \" href=\"mobipreview.htm?19/32/19969\">",
"     picture 2",
"    </a>",
"    ). To prevent proximal migration of the balloon during inflation, the endoscope should be positioned just above the proximal end of the balloon, while holding the balloon sheath tightly. Successful dilation can usually be inferred by the ability to move the inflated balloon freely through the treated stricture.",
"   </p>",
"   <p>",
"    Fluoroscopic observation during balloon inflation assures that the maximum diameter has been achieved. To be visible, the balloon needs to be filled with a 1:3 dilution of water soluble contrast. Adequate dilation is seen as obliteration of the balloon \"waist,\" which corresponds with stricture stretching or splitting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal number and duration of inflations have not been established. Most endoscopists perform two to three dilations in a session, maintaining balloon inflation for 30 to 60 seconds per dilation. It is the author&rsquo;s practice to perform two dilations per session, maintaining balloon inflation for 30 seconds per dilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Number of dilations per session",
"    </span>",
"    &nbsp;&mdash;&nbsp;A generally accepted rule is that, when a bougie dilator is being used, no more than three dilators of progressively increasing diameter should be passed in a single session and that the luminal stenosis should be increased by no more than 6 French (2 mm) over the initial dilation (eg, if the initial dilation is performed with a 21 Fr dilator, the maximum dilator size used should be no more than 27 Fr) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Similarly, for balloon dilators, most endoscopists will limit the dilation to no more than three incremental inflations (eg, sequential inflations of 10, 11 and 12 mm). For very tight or for long strictures, only one or two dilations should be performed per session. These rules help to reduce the likelihood of adverse sequelae related to overly exuberant dilation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/57/10137?source=see_link\">",
"     \"Complications of endoscopic esophageal stricture dilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, experienced endoscopists may perform more aggressive dilation in selected cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/19\">",
"     19",
"    </a>",
"    ]. The effectiveness of dilation is approximated by the degree of resistance during passage of the dilator. Experience assists in determining the maximal resistance that can be safely tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Repeated sessions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of repeated dilation sessions depends upon the success of initial dilation and the patient's past response to dilation. Patients undergoing esophageal dilation for the first time may require multiple sessions, especially if the stricture has a narrow diameter and exhibits significant resistance during dilation. Such patients may require repeated sessions every five to seven days. After sufficient progress has been achieved, less frequent dilating sessions may be satisfactory. In some patients, however, symptoms tend to recur rapidly following dilation. Such patients require more frequent dilations based upon symptoms. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Endpoint of dilation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As a general rule, the last dilator used in the previous session can be passed first. However, shrinkage of strictures following dilation should be expected, and not all patients will tolerate passage of the largest diameter dilator used during the previous session. Since the amount of shrinkage is hard to predict, it is helpful to reassess the stricture diameter prior to dilation. If there has been significant shrinkage a smaller sized dilator may be required. The experience during previous dilating sessions with an individual patient may also influence the choice of dilator size.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Safety of mucosal biopsy prior to dilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucosal biopsy of the esophagus prior to dilation carries the theoretical risk of causing a lead point for excessive mucosal tearing during dilation. This concern has led to the general recommendation that biopsies be performed after dilation. However, this is not always practical, since it requires reinsertion of the endoscope if a mechanical dilation method has been used.",
"   </p>",
"   <p>",
"    Although few data have directly addressed this issue, it is frequent practice and is probably safe to perform dilation immediately after endoscopic mucosal biopsy. In support of this practice is a small series of 48 patients who underwent esophageal dilation following mucosal biopsy; no complications related to the mucosal biopsy were observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ENDPOINT OF DILATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus as to how much dilatation is sufficient. As a general rule, the size of the lumen following dilation corresponds to symptom relief and the need for recurrent dilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/1\">",
"     1",
"    </a>",
"    ]. Dilation to 18 mm (54 French) allows intake of a regular diet unless there is a coexisting motility disturbance. By comparison, patients with an esophageal lumen less than 13 mm (39 French) will usually experience solid food dysphagia. Some endoscopists advocate use of an objective measure (such as passage of a 12 mm",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    tablet) as the endpoint for dilation (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some strictures are more difficult to dilate and narrower luminal diameters may need to be accepted. Patients dilated to a diameter of 15 mm (45 French) are generally able to eat a modified regular diet. Such patients should be instructed to chew their food well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     POST-DILATION ACID CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with a proton pump inhibitor following dilation may decrease the risk of stricture recurrence. In older studies of patients with esophageal strictures, approximately 70 percent of patients required repeated dilations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/1,4,5,13,26\">",
"     1,4,5,13,26",
"    </a>",
"    ]. The risk was greatest within the first year after initial dilation and patients who required redilation were more likely to require continued dilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. However, many studies of the natural history of esophageal strictures were performed prior to the introduction of proton pump inhibitors.",
"   </p>",
"   <p>",
"    Proton pump inhibitors in patients with peptic strictures reduce the need for subsequent dilation and are more effective than H2 antagonists for this purpose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/27-32\">",
"     27-32",
"    </a>",
"    ]. In one study, for example, 336 patients with peptic esophageal strictures were randomized to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    (20 mg daily) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    (150 mg twice daily) for one year after esophageal dilation to 12 to 18 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/28\">",
"     28",
"    </a>",
"    ]. Subsequent endoscopy and dilation were performed when clinically indicated. The omeprazole-treated patients required significantly fewer repeated dilation sessions (30 percent versus 46 percent) and had improved dysphagia scores compared with the ranitidine-treated group. The greater effectiveness of proton pump inhibitors is in part explained by the observation that dysphagia in patients with peptic strictures is related to the stricture diameter and the presence of esophagitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/33\">",
"     33",
"    </a>",
"    ]. Our practice is to treat most patients with omeprazole 20 mg twice daily for one year following dilation, though some patients (such as those with significant reflux) may require up to 40 mg twice daily.",
"   </p>",
"   <p>",
"    However, use of a proton pump inhibitor does not obviate the need for achieving adequate dilation for peptic strictures. It has been suggested that objective evidence of stricture size following dilation is important, even when patients are treated with a proton pump inhibitor. In one study, objective evidence of successful dilation was defined as passage of a 12 mm",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    pill following dilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/25\">",
"     25",
"    </a>",
"    ]. Compared with patients managed by subjective reporting of dysphagia relief, patients who passed the barium pill had less recurrent dysphagia and needed fewer repeat dilation sessions.",
"   </p>",
"   <p>",
"    Symptom relief while on acid suppression does not always correlate accurately with protection from pathologic acid reflux [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/32\">",
"     32",
"    </a>",
"    ]. Patients with recurrent peptic strictures despite use of a proton pump inhibitor may benefit from ambulatory 24-hour pH monitoring while on therapy to assure the adequacy of acid suppression. Patients with persistent heartburn despite proton pump inhibitors are at increased risk for stricture recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical options should be discussed with young patients with peptic strictures who require frequent dilation or are dependent upon proton pump inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/57/42905?source=see_link\">",
"     \"Surgical management of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     REFRACTORY STRICTURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with benign esophageal strictures do not achieve acceptable symptom relief despite an intensive dilation schedule and gastroesophageal reflux therapy. These patients are often poor surgical candidates. In addition, for those who are surgical candidates, successful antireflux surgery for peptic strictures depends upon adequate preoperative esophageal dilation, which may be difficult to accomplish safely.",
"   </p>",
"   <p>",
"    Motivated patients with simple strictures may benefit from a schedule of regular self-dilation with a Maloney dilator. However, home dilation is not without risks and many patients are not suitable candidates.",
"   </p>",
"   <p>",
"    Several endoscopic techniques have been used to prevent stricture recurrence and improve dysphagia in cases of recalcitrant esophageal strictures. The most commonly used technique is the intralesional injection of corticosteroids. Its efficacy is not well established, as most reported experience is derived from case reports and small series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/35-39\">",
"     35-39",
"    </a>",
"    ]. Removable esophageal stents are also being used for the management of refractory strictures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Intralesional injection of corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The injection of corticosteroids into the stricture may reduce stricture recurrence following dilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/40\">",
"     40",
"    </a>",
"    ]. The mechanism of action is not well understood, but corticosteroids may impede collagen deposition and enhance its breakdown locally, thereby reducing scar formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/41\">",
"     41",
"    </a>",
"    ]. A sham-controlled trial involving 30 patients with a peptic stricture and recurrent dysphagia found a significant reduction in the need for repeat dilation (13 versus 60 percent) one year after the procedure in patients who received steroid injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to dilation with balloon or mechanical dilators, a standard sclerotherapy needle to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide (Kenalog, Bristol-Myers Squibb, Princeton, NJ) into four quadrants at the narrowest region of the stricture. Some authors have used four quadrant injections of 0.5 mL aliquots of triamcinolone acetonide at concentrations of 20",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    to 40",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/40,42\">",
"     40,42",
"    </a>",
"    ]. However, it can be difficult to inject full strength solutions through a standard sclerotherapy needle, so diluting the solution to 10",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    and injecting larger volumes (eg, 1 mL aliquots) may be technically easier. An ultrasound miniprobe passed through a regular upper endoscope has been used to assist in guiding injection into the thickest segment of the stricture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/43\">",
"     43",
"    </a>",
"    ]. Intralesional steroids have also been combined with systemic corticosteroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Nonmetal stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing experience has suggested that temporary placement of nonmetal expandable stents can be effective for managing refractory benign strictures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. A silicone coated self-expanding plastic stent (SEPS; Polyflex stent, Rusch International, distributed by Boston Scientific Corporation, Natick, MA) has been approved for use in patients with refractory benign strictures. SEPS should optimally be left in place for at least six weeks to allow for remodeling of the scar tissue. A longer period may be required in patients with post-radiation or anastomotic strictures, which have a greater tendency to recur.",
"   </p>",
"   <p>",
"    Published experience with the Polyflex stent for benign esophageal conditions has been mixed and clinical experience with this stent in benign strictures suggests that migration has been a problem. Thus, the safety of this approach is unclear.",
"   </p>",
"   <p>",
"    The following illustrate the range of findings in the largest published series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/46-49\">",
"     46-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest study included 40 patients with refractory, benign esophageal strictures who were treated with a Polyflex stent for four weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/49\">",
"       49",
"      </a>",
"      ]. The technical success in stent placement and removal were 95 and 94 percent, respectively. Median dysphagia scores improved, but at a median follow-up of one year, only 40 percent were dysphagia-free. Complications included stent migration, severe chest pain, bleeding, perforation, gastroesophageal reflux, stent impaction, and fistula formation, emphasizing that the procedure should be considered only in carefully selected patients.",
"     </li>",
"     <li>",
"      One series included a total of 30 patients with a variety of benign esophageal lesions who underwent a total of 83 stent placements [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/48\">",
"       48",
"      </a>",
"      ]. Overall, the intervention was considered to have led to long-term improvement in only 6 percent of cases. Stent migration was common (70 to 80 percent, depending upon location).",
"     </li>",
"     <li>",
"      Another study included 21 patients with dysphagia due to a variety of benign strictures (including peptic, caustic, post-radiotherapy, anastomotic, and hyperplastic from a self-expanding metal stent) who underwent placement of the Polyflex stent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/47\">",
"       47",
"      </a>",
"      ]. Stents were later removed in all patients (from as early as one week to as late as 13 months after placement). Early stent migration was observed in five patients, while late migration occurred in seven. Stent placement was considered to be \"curative\" in 17 patients, particularly those with caustic and hyperplastic strictures, with a median of 21 months follow-up.",
"     </li>",
"     <li>",
"      A fourth study included 11 patients with anastomotic strictures after curative esophagogastrectomy for esophageal neoplasms. All 11 patients had satisfactory relief of dysphagia to solids. Stent migration occurred in seven instances. Dysphagia remediation after subsequent stent removal was observed in only 23 percent of cases. Placement of a partially covered metal stent within a Polyflex stent was necessary in one case due to epithelial hyperplasia. The mean time for repeat dilation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      Polyflex reinsertion due to recurrent dysphagia after stent removal was 37 days (range 6 to 120 days) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A systematic review of ten studies with 130 patients found that insertion of a SEPS was technically successful in 128 of 130 patients (98 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/51\">",
"     51",
"    </a>",
"    ]. However, only 68 patients (52 percent) were symptom-free without the need for further endoscopic dilations after a median follow-up of 13 months. Stent migration occurred in 23 percent of patients within four weeks, and endoscopic reintervention was required in 21 percent. In addition to stent migration, complications included perforation (three patients), bleeding (three patients with one death), tracheal compression or chest pain (two patients), inability to remove the stent (two patients), and a tracheal fistula (one patient).",
"   </p>",
"   <p>",
"    Other nonmetal stents continue to be developed. A prototype biodegradable esophageal stent made from a coil of poly-L-lactide (InStent, Eden Prairie, MN) has been used in case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. A second self-expandable biodegradable stent has been developed and is available outside the United States, though it is expected that this stent will ultimately be available in the United States. The SX-ELLA Esophageal Degradable BD (BD Stent) (Ella-CS, Czech Republic) is made from woven surgical suture material, polydioxanone. It is uncovered and does not have an anti-reflux valve. The stent fully degrades in approximately three months. The stent has been used for the treatment of benign refractory strictures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/54-60\">",
"     54-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The polydioxanone stent was compared with SEPS in a small series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/54\">",
"     54",
"    </a>",
"    ]. The initial group of 20 patients with refractory benign esophageal strictures all received SEPS, followed by a group of 16 patients treated with the biodegradable stent. There was no difference between the SEPS and the biodegradable stent in the proportion of patients who were dysphagia free at the end of follow-up (30 versus 33 percent), in the development of recurrent dysphagia (50 versus 67 percent), or in major complications (10 versus 22 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92263143\">",
"    <span class=\"h2\">",
"     Metal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of expandable uncovered metal stents for benign esophageal strictures is",
"    <strong>",
"     not",
"    </strong>",
"    recommended. There is a high incidence of complications, varying from stent migration to stent-induced trauma leading to fistulization. The most common complication, which has been described in approximately 40 percent of patients, is stent-induced stenosis caused by granulation tissue and fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fully-covered self-expanding metal stents (FCSEMS) have been described for use in benign esophageal disease. FCSEMSs offer the advantage of a thin, flexible delivery catheter that can be easily operated and deployed within the esophagus. The fully covered nature of these metal stents may allow removability, thus permitting their use in benign",
"    <a class=\"external\" href=\"file://www.giejournal.org/article/S0016-5107(11)00219-7/fulltext\">",
"    </a>",
"    disease.",
"   </p>",
"   <p>",
"    Four studies examined the use of a FCSEMS without flared flanges (Alimaxx-ES esophageal stent, Merit Medical Systems Inc, South Jordan, Utah) in benign esophageal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/62-65\">",
"     62-65",
"    </a>",
"    ]. In one study, the long-term success rate in patients with refractory strictures was only 29 percent, and overall stent migration was observed in nearly one-third of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/62\">",
"     62",
"    </a>",
"    ]. Three other studies found relatively high rates of stent migration (34 to 39 percent). Treatment success varied from 21 to 100 percent, depending upon the indication for stent placement",
"    <span class=\"nowrap\">",
"     (fistula/leak",
"    </span>",
"    or perforation and strictures) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/63-65\">",
"     63-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three additional types of newly developed FCSEMSs with the presence of flared flanges (ie, \"dog bone\" design) have been used with success:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Wallflex esophageal stent (Boston Scientific Inc, Natick, MA)",
"     </li>",
"     <li>",
"      Bonastent esophageal stent (EndoChoice Inc, Alpharetta, GA)",
"     </li>",
"     <li>",
"      Evolution esophageal stent (Cook Medical Inc, Winston-Salem, NC)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one study, a total of 31 patients underwent FCSEMS placement for benign esophageal conditions including fistula or leak (n = 15), benign refractory stricture (n = 9), anastomotic stricture (n = 4), and radiation-induced stricture (n = 3) with one of the three above-mentioned stents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/66\">",
"     66",
"    </a>",
"    ]. In total, 28 of 31 patients (90 percent) had an improvement in their dysphagia score or resolution of their fistula or leak. Stent migration occurred in 26 percent (11 of 43 stents). Nearly all of the stent migration events occurred within 30 days of insertion (10 of 11 migration events). This lower rate of migration may be due to the presence of flared flanges in all three types of FCSEMSs used in this series and not present on the Alimaxx-ES stent. The stents were successfully removed endoscopically in 29 of 31 patients. One stent was removed during the surgical correction of a fistula. In another patient, endoscopic removal failed on the first attempt, and a second stent was placed within the first stent. Both stents were successfully removed during a third endoscopic procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Other methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with other nonsurgical methods for the management of recalcitrant strictures is limited. Scattered case reports have demonstrated the efficacy of endoscopic electrosurgical incision of peptic strictures, postoperative strictures, and Schatzki rings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/67-70\">",
"     67-70",
"    </a>",
"    ]. The safety of these techniques is uncertain. Injection of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    C (a chemotherapy agent) after dilation was effective in a case report of a patient with a recalcitrant proximal esophageal stricture after radiotherapy for thyroid cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/71\">",
"     71",
"    </a>",
"    ] and in a series of five patients with refractory strictures following endoscopic submucosal dissection for early esophageal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39305/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/41/33426?source=see_link\">",
"       \"Patient information: Upper endoscopy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/19/10546?source=see_link\">",
"       \"Patient information: Esophageal stricture (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/0/21506?source=see_link\">",
"       \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goals of therapy for benign esophageal strictures are the relief of dysphagia and the prevention of stricture recurrence.",
"     </li>",
"     <li>",
"      Accurate diagnosis is required to determine the appropriate treatment strategy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Evaluation prior to dilation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Therapeutic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several comorbidities can increase the risk of esophageal dilation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Contraindications to dilation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two major categories of dilators: mechanical (push-type or Bougie) dilators and balloon dilators. The success of one technique versus another depends largely upon the endoscopist&rsquo;s experience and familiarity with a particular system. However, we recommend that strictures with complex features be dilated with a guidewire-based mechanical or balloon dilating system (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Types of esophageal dilators'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Therapeutic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following esophageal dilation, patients should be treated with proton pump inhibitors to promote healing and reduce the risk of stricture recurrence. Our practice is to treat most patients with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      20 mg twice daily for one year following dilation. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Post-dilation acid control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with refractory strictures, we generally suggest an attempt at dilation with intralesional injection of steroids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Although we do not have personal experience, it is reasonable to offer temporary placement of a self-expanding plastic stent for patients who continue to have refractory strictures, advising patients that their efficacy and safety have not been well established. Stents should optimally be left in place for at least six weeks to allow for remodeling of the scar tissue. A longer period may be required in patients with post-radiation or anastomotic strictures, which have a greater tendency to recur. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Refractory strictures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The complications of esophageal stricture dilation are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/57/10137?source=see_link\">",
"       \"Complications of endoscopic esophageal stricture dilation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/1\">",
"      Patterson DJ, Graham DY, Smith JL, et al. Natural history of benign esophageal stricture treated by dilatation. Gastroenterology 1983; 85:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/2\">",
"      Marks RD, Richter JE. Peptic strictures of the esophagus. Am J Gastroenterol 1993; 88:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/3\">",
"      Standards of Practice Committee, Egan JV, Baron TH, et al. Esophageal dilation. Gastrointest Endosc 2006; 63:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/4\">",
"      Shemesh E, Czerniak A. Comparison between Savary-Gilliard and balloon dilatation of benign esophageal strictures. World J Surg 1990; 14:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/5\">",
"      Cox JG, Winter RK, Maslin SC, et al. Balloon or bougie for dilatation of benign esophageal stricture? Dig Dis Sci 1994; 39:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/6\">",
"      Saeed ZA, Winchester CB, Ferro PS, et al. Prospective randomized comparison of polyvinyl bougies and through-the-scope balloons for dilation of peptic strictures of the esophagus. Gastrointest Endosc 1995; 41:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/7\">",
"      Scolapio JS, Pasha TM, Gostout CJ, et al. A randomized prospective study comparing rigid to balloon dilators for benign esophageal strictures and rings. Gastrointest Endosc 1999; 50:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/8\">",
"      Abele JE. The physics of esophageal dilatation. Hepatogastroenterology 1992; 39:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/9\">",
"      McLean GK, LeVeen RF. Shear stress in the performance of esophageal dilation: comparison of balloon dilation and bougienage. Radiology 1989; 172:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/10\">",
"      Kozarek RA. Esophageal dilation. Mayo Clin Proc 1992; 67:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/11\">",
"      Piotet E, Escher A, Monnier P. Esophageal and pharyngeal strictures: report on 1,862 endoscopic dilatations using the Savary-Gilliard technique. Eur Arch Otorhinolaryngol 2008; 265:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/12\">",
"      Jones MP, Bratten JR, McClave SA. The Optical Dilator: a clear, over-the-scope bougie with sequential dilating segments. Gastrointest Endosc 2006; 63:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/13\">",
"      Wesdorp IC, Bartelsman JF, den Hartog Jager FC, et al. Results of conservative treatment of benign esophageal strictures: a follow-up study in 100 patients. Gastroenterology 1982; 82:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/14\">",
"      Atkinson M, Robertson CS. Benign oesophageal stricture in Barrett's columnar epithelialised oesophagus and its responsiveness to conservative management. Gut 1988; 29:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/15\">",
"      Hernandez LV, Jacobson JW, Harris MS, Hernandez LJ. Comparison among the perforation rates of Maloney, balloon, and savary dilation of esophageal strictures. Gastrointest Endosc 2000; 51:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/16\">",
"      Jacobs JW Jr, Spechler SJ. A systematic review of the risk of perforation during esophageal dilation for patients with eosinophilic esophagitis. Dig Dis Sci 2010; 55:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/17\">",
"      Saeed ZA. Balloon dilatation of benign esophageal stenoses. Hepatogastroenterology 1992; 39:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/18\">",
"      Pereira-Lima JC, Ramires RP, Zamin I Jr, et al. Endoscopic dilation of benign esophageal strictures: report on 1043 procedures. Am J Gastroenterol 1999; 94:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/19\">",
"      Kozarek RA, Patterson DJ, Ball TJ, et al. Esophageal dilation can be done safely using selective fluoroscopy and single dilating sessions. J Clin Gastroenterol 1995; 20:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/20\">",
"      Ho SB, Cass O, Katsman RJ, et al. Fluoroscopy is not necessary for Maloney dilation of chronic esophageal strictures. Gastrointest Endosc 1995; 41:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/21\">",
"      Kozarek RA. To stretch or to shear: a perspective on balloon dilators. Gastrointest Endosc 1987; 33:459.",
"     </a>",
"    </li>",
"    <li>",
"     Boyce HW, Palmer ED. Techniques of Clinical Gastroenterology, (Section III), Charles C Thomas, Springfield, IL 1975.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/23\">",
"      Tulman AB, Boyce HW Jr. Complications of esophageal dilation and guidelines for their prevention. Gastrointest Endosc 1981; 27:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/24\">",
"      Barkin JS, Taub S, Rogers AI. The safety of combined endoscopy, biopsy and dilation in esophageal strictures. Am J Gastroenterol 1981; 76:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/25\">",
"      Saeed ZA, Ramirez FC, Hepps KS, et al. An objective end point for dilation improves outcome of peptic esophageal strictures: a prospective randomized trial. Gastrointest Endosc 1997; 45:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/26\">",
"      Glick ME. Clinical course of esophageal stricture managed by bougienage. Dig Dis Sci 1982; 27:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/27\">",
"      Marks RD, Richter JE, Rizzo J, et al. Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994; 106:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/28\">",
"      Smith PM, Kerr GD, Cockel R, et al. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Restore Investigator Group. Gastroenterology 1994; 107:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/29\">",
"      Jaspersen D, Schwacha H, Schorr W, et al. Omeprazole in the treatment of patients with complicated gastro-oesophageal reflux disease. J Gastroenterol Hepatol 1996; 11:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/30\">",
"      Silvis SE, Farahmand M, Johnson JA, et al. A randomized blinded comparison of omeprazole and ranitidine in the treatment of chronic esophageal stricture secondary to acid peptic esophagitis. Gastrointest Endosc 1996; 43:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/31\">",
"      Swarbrick ET, Gough AL, Foster CS, et al. Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine. Eur J Gastroenterol Hepatol 1996; 8:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/32\">",
"      Katzka DA, Paoletti V, Leite L, Castell DO. Prolonged ambulatory pH monitoring in patients with persistent gastroesophageal reflux disease symptoms: testing while on therapy identifies the need for more aggressive anti-reflux therapy. Am J Gastroenterol 1996; 91:2110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/33\">",
"      Dakkak M, Hoare RC, Maslin SC, Bennett JR. Oesophagitis is as important as oesophageal stricture diameter in determining dysphagia. Gut 1993; 34:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/34\">",
"      Said A, Brust DJ, Gaumnitz EA, Reichelderfer M. Predictors of early recurrence of benign esophageal strictures. Am J Gastroenterol 2003; 98:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/35\">",
"      Holder TM, Ashcraft KW, Leape L. The treatment of patients with esophageal strictures by local steroid injections. J Pediatr Surg 1969; 4:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/36\">",
"      Kirsch M, Blue M, Desai RK, Sivak MV Jr. Intralesional steroid injections for peptic esophageal strictures. Gastrointest Endosc 1991; 37:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/37\">",
"      Zein NN, Greseth JM, Perrault J. Endoscopic intralesional steroid injections in the management of refractory esophageal strictures. Gastrointest Endosc 1995; 41:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/38\">",
"      Lee M, Kubik CM, Polhamus CD, et al. Preliminary experience with endoscopic intralesional steroid injection therapy for refractory upper gastrointestinal strictures. Gastrointest Endosc 1995; 41:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/39\">",
"      Miyashita M, Onda M, Okawa K, et al. Endoscopic dexamethasone injection following balloon dilatation of anastomotic stricture after esophagogastrostomy. Am J Surg 1997; 174:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/40\">",
"      Kochhar R, Makharia GK. Usefulness of intralesional triamcinolone in treatment of benign esophageal strictures. Gastrointest Endosc 2002; 56:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/41\">",
"      Russell SB, Trupin JS, Myers JC, et al. Differential glucocorticoid regulation of collagen mRNAs in human dermal fibroblasts. Keloid-derived and fetal fibroblasts are refractory to down-regulation. J Biol Chem 1989; 264:13730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/42\">",
"      Ramage JI Jr, Rumalla A, Baron TH, et al. A prospective, randomized, double-blind, placebo-controlled trial of endoscopic steroid injection therapy for recalcitrant esophageal peptic strictures. Am J Gastroenterol 2005; 100:2419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/43\">",
"      Bhutani MS, Usman N, Shenoy V, et al. Endoscopic ultrasound miniprobe-guided steroid injection for treatment of refractory esophageal strictures. Endoscopy 1997; 29:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/44\">",
"      Morikawa N, Honna T, Kuroda T, et al. High dose intravenous methylprednisolone resolves esophageal stricture resistant to balloon dilatation with intralesional injection of dexamethasone. Pediatr Surg Int 2008; 24:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/45\">",
"      Song HY, Jung HY, Park SI, et al. Covered retrievable expandable nitinol stents in patients with benign esophageal strictures: initial experience. Radiology 2000; 217:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/46\">",
"      Repici A, Conio M, De Angelis C, et al. Temporary placement of an expandable polyester silicone-covered stent for treatment of refractory benign esophageal strictures. Gastrointest Endosc 2004; 60:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/47\">",
"      Evrard S, Le Moine O, Lazaraki G, et al. Self-expanding plastic stents for benign esophageal lesions. Gastrointest Endosc 2004; 60:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/48\">",
"      Holm AN, de la Mora Levy JG, Gostout CJ, et al. Self-expanding plastic stents in treatment of benign esophageal conditions. Gastrointest Endosc 2008; 67:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/49\">",
"      Dua KS, Vleggaar FP, Santharam R, Siersema PD. Removable self-expanding plastic esophageal stent as a continuous, non-permanent dilator in treating refractory benign esophageal strictures: a prospective two-center study. Am J Gastroenterol 2008; 103:2988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/50\">",
"      Oh YS, Kochman ML, Ahmad NA, Ginsberg GG. Clinical outcomes after self-expanding plastic stent placement for refractory benign esophageal strictures. Dig Dis Sci 2010; 55:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/51\">",
"      Repici A, Hassan C, Sharma P, et al. Systematic review: the role of self-expanding plastic stents for benign oesophageal strictures. Aliment Pharmacol Ther 2010; 31:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/52\">",
"      Fry SW, Fleischer DE. Management of a refractory benign esophageal stricture with a new biodegradable stent. Gastrointest Endosc 1997; 45:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/53\">",
"      Saito Y, Tanaka T, Andoh A, et al. Novel biodegradable stents for benign esophageal strictures following endoscopic submucosal dissection. Dig Dis Sci 2008; 53:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/54\">",
"      van Boeckel PG, Vleggaar FP, Siersema PD. A comparison of temporary self-expanding plastic and biodegradable stents for refractory benign esophageal strictures. Clin Gastroenterol Hepatol 2011; 9:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/55\">",
"      Hirdes MM, Siersema PD, van Boeckel PG, Vleggaar FP. Single and sequential biodegradable stent placement for refractory benign esophageal strictures: a prospective follow-up study. Endoscopy 2012; 44:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/56\">",
"      Canena JM, Liberato MJ, Rio-Tinto RA, et al. A comparison of the temporary placement of 3 different self-expanding stents for the treatment of refractory benign esophageal strictures: a prospective multicentre study. BMC Gastroenterol 2012; 12:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/57\">",
"      ASGE Technology Committee, Tokar JL, Banerjee S, et al. Drug-eluting/biodegradable stents. Gastrointest Endosc 2011; 74:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/58\">",
"      van Hooft JE, van Berge Henegouwen MI, Rauws EA, et al. Endoscopic treatment of benign anastomotic esophagogastric strictures with a biodegradable stent. Gastrointest Endosc 2011; 73:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/59\">",
"      Repici A, Vleggaar FP, Hassan C, et al. Efficacy and safety of biodegradable stents for refractory benign esophageal strictures: the BEST (Biodegradable Esophageal Stent) study. Gastrointest Endosc 2010; 72:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/60\">",
"      Stivaros SM, Williams LR, Senger C, et al. Woven polydioxanone biodegradable stents: a new treatment option for benign and malignant oesophageal strictures. Eur Radiol 2010; 20:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/61\">",
"      Sandha GS, Marcon NE. Expandable metal stents for benign esophageal obstruction. Gastrointest Endosc Clin N Am 1999; 9:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/62\">",
"      Eloubeidi MA, Lopes TL. Novel removable internally fully covered self-expanding metal esophageal stent: feasibility, technique of removal, and tissue response in humans. Am J Gastroenterol 2009; 104:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/63\">",
"      Bakken JC, Wong Kee Song LM, de Groen PC, Baron TH. Use of a fully covered self-expandable metal stent for the treatment of benign esophageal diseases. Gastrointest Endosc 2010; 72:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/64\">",
"      Senousy BE, Gupte AR, Draganov PV, et al. Fully covered Alimaxx esophageal metal stents in the endoscopic treatment of benign esophageal diseases. Dig Dis Sci 2010; 55:3399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/65\">",
"      Eloubeidi MA, Talreja JP, Lopes TL, et al. Success and complications associated with placement of fully covered removable self-expandable metal stents for benign esophageal diseases (with videos). Gastrointest Endosc 2011; 73:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/66\">",
"      Buscaglia JM, Ho S, Sethi A, et al. Fully covered self-expandable metal stents for benign esophageal disease: a multicenter retrospective case series of 31 patients. Gastrointest Endosc 2011; 74:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/67\">",
"      Thorsen G, Rosseland AR. Endoscopic incision of postoperative stenoses in the upper gastrointestinal tract. Gastrointest Endosc 1983; 29:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/68\">",
"      Moret&oacute; M, Zaballa M, Ib&aacute;&ntilde;ez S. Endoscopic incision as an alternative to bougienage in the treatment of peptic esophageal stricture. Endoscopy 1990; 22:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/69\">",
"      Guelrud M, Villasmil L, Mendez R. Late results in patients with Schatzki ring treated by endoscopic electrosurgical incision of the ring. Gastrointest Endosc 1987; 33:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/70\">",
"      Shah JN. Benign refractory esophageal strictures: widening the endoscopist's role. Gastrointest Endosc 2006; 63:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/71\">",
"      Spier BJ, Sawma VA, Gopal DV, Reichelderfer M. Intralesional mitomycin C: successful treatment for benign recalcitrant esophageal stricture. Gastrointest Endosc 2009; 69:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39305/abstract/72\">",
"      Machida H, Tominaga K, Minamino H, et al. Locoregional mitomycin C injection for esophageal stricture after endoscopic submucosal dissection. Endoscopy 2012; 44:622.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2270 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-FDEBE4EB0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_24_39305=[""].join("\n");
var outline_f38_24_39305=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVALUATION PRIOR TO DILATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Barium studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CONTRAINDICATIONS TO DILATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TYPES OF ESOPHAGEAL DILATORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Mechanical dilators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Balloon dilators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      THERAPEUTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Simple strictures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Complex strictures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7991840\">",
"      Mechanical dilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7991997\">",
"      TTS balloon dilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Number of dilations per session",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Repeated sessions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Safety of mucosal biopsy prior to dilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ENDPOINT OF DILATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      POST-DILATION ACID CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      REFRACTORY STRICTURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Intralesional injection of corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Nonmetal stents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H92263143\">",
"      Metal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Other methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2270\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2270|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?4/11/4286\" title=\"diagnostic image 1\">",
"      Epiphrenic diverticulum Barium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2270|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/43/25279\" title=\"picture 1\">",
"      TTS balloon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/32/19969\" title=\"picture 2\">",
"      Balloon dilat stricture Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2270|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/19/31037\" title=\"table 1\">",
"      ASGE guidelines Abx prophylxs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41367?source=related_link\">",
"      Antibiotic prophylaxis for gastrointestinal endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/38/40551?source=related_link\">",
"      Caustic esophageal injury in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/57/10137?source=related_link\">",
"      Complications of endoscopic esophageal stricture dilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19253?source=related_link\">",
"      Complications of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42006?source=related_link\">",
"      Endoscopic palliation of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/34/12838?source=related_link\">",
"      Esophageal webs and rings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/17/12569?source=related_link\">",
"      Evaluation of dysphagia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/41/6809?source=related_link\">",
"      Expandable stents in the treatment of esophageal obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21014?source=related_link\">",
"      Management of anticoagulants in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5702?source=related_link\">",
"      Management of antiplatelet agents in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/19/10546?source=related_link\">",
"      Patient information: Esophageal stricture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/0/21506?source=related_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/32/12810?source=related_link\">",
"      Pneumatic dilation and botulinum toxin injection for achalasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/57/42905?source=related_link\">",
"      Surgical management of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/16/44297?source=related_link\">",
"      Treatment of eosinophilic esophagitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_24_39306="Overview of contraception";
var content_f38_24_39306=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of contraception",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/24/39306/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/24/39306/contributors\">",
"     Mimi Zieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/24/39306/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/24/39306/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/24/39306/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/24/39306/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/24/39306/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review estimated contraceptive prevalence &nbsp;among women of reproductive age who were married or in a union was 63 percent worldwide and 77 percent in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/1\">",
"     1",
"    </a>",
"    ]. Unintended pregnancy is a common problem in the United States. In a study from the Guttmacher Institute using data from several sources, 49 percent of the 6.7 million pregnancies in the United States in 2006 were unintended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/2\">",
"     2",
"    </a>",
"    ]. About 5 percent of women of reproductive age had an unintended pregnancy that year, comprising 3.2 million pregnancies. The demographic characteristics of these women are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef70753 \" href=\"mobipreview.htm?0/62/1006\">",
"     table 1",
"    </a>",
"    ). Forty-three percent of the unintended pregnancies were terminated.",
"   </p>",
"   <p>",
"    These alarmingly high statistics occurred even though most women reported using some form of contraception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/3\">",
"     3",
"    </a>",
"    ]. The high rate of unintended pregnancy despite contraception highlights the importance of understanding contraceptive efficacy in terms of typical, rather than perfect, use (see",
"    <a class=\"local\" href=\"#H12168818\">",
"     'Effectiveness'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Explanations for the apparent failure of contraception when used by the typical patient include inconsistent adherence to method requirements, incorrect use, gaps in use, discontinuation of the method, as well as failure of the method itself. Cost and drug coverage issues also impact upon use of and adherence to contraception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/4\">",
"     4",
"    </a>",
"    ]. As an example, many insurance plans require women to fill prescriptions for contraception on a monthly basis, which increases the chance of a delay in obtaining a needed contraceptive refill. This is a common reason for contraceptive failure. The best way to address the problem of high failure with typical use is by encouraging women to choose long acting, highly effective reversible methods (long-acting reversible contraceptives, LARCs) such as intrauterine devices (IUDs) and implants, which are underutilized in the United States, and providing them at low or no cost [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/5\">",
"     5",
"    </a>",
"    ]. The efficacy of this approach was illustrated by a study in the United States that enrolled 9256 women and provided free contraceptives for three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/6\">",
"     6",
"    </a>",
"    ]. The contraceptive failure rate among participants using pills, patch, or ring was significantly higher than among participants using LARC, who had a very low failure rate (4.55 versus 0.27 per 100 participant-years; hazard ratio after adjustment for age, educational level, and history with respect to unintended pregnancy 21.8; 95% CI 13.7-34.9).",
"   </p>",
"   <p>",
"    In addition, some women choose to not use birth control. The reasons for nonuse were addressed in a report from the Pregnancy Risk Assessment Monitoring System (PRAMS) which surveyed almost 8000 women with a recent unintended viable pregnancy who stated they had not used birth control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/7\">",
"     7",
"    </a>",
"    ]. These women gave the following reasons for unprotected intercourse: 33 percent felt they could not get pregnant at the time of conception, 30 percent did not really mind if they got pregnant, 22 percent stated their partner did not want to use contraception, 16 percent cited side effects, 10 percent felt they or their partner were sterile, 10 percent cited access problems, and 18 percent selected \"other.\" That one-third of these women did not perceive themselves to be at risk of becoming pregnant speaks to the need for more education.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHOOSING A METHOD OF CONTRACEPTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12170197\">",
"    <span class=\"h2\">",
"     Factors to consider",
"    </span>",
"    &nbsp;&mdash;&nbsp;An understanding of the available contraceptive methods allows clinicians to counsel women about methods that are most consistent with their lifestyle and beliefs, and therefore most likely to be successful. Factors to consider include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Efficacy",
"     </li>",
"     <li>",
"      Convenience",
"     </li>",
"     <li>",
"      Duration of action",
"     </li>",
"     <li>",
"      Reversibility and time to return of fertility",
"     </li>",
"     <li>",
"      Effect on uterine bleeding",
"     </li>",
"     <li>",
"      Frequency of side effects and adverse events",
"     </li>",
"     <li>",
"      Affordability",
"     </li>",
"     <li>",
"      Protection against sexually transmitted diseases",
"     </li>",
"     <li>",
"      Medical contraindications (see",
"      <a class=\"local\" href=\"#H3870905\">",
"       'Contraception for women with medical issues'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most popular methods of contraception are shown in the table (",
"    <a class=\"graphic graphic_figure graphicRef61949 \" href=\"mobipreview.htm?35/38/36461\">",
"     figure 1",
"    </a>",
"    ). No method of contraception is perfect. Each woman must balance the advantages of each method against the disadvantages and decide which method she prefers (",
"    <a class=\"graphic graphic_table graphicRef80393 \" href=\"mobipreview.htm?5/22/5486\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef57795 \" href=\"mobipreview.htm?31/46/32488\">",
"     figure 2",
"    </a>",
"    ). A list of questions that are useful for defining the patient's preferences are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef51849 \" href=\"mobipreview.htm?24/1/24603\">",
"     table 3",
"    </a>",
"    ). Women should be counseled to choose the most effective method that they are likely to be able to use successfully. This means they will be able to comply with the requirements of using the method and they will likely adhere to the method despite these requirements and the method&rsquo;s potential side effects. The best strategy for counseling women so they will achieve this goal is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/0/32777?source=see_link\">",
"     \"Counseling women considering combined hormonal contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12168818\">",
"    <span class=\"h2\">",
"     Effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of a contraceptive method is expressed as both the theoretical (perfect use) efficacy and the actual (typical use) effectiveness (",
"    <a class=\"graphic graphic_table graphicRef70218 \" href=\"mobipreview.htm?12/56/13197\">",
"     table 4",
"    </a>",
"    ). The former refers to the pregnancy rate among those who use the method correctly on every occasion; actual effectiveness is usually lower due to inconsistent or incorrect use. Actual effectiveness is also influenced by frequency of intercourse, age, and regularity of menstrual cycles, as pregnancy is less likely in women who are older, have infrequent sexual intercourse, and have irregular menstrual cycles.",
"   </p>",
"   <p>",
"    Effectiveness is often quantitated by the Pearl Index, which is defined as the number of unintended pregnancies per hundred women per year (ie, the number of pregnancies in 1200 observed months of use). One problem with this index is that it does not account for the fact that contraceptive failure rates generally decline with continued use; therefore, a Pearl Index determined by a study of new and short-term users of a method will likely be higher than that in a study including long-term users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/9\">",
"     9",
"    </a>",
"    ]. Demographic factors are also not considered, but influence method compliance and, in turn, efficacy.",
"   </p>",
"   <p>",
"    In practice, contraceptive methods can be divided into three categories based upon their theoretical and actual effectiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/3,10\">",
"     3,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Most effective",
"      </strong>",
"      : Long-acting reversible contraception (intrauterine contraception, contraceptive implants) and sterilization are associated with a low pregnancy rate regardless of the population studied, as the rate is minimally influenced by adherence. Women should be encouraged to first consider a method from this tier of options.",
"     </li>",
"     <li>",
"      <strong>",
"       Effective",
"      </strong>",
"      : Injectable contraceptives are the most effective in this tier of choices. OCs, the transdermal contraceptive system, and the vaginal ring are also associated with a very low pregnancy rate if they are taken consistently and correctly, but actual pregnancy rates are substantially higher because of",
"      <span class=\"nowrap\">",
"       inconsistent/incorrect",
"      </span>",
"      use.",
"     </li>",
"     <li>",
"      <strong>",
"       Least effective",
"      </strong>",
"      : Other methods of contraception, including",
"      <span class=\"nowrap\">",
"       diaphragm/cervical",
"      </span>",
"      caps, condoms, spermicides, withdrawal, and periodic abstinence are associated with actual pregnancy rates that are much higher than perfect use rates. The overall pregnancy rates associated with these methods have varied considerably among studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11463800\">",
"    <span class=\"h3\">",
"     Long-acting reversible contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-acting reversible contraceptives (LARCs), such as intrauterine devices and contraceptive implants, are the most effective reversible contraceptives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/11\">",
"     11",
"    </a>",
"    ]. They do not require ongoing effort on the part of the user for long-term effective use, they are safe, and they are economical when used over as little as a two-year period, and provide prompt return of fertility after removal. In addition, almost all women are eligible for use of one of the LARCs, including nulliparous women, adolescents, and women who should avoid exogenous estrogen. For these reasons, LARCs should be discussed with all women seeking contraception who are appropriate candidates for these methods. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32058?source=see_link&amp;anchor=H23833362#H23833362\">",
"     \"Overview of intrauterine contraception\", section on 'Candidates for intrauterine contraception'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/27/3512?source=see_link\">",
"     \"Etonogestrel contraceptive implant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The advantages of LARCs are illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective cohort study (n = 5000 women) to promote the use of long-acting reversible contraceptive methods as a means of reducing unintended pregnancies, 68 percent of women chose a LARC when specifically counseled to consider one of these options because of greatest effectiveness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/12\">",
"       12",
"      </a>",
"      ]. Women who chose a LARC method had the highest continuation rates at one year of use, 86 versus 55 percent for users of oral contraceptive pills. Satisfaction was similarly high: greater than 84 percent for IUD users versus 54 percent for pill users.",
"     </li>",
"     <li>",
"      The same authors subsequently reported a significantly higher pregnancy rate among participants using pills, patch, or ring compared with those using LARC (4.55 versus 0.27 pregnancies per 100 participant-years; hazard ratio 21.8, 95% CI 13.7-34.9, after adjustment for age, educational level, and history with respect to unintended pregnancy) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/6\">",
"       6",
"      </a>",
"      ]. Rates of unintended pregnancy were similar for LARC and DMPA users.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12169534\">",
"    <span class=\"h2\">",
"     Cost",
"    </span>",
"    &nbsp;&mdash;&nbsp;An economic analysis of contraception for women constructed a Markov model to compare cost-effectiveness among the most common contraceptive methods versus no contraception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/13\">",
"     13",
"    </a>",
"    ]. This model assumed users were not intending to have children for five years and would not switch methods. It took into account factors such as costs of office visits, method failure, management of side effects, and",
"    <span class=\"nowrap\">",
"     prescription/procedure/device",
"    </span>",
"    costs, but did not account for noncontraceptive benefits of some contraceptives (eg, reduction in sexually transmitted disease with condom use, reduction of menorrhagia with some hormonal contraceptives). The major findings of the analysis were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cost and effectiveness of any contraceptive method was superior to using no method.",
"     </li>",
"     <li>",
"      The most cost-effective methods were intrauterine contraception and vasectomy.",
"     </li>",
"     <li>",
"      Cost analysis was very sensitive to variations in the cost of contraceptive methods and unintended pregnancy, and the planned duration of use.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12168768\">",
"    <span class=\"h1\">",
"     CONTRACEPTIVE USE IN THE UNITED STATES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3617390\">",
"    <span class=\"h2\">",
"     Prevalence by method",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, the National Survey of Family Growth (NSFG) found that 62 percent of reproductive aged women reported using contraception from 2006 to 2010 and the most frequently used methods were: oral contraceptive pill (28 percent), female sterilization (27 percent), male condom (16 percent), male sterilization (10 percent), IUD (5.6 percent), non-oral hormonal methods such as implant, patch, ring, injection (7.2 percent), periodic",
"    <span class=\"nowrap\">",
"     abstinence/fertility",
"    </span>",
"    awareness-based methods (1.2 percent), other methods (5.7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12496697\">",
"    <span class=\"h2\">",
"     Adherence by contraceptive method",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discontinuation of contraception for method-related reasons is common, and accounts for a significant proportion of unintended pregnancies since many women switch to less effective methods or use no method at all. In the 2002 National Survey of Family Growth, 46 percent of women reported discontinuing at least one method because they were dissatisfied with it [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Continuation rates at 12 months by method are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Implanon (84 percent)",
"     </li>",
"     <li>",
"      Intrauterine contraceptive device (78 to 80 percent)",
"     </li>",
"     <li>",
"      Vaginal ring, contraceptive patch, combined or progestin-only pill (68 percent)",
"     </li>",
"     <li>",
"      Diaphragm (57 percent)",
"     </li>",
"     <li>",
"      Depo-provera (56 percent)",
"     </li>",
"     <li>",
"      Male condom (53 percent), female condom (49 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two-thirds of women discontinued hormonal methods because of side effects, while almost 40 percent of those who discontinued the condom did so because of partner dissatisfaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12169638\">",
"    <span class=\"h1\">",
"     HOW TO SWITCH FROM ONE METHOD TO ANOTHER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending on the contraceptive methods, switching from one method to another may require a period of back-up contraception (",
"    <a class=\"graphic graphic_table graphicRef77410 \" href=\"mobipreview.htm?4/46/4846\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12168946\">",
"    <span class=\"h1\">",
"     WHEN IS IT SAFE TO STOP USING CONTRACEPTION?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experts suggest that women &ge;age 50 continue to use contraception for one year after their last menstrual period (ie, menopause) and women &lt;age 50 continue to use contraception for two years after their last menstrual period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contraception remains important during perimenopause, as women cannot be certain of infertility until they reach menopause (ie, 12 months without menses). A false presumption of infertility is one reason for the high rate of unintended pregnancy in perimenopausal women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12168953\">",
"    <span class=\"h2\">",
"     Hormonal contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determining when hormonal contraception can be safely discontinued is challenging because the effects of hormones on bleeding patterns (eg, amenorrhea, regular withdrawal bleeding) make it difficult to diagnose menopause and there is no blood test that reliably diagnoses menopause in women using hormonal contraception. One approach in healthy nonsmoking women is to discontinue hormonal contraception when the risk of pregnancy is clearly remote based on age: experts put this age between 53 and 55 years of age.",
"   </p>",
"   <p>",
"    If a woman desires to stop hormonal contraceptives earlier, a reasonable approach is to choose the median age of menopause, 51 years, and switch to a nonhormonal contraceptive. If over time she can be diagnosed as menopausal, then the nonhormonal contraceptive can be discontinued, as well.",
"   </p>",
"   <p>",
"    Use of combined hormonal contraception in older women has noncontraceptive benefits, including reduction in hot flashes, regulated",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduced menstrual bleeding in the perimenopause, and maintenance of bone strength.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12169710\">",
"    <span class=\"h1\">",
"     CONTRACEPTIVE OPTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12169159\">",
"    <span class=\"h2\">",
"     Sterilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sterilization is an effective form of contraception that requires no further contraceptive actions after the procedure is performed (",
"    <a class=\"graphic graphic_table graphicRef70218 \" href=\"mobipreview.htm?12/56/13197\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/19\">",
"     19",
"    </a>",
"    ]. While tubal",
"    <span class=\"nowrap\">",
"     ligation/obstruction",
"    </span>",
"    and vasectomy may be reversible, these procedures should be considered permanent and therefore performed only after thorough patient counseling. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15018?source=see_link\">",
"     \"Surgical sterilization of women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12169250\">",
"    <span class=\"h3\">",
"     Women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tubal obstruction or ligation refers to any procedure that prevents pregnancy by occluding or disrupting tubal patency. Laparoscopic procedures are usually performed under general or regional anesthesia in outpatients; hysteroscopic procedures are often performed under local anesthesia. Postpartum women can undergo surgical sterilization shortly after birth via a small infraumbilical incision.",
"   </p>",
"   <p>",
"    The techniques for tubal obstruction include ligating or removing a section of the fallopian tubes; mechanical blockade using clips, rings, coils, or plugs; and coagulation-induced blockage using electrical current or chemical agents. Laparoscopic coagulation is the most common technique in women who are not postpartum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/20\">",
"     20",
"    </a>",
"    ]; partial salpingectomy is most common in women who have just given birth.",
"   </p>",
"   <p>",
"    Each of these techniques has advantages and disadvantages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bipolar coagulation is associated with a higher risk of ectopic pregnancy than partial salpingectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Silicone rubber-band or spring-clip application is most likely to be successfully reversed by tubal reanastomosis because the length of damaged tube is small [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Insertion of a plug by hysteroscopy (eg, Essure and Adiana systems) does not require an incision, but successful placement is more difficult to achieve and back-up contraception is required for the first three months. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/23/12665?source=see_link\">",
"       \"Hysteroscopic sterilization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Postpartum sterilization procedure is associated with an increased risk of regret about having been sterilized, although young age is the most important factor associated with regret overall [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pregnancy is uncommon after tubal sterilization. It may result from a conception that occurred before the procedure, incomplete tubal occlusion, formation of fistulas, or surgical error. The risk appears to be related to age and the type of procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. When pregnancy does occur, the risk that it will be an ectopic pregnancy is increased, with approximately 33 percent of pregnancies being ectopic and almost always tubal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/21,26\">",
"     21,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A reduction in development of ovarian cancer is a noncontraceptive benefit of tubal ligation. The explanation for this association is unclear, but the procedure may limit the potential for upward migration of carcinogens through the vagina, cervix, and fallopian tubes into the peritoneal cavity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/52/17224?source=see_link\">",
"     \"Epithelial ovarian cancer: Pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adverse effects associated with tubal ligation include perioperative anesthetic or surgical complications. There are no long-term differences in menstrual cycles, bleeding between periods, prolonged or heavy flow, or dysmenorrhea, as compared with unsterilized women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. More sterilized women ultimately undergo hysterectomy (4.5 versus 2.2 percent), possibly because of a lower threshold for choosing hysterectomy as a treatment for uterine disorders after a woman is sterilized.",
"   </p>",
"   <p>",
"    Details of surgical sterilization in women are described elsewhere (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15018?source=see_link\">",
"     \"Surgical sterilization of women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/23/12665?source=see_link\">",
"     \"Hysteroscopic sterilization\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12169257\">",
"    <span class=\"h3\">",
"     Men",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sterilization in males is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39893?source=see_link\">",
"     \"Overview of vasectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hormonal methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hormonal contraceptives may be taken orally, injected, or released from a subdermal implant, transdermal patch, or intrauterine or intravaginal contraceptive device.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3077748\">",
"    <span class=\"h3\">",
"     Patient assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hormonal contraception can be safely provided after an appropriate medical history and blood pressure measurement to exclude contraindications to estrogen use (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"     table 6",
"    </a>",
"    ). While breast and pelvic exams, cervical cancer screening, and screening for sexually transmitted diseases are important, most groups, including the American College of Obstetricians, WHO, and the Royal College of Obstetricians and Gynecologists agree that these procedures are not necessary before a first, or a renewed, prescription for hormonal contraception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/30\">",
"     30",
"    </a>",
"    ]. Chlamydia screening, if indicated, can be performed on urine. Some groups recommend documentation of body mass index when initially prescribing hormonal contraceptives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42728?source=see_link&amp;anchor=H17#H17\">",
"     \"Genital Chlamydia trachomatis infections in women\", section on 'Nucleic acid amplification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3870905\">",
"    <span class=\"h3\">",
"     Contraception for women with medical issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Choosing a hormonal contraceptive method is more complicated for women with certain medical disorders or personal characteristics, since physiologic changes and side effects associated with the method or with pregnancy may increase the risk of",
"    <span class=\"nowrap\">",
"     morbidity/mortality",
"    </span>",
"    in these women. Unintended pregnancy can be particularly serious for women with certain medical conditions (",
"    <a class=\"graphic graphic_table graphicRef60799 \" href=\"mobipreview.htm?3/60/4044\">",
"     table 7",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/0/32777?source=see_link\">",
"     \"Counseling women considering combined hormonal contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One clinical scenario that has not been studied is the optimum hormonal method of contraception for women with limited mobility, such as those in wheel chairs. Factors to consider include the negative effect of depot",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (DMPA) and immobility itself on bone mineral density, as well as the increased risk of thrombosis associated with estrogen-progestin contraceptives and third generation progestins. A",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    -releasing IUD which lessens menstrual bleeding and requires little to no attention while not carrying either of these risks appears to be a good option. Progestin-only pills are an alternative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3870962\">",
"    <span class=\"h4\">",
"     World Health Organization tables",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) has published comprehensive tables of medical conditions and personal characteristics that may affect contraceptive choice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/32\">",
"     32",
"    </a>",
"    ]. These tables can be found on-line, and are summarized below.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Personal characteristics (",
"      <a class=\"graphic graphic_table graphicRef82680 \" href=\"mobipreview.htm?20/51/21311\">",
"       table 8",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cardiovascular disease (",
"      <a class=\"graphic graphic_table graphicRef65586 \" href=\"mobipreview.htm?39/25/40350\">",
"       table 9",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Headache and epilepsy (",
"      <a class=\"graphic graphic_table graphicRef62351 \" href=\"mobipreview.htm?36/61/37853\">",
"       table 10",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Depression (",
"      <a class=\"graphic graphic_table graphicRef61848 \" href=\"mobipreview.htm?1/1/1052\">",
"       table 11",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Reproductive",
"      <span class=\"nowrap\">",
"       tract/",
"      </span>",
"      breast abnormalities, cancer, infections (",
"      <a class=\"graphic graphic_table graphicRef60832 \" href=\"mobipreview.htm?33/28/34255\">",
"       table 12",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      HIV (",
"      <a class=\"graphic graphic_table graphicRef75345 \" href=\"mobipreview.htm?38/20/39245\">",
"       table 13",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Gastrointestinal disease (",
"      <a class=\"graphic graphic_table graphicRef55954 \" href=\"mobipreview.htm?5/40/5774\">",
"       table 14",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Thalassemia and sickle cell anemia (",
"      <a class=\"graphic graphic_table graphicRef78542 \" href=\"mobipreview.htm?22/49/23324\">",
"       table 15",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Diabetes and thyroid disease (",
"      <a class=\"graphic graphic_table graphicRef69329 \" href=\"mobipreview.htm?19/34/20013\">",
"       table 16",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Drugs and drug interactions (",
"      <a class=\"graphic graphic_table graphicRef54244 \" href=\"mobipreview.htm?36/54/37741\">",
"       table 17",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Rheumatological issues (",
"      <a class=\"graphic graphic_table graphicRef65563 \" href=\"mobipreview.htm?41/14/42220\">",
"       table 18",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &ldquo;Initiation&rdquo; recommendations apply to women in whom the medical condition precedes initiation of the method, &ldquo;continuation&rdquo; recommendations apply to women who develop the medical condition while using the method.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3870998\">",
"    <span class=\"h4\">",
"     CDC tables",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2010, the Centers for Disease Control and Prevention (CDC) modified the WHO tables for medical eligibility criteria for contraceptive use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/33\">",
"     33",
"    </a>",
"    ]. Selected WHO recommendations were adapted for US clinicians and patients, the number of medical conditions was expanded and recommendations added, and contraceptive methods not available in the US were removed. The",
"    <a class=\"external\" href=\"file://www.cdc.gov/reproductivehealth/unintendedpregnancy/USMEC.htm\">",
"     US Medical Eligibility Criteria for Contraceptive Use",
"    </a>",
"    are available online and in the table (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33310319\">",
"    <span class=\"h4\">",
"     Other guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other national organizations have also published guidelines for contraceptive use in women with medical issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      United Kingdom Medical Eligibility Criteria (available at",
"      <a class=\"external\" href=\"file://www.fsrh.org/pdfs/UKMEC2009.pdf\">",
"       www.fsrh.org/pdfs/UKMEC2009.pdf",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Society of Family Planning (SFP) clinical guidelines for contraception in women with cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/34\">",
"       34",
"      </a>",
"      ]. These recommendations are similar to those published by the CDC, but they also recommend avoiding combined hormonal contraception in (1) women with active cancer or who have been treated for cancer within six months because they are at increased risk of venous thrombosis and (2) women who have a history of chest wall irradiation for cancer because they are at increased risk of developing breast cancer. They also suggest the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"       levonorgestrel",
"      </a>",
"      -releasing IUD for women with breast cancer treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3871489\">",
"    <span class=\"h4\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the absolute and relative contraindications to hormonal contraception listed in the WHO and CDC tables described above are discussed in detail in the following topics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/0/32777?source=see_link\">",
"       \"Counseling women considering combined hormonal contraception\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link\">",
"       \"Overview of the use of estrogen-progestin contraceptives\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/8/4233?source=see_link\">",
"       \"Contraception counseling for obese women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link\">",
"       \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/8/24713?source=see_link\">",
"       \"Postpartum and postabortion contraception\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26759?source=see_link\">",
"       \"Contraception for women with inherited thrombophilias\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27579201\">",
"    <span class=\"h3\">",
"     Estrogen-progestin versus progestin-only contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the estrogen and progestin components of combined contraceptives provide contraceptive actions, but the estrogen component also provides cycle control (ie, reduces the frequency and duration of scheduled and unscheduled bleeding), which is beneficial. Another benefit is that estrogen maintains or improves bone density [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Disadvantages of combined contraceptives include estrogen-related side effects (eg, nausea, breast tenderness, bloating, headache), estrogen related risks (eg, venous thromboembolism), and the number of medical contraindications to use of exogenous estrogen (see",
"    <a class=\"local\" href=\"#H3870905\">",
"     'Contraception for women with medical issues'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The various types of combined contraceptive products (pill, ring, patch) are similarly efficacious (",
"    <a class=\"graphic graphic_table graphicRef70218 \" href=\"mobipreview.htm?12/56/13197\">",
"     table 4",
"    </a>",
"    ). The side effect profiles differ and depend on the concentration of each hormone, the specific type of progestin, and local factors related to the application site (skin, vagina). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41127?source=see_link\">",
"     \"Transdermal contraceptive patch\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/54/33640?source=see_link\">",
"     \"Contraceptive vaginal ring\"",
"    </a>",
"    .) The pharmacokinetics vary by delivery system. Oral estrogen administration is subject to a first-pass effect and enterohepatic recirculation leading to peaks and troughs in serum estrogen concentrations, whereas the controlled release vaginal contraceptive ring and transdermal contraceptive patch are associated with relatively constant serum estrogen levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/37\">",
"     37",
"    </a>",
"    ]. Estrogen exposure is lowest with the vaginal ring and highest with the patch.",
"   </p>",
"   <p>",
"    A major advantage of progestin-only contraception is that it offers the option of long-term, &ldquo;forgettable&rdquo; contraception. All long-acting contraceptives are progestin-only (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    intrauterine system, depot",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    injections,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    implant). There are few contraindications to progestin use. WHO guidelines only list current breast cancer as a condition where the health risks of a progestin-only contraceptive are unacceptable. For several other conditions, the risks usually outweigh the benefits. These conditions include severe decompensated cirrhosis, liver tumor, past breast cancer, systemic lupus erythematosus with antiphospholipid antibodies, acute deep vein thrombosis or pulmonary embolism, breastfeeding during the first six weeks after delivery, ischemic heart disease, stroke, migraine with aura, and some other conditions where one progestin-only method may be safer than another such method.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31525262\">",
"    <span class=\"h3\">",
"     Return to fertility after discontinuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Return to fertility after discontinuation of contraception is an important advantage of reversible methods of contraception. Comprehensive reviews of studies that evaluated this issue found that in women who discontinue contraception in order to conceive, the pregnancy rate in the 12 months following discontinuation of oral contraceptives (cyclic combined or extended regimen) is similar to the pregnancy rate after discontinuation of other contraceptives, such as intrauterine devices, condoms, natural family planning, and progestin-only pills [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. For all of these methods, 70 to 95 percent of women trying to conceive became pregnant within 12 months. By comparison, the time to conception after discontinuing use of progestin-only implants and injections appears somewhat delayed; 70 to 80 percent of women conceived within 12 months of discontinuation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35252209\">",
"    <span class=\"h3\">",
"     Counseling and strategies to enhance compliance",
"    </span>",
"    &nbsp;&mdash;&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/0/32777?source=see_link&amp;anchor=H19#H19\">",
"     \"Counseling women considering combined hormonal contraception\", section on 'Strategies for enhancing compliance and continuation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Oral contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;OCs have several mechanisms of action. The most important action is",
"    <span class=\"nowrap\">",
"     estrogen/progestin-induced",
"    </span>",
"    inhibition of the midcycle surge of gonadotropin secretion, so that ovulation is suppressed. They also alter endometrial receptivity and inhibit the ability of sperm to access the upper genital tract. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the use of estrogen-progestin contraceptives\", section on 'Mechanisms of action'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h4\">",
"     Combined (estrogen-progestin) pills",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19642726\">",
"    <span class=\"h5\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined (estrogen-progestin) OCs are a reliable form of contraception (",
"    <a class=\"graphic graphic_table graphicRef70218 \" href=\"mobipreview.htm?12/56/13197\">",
"     table 4",
"    </a>",
"    ), which are available in several formulations (",
"    <a class=\"graphic graphic_table graphicRef69223 \" href=\"mobipreview.htm?10/59/11184\">",
"     table 19",
"    </a>",
"    ). There is no evidence that generic OCs are less effective than brand name OCs or that different OCs have different perfect use failure rates, although few comparative studies have been performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19642791\">",
"    <span class=\"h5\">",
"     Noncontraceptive benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined OCs have several noncontraceptive benefits, including reductions in dysmenorrhea, menorrhagia, acne, ovarian cancer, premenstrual dysphoric disorder, and, due to the progestin component, endometrial cancer. There is also a modest reduction in colorectal cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the use of estrogen-progestin contraceptives\", section on 'Noncontraceptive benefits'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h5\">",
"     Initiation and administration of combined OCs",
"    </span>",
"    &nbsp;&mdash;&nbsp;OCs can be started anytime during the cycle (",
"    <a class=\"graphic graphic_algorithm graphicRef56863 \" href=\"mobipreview.htm?17/45/18129\">",
"     algorithm 1",
"    </a>",
"    ). We prefer the",
"    <strong>",
"     Quick Start",
"    </strong>",
"    method in which the woman begins taking OCs on the day that she is given the prescription, as long as pregnancy is reasonably excluded (",
"    <a class=\"graphic graphic_table graphicRef67567 \" href=\"mobipreview.htm?9/23/9595\">",
"     table 20",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/43\">",
"     43",
"    </a>",
"    ]. An alternative is the",
"    <strong>",
"     Sunday Start",
"    </strong>",
"    approach where the woman starts the pill on the first Sunday after her period begins (because most pill packs are arranged for a Sunday start to avoid withdrawal bleeding on a weekend). Some form of back-up contraception is needed for the first seven days of use if one chooses the Quick or Sunday Start methods because the full contraceptive effect might not be provided immediately. The",
"    <strong>",
"     First Day Start",
"    </strong>",
"    requires that the woman begin the pill on the first day of menses, which provides the maximum contraceptive effect in the first cycle; back-up contraception for the first seven days of use is not needed. The disadvantages of the Sunday and First Day Start approaches are that some women don't get around to filling their prescriptions or become confused about instructions or pregnant before it is time to start the OC.",
"   </p>",
"   <p>",
"    OCs are given on a monthly or an extended cycle. An extended cycle regimen reduces the number of episodes of withdrawal bleeding per year, and can completely eliminate these episodes. The hormone free interval may be 0, 2, 4, or 7 days. Shortening the hormone free interval may reduce symptoms associated with hormone withdrawal (eg, headache, pelvic pain). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link&amp;anchor=H30#H30\">",
"     \"Overview of the use of estrogen-progestin contraceptives\", section on 'Continuous pill'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3832?source=see_link\">",
"     \"Hormonal contraception for suppression of menstruation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Contraceptive follow-up can be addressed during routine periodic exams scheduled for other health maintenance issues. A specific follow-up exam just to address contraception is not needed. Women should be encouraged to return if they have any concerns about their method or want to discontinue or switch methods. Continuation of the contraceptive method is enhanced if the patient receives a prescription, or even better, a supply for a full year of pills [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hormonal contraception can be continued until the age of menopause (age 51 to 55 years) in healthy nonsmoking women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/45\">",
"     45",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H12168953\">",
"     'Hormonal contraception'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h5\">",
"     Missed pills",
"    </span>",
"    &nbsp;&mdash;&nbsp;Missed pills (particularly if the seven-day hormone-free interval is extended on either end) are a common cause of contraceptive failure.",
"   </p>",
"   <p>",
"    If a single pill is missed anywhere in the packet, the forgotten pill needs to be taken when noticed and the next pill is taken when it is due, which may mean taking two pills on the same day. No additional contraception is required.",
"   </p>",
"   <p>",
"    Back-up contraception is generally needed if two or more consecutive pills are missed. Although WHO states that no back-up or emergency contraception is needed unless three or more 30 to 35 mcg ethinyl estradiol pills have been forgotten (or two or more 20 to 25 mcg pills) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/46\">",
"     46",
"    </a>",
"    ], other experts recommend back-up contraception after missing two pills of any dose of combined oral contraceptives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. We agree with the simpler recommendation that back-up contraception be used for seven days after two missed active hormonal pills, regardless of dose. In addition:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women should take one of the missed active (hormonal) pills as soon as possible and then continue taking one pill each day as prescribed. Depending on when she remembers her missed pill, she may take two pills on the same day.",
"     </li>",
"     <li>",
"      If the two or more pills are missed in the first week of the cycle and unprotected intercourse occurs during this week, use of emergency contraception could decrease the risk of pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Also, if",
"    <strong>",
"     seven or more",
"    </strong>",
"    pills are left in the pack after the last missed pill, she should finish the pack and have the usual seven day break. If",
"    <strong>",
"     less than seven",
"    </strong>",
"    pills are left in the pack after the missed pill, she should finish the pack and begin a new pack the next day (omit hormone free days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3818891\">",
"    <span class=\"h5\">",
"     Extra pills",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient takes two pills in one day by mistake, she should resume her normal schedule of taking one pill daily the next day; she should not skip a day. She will complete the pill pack one day early.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h5\">",
"     Risks and side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risks and side effects of OCs are influenced by the type, dose, and route of administration of estrogen, as well as the dose and type of the progestin. Lower estrogen dose OCs are associated with reduced risks of venous thromboembolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/50,51\">",
"     50,51",
"    </a>",
"    ] and bothersome estrogenic side effects, such as breast tenderness, nausea, and bloating [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/52\">",
"     52",
"    </a>",
"    ], compared with higher estrogen dose OCs. Very low-dose estrogen OCs (10 to 20 mcg) are associated with higher rates of bleeding pattern disruptions, which is a common reason for discontinuation of this method [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/53\">",
"     53",
"    </a>",
"    ]. Irrespective of the formulation used, the number of",
"    <span class=\"nowrap\">",
"     bleeding/spotting",
"    </span>",
"    days is highest in the first three months of use, and decreases thereafter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/10/22698?source=see_link&amp;anchor=H15719109#H15719109\">",
"     \"Management of unscheduled bleeding in women using contraception\", section on 'Estrogen-progestin contraceptives'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risks and side effects of estrogen-progestin OCs are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h4\">",
"     Progestin only pills",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progestin-only pills are an option for women who want a contraceptive pill, but need to avoid estrogen (",
"    <a class=\"graphic graphic_table graphicRef60293 \" href=\"mobipreview.htm?7/15/7419\">",
"     table 21",
"    </a>",
"    ). They are associated with more unscheduled (breakthrough) bleeding and slightly higher failure rates than combined OCs. Ovulation is suppressed in 57 percent of cycles compared with 95 to 99 percent of cycles with estrogen-progestin contraceptives; however, the mechanism of action relies mostly on thickening of cervical mucus, which inhibits sperm penetration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The \"minipill\" has a dose of progestin that is close to the threshold of contraceptive efficacy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/52/16199?source=see_link\">",
"     norethindrone",
"    </a>",
"    0.35 mg); therefore, these pills should be taken at the same time each day and are taken",
"    <strong>",
"     every",
"    </strong>",
"    day without a pill-free interval. Variation of only a few hours in administration can reduce contraceptive effectiveness so women should be prepared to use a back-up method not only if one pill is missed, but also if there is a greater than three-hour delay in taking the pill. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/52/9031?source=see_link\">",
"     \"Progestin-only pills (minipills) for contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Injectable contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only injectable contraceptive available in the US is depot",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (DMPA), although other injectables are available elsewhere (eg, estradiol cypionate-medroxyprogesterone acetate [Cyclofem], estradiol valerate-norethisterone enanthate [Mesigyna]).",
"   </p>",
"   <p>",
"    Injectable contraception is highly effective, reversible, and avoids the need for compliance daily or near the time of sexual intercourse. Progestin injections reduce the risk of endometrial cancer and the volume of menstrual bleeding (amenorrhea may occur).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h4\">",
"     Depot medroxyprogesterone acetate",
"    </span>",
"    &nbsp;&mdash;&nbsp;DMPA (150 mg) is given by deep intramuscular injection and results in effective contraception for three months. Theoretical exceeds actual effectiveness because some users do not return for their injections as scheduled (",
"    <a class=\"graphic graphic_table graphicRef70218 \" href=\"mobipreview.htm?12/56/13197\">",
"     table 4",
"    </a>",
"    ). A new lower-dose DMPA formulation (DMPA-SC, 104",
"    <span class=\"nowrap\">",
"     mg/0.65",
"    </span>",
"    mL), which is administered subcutaneously every three months is also available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/56\">",
"     56",
"    </a>",
"    ]. The new formulation provides slower and more sustained absorption of the progestin than conventional DMPA, which allows for a 30 percent lower dose of progestin, but with the same duration of effect as conventional DMPA. Administration via the subcutaneous route is less painful than intramuscular injection and potentially may allow patient self-administration. Intramuscular DMPA is available as a generic formulation, which is less costly than DMPA-SC. Otherwise, the risks and benefits are similar to those with intramuscular administration. Local reactions have been reported when DMPA is given subcutaneously.",
"   </p>",
"   <p>",
"    DMPA (or the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    -releasing intrauterine contraception) may be a particularly good choice in women in whom an estrogen-containing contraceptive is either contraindicated or causes additional health concerns. As an example, women who have exacerbations of migraine while taking a combination OC do not typically have problems with a progestin-containing contraceptive. In addition, women who take enzyme inducing anticonvulsant drugs (in whom the failure rate of OCs is increased) can safely use DMPA without affecting contraceptive effectiveness. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of the management of epilepsy in adults\", section on 'Oral contraceptive therapy'",
"    </a>",
"    .) DMPA is also a good choice for women with sickle cell anemia, fibroids, and older women who smoke (",
"    <a class=\"graphic graphic_table graphicRef60293 \" href=\"mobipreview.htm?7/15/7419\">",
"     table 21",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Noncontraceptive benefits of DMPA include a decreased risk of endometrial cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/58\">",
"     58",
"    </a>",
"    ] and of pelvic inflammatory disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/57\">",
"     57",
"    </a>",
"    ]. The latter also occurs in women who take an OC, and may be related to changes in cervical mucus, decreased menstrual blood flow, and a reduction in retrograde menstruation. This method of contraception is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/45/34522?source=see_link\">",
"     \"Depot medroxyprogesterone acetate for contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Contraceptive implants",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of contraceptive implants are available worldwide, but all implants are not widely available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H655813722\">",
"    <span class=\"h4\">",
"     Etonogestrel implant",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single-rod progestin implant (Implanon&reg;, Nexplanon&reg;) provides contraception for three years by slow release of 68 mg of the progestin",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    . Training sponsored by the manufacturer is required before the practitioner can purchase and insert the implant. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/27/3512?source=see_link\">",
"     \"Etonogestrel contraceptive implant\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Irregular bleeding was the primary reason for discontinuation in premarketing studies, and accounted for 19 percent of discontinuations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H655813729\">",
"    <span class=\"h4\">",
"     Levonorgestrel implants",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17361816\">",
"    <span class=\"h5\">",
"     Jadelle",
"    </span>",
"    &nbsp;&mdash;&nbsp;A two-rod subdermal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    implant (Jadelle&reg;) was approved by the FDA for five years of use, although it has not been marketed in the United States. It is available in most other countries. The cumulative pregnancy rate in clinical trials was 0.3 at three years and 1.1 percent at five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/60\">",
"     60",
"    </a>",
"    ], which is a lower failure rate than that of OCs and most IUCs, and comparable to that of surgical sterilization. Efficacy may be reduced slightly as body weight increases. In a multicenter study, there were no pregnancies in women weighing less than 50 kg or with levonorgestrel serum concentrations greater than 180",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/61\">",
"     61",
"    </a>",
"    ]. The major side effect is irregular bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/62\">",
"     62",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Each rod is 0.25 cm in diameter, 4.3 cm long, and contains 75 mg of levonorgestrel. Under local anesthesia, a #10 trocar is used to place the rods in a V configuration subdermally at the inner part of the nondominant upper arm (mean procedure time two minutes). The progestin is released at 80 mcg per day in the first month, gradually decreasing to 50 mcg day by nine months, and then falling to 25 to 30 mcg per day thereafter. Removal is performed under local anesthesia by grasping the ends of the rods through a 3 to 4 mm incision at the apex of the V (mean time five minutes).",
"    <br/>",
"    <br/>",
"    Amenorrhea occurs, but is much less common than with depot",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (DMPA) injections. A systematic review determined the weighted prevalence of amenorrhea over successive 90 day periods was 11, 13, 9 and 13 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/63\">",
"     63",
"    </a>",
"    ]. By comparison, approximately 50 percent of DMPA users are amenorrheic after one year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H655813736\">",
"    <span class=\"h5\">",
"     Sino-implant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sino-implant (II) is a two rod contraceptive implant; each rod contains 75 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    . The main difference from Jadelle is that it can be left in place for up to four years (Jadelle can be left in place for up to five years). Four randomized trials with a total of 15,943 women assigned to Sino-implant (II) had first-year probabilities of pregnancy ranging from 0 to 0.1 percent and cumulative probabilities of pregnancy were 0.9 and 1.06 percent in the two trials that presented data for four-year use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Transdermal contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;A transdermal contraceptive patch (Ortho Evra) is another option for providing hormonal contraception. The transdermal drug delivery provides continuous sustained release of hormonal contraception over several days, thereby avoiding peak and trough hormone levels and the need for daily patient action [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/65\">",
"     65",
"    </a>",
"    ]. The Ortho Evra patch delivers 20 mcg of ethinyl estradiol and 150 mcg of norelgestromin daily; a new patch is applied weekly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41127?source=see_link\">",
"     \"Transdermal contraceptive patch\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefits, risks, and contraindications to use of the patch are similar to those with combined OCs, except the patch may be associated with more estrogen-related adverse events, including venous thromboembolism (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41127?source=see_link&amp;anchor=H16#H16\">",
"     \"Transdermal contraceptive patch\", section on 'Major adverse events'",
"    </a>",
"    ), and has the benefit of convenience of weekly administration. This convenience generally appears to improve compliance, thus increasing the cost-effectiveness of the patch compared to daily OCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/67\">",
"     67",
"    </a>",
"    ], although a few studies have reported low continuation and effectiveness rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/68\">",
"     68",
"    </a>",
"    ]. In addition, the patch appears to suppress ovulation better than OCs when a dose is missed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/69\">",
"     69",
"    </a>",
"    ]. The patch carries a precaution regarding increased risk of failure in heavier women, specifically those who weigh more than 90 kg. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/8/4233?source=see_link\">",
"     \"Contraception counseling for obese women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Only one trial comparing the patch to the ring has been performed; it was sponsored by the manufacturer of the ring. Five hundred women who had previously used OCs and were satisfied with OC use were randomly assigned to use the contraceptive ring or the contraceptive patch [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/70\">",
"     70",
"    </a>",
"    ]. After the study, ring users generally expressed a preference for the ring over OCs, but patch users preferred OCs to the patch. When the study was over, 21.6 percent of ring users and 41.6 percent of patch users resumed using OCs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Contraceptive vaginal ring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraceptive vaginal rings are based on the principle that the vaginal epithelium can absorb steroids and steroids can be released from a silicone elastomer into the vagina at a constant rate. Avoiding gastrointestinal absorption and hepatic first pass metabolism allows use of lower hormone doses to achieve contraceptive effects. However, the effects of combined hormonal contraceptives on clotting factors, markers of coagulation and fibrinolysis, and lipids are largely independent of the route of administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/71-73\">",
"     71-73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contraceptive vaginal rings are as effective as OCs, and have several advantages: once per month dosing, they do not need to be fitted, and they can be placed anywhere in the vagina [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/74,75\">",
"     74,75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1598978121\">",
"    <span class=\"h4\">",
"     Estrogen-progestin contraceptive ring",
"    </span>",
"    &nbsp;&mdash;&nbsp;An estrogen-progestin contraceptive ring (NuvaRing, which delivers 15 mcg ethinyl estradiol and 120 mcg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    daily) is worn intravaginally for three weeks of each four-week cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/76\">",
"     76",
"    </a>",
"    ]. Advantages of this method include rapid return to ovulation after discontinuation, lower doses of hormones, ease and convenience, and improved cycle control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. The device comes in one size and does not need to be fitted.",
"   </p>",
"   <p>",
"    A systematic review of randomized trials comparing the contraceptive vaginal ring to oral contraceptive pills found that systemic exposure to ethinyl estradiol with the ring was half that of 30-mcg ethinyl estradiol containing pills, with less variation in serum levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/79\">",
"     79",
"    </a>",
"    ]. The two methods were equally effective contraceptives. Mean blood pressure and body weight did not change with either agent and the incidence of side effects (breast tenderness, headache, nausea) was comparable for both groups. Patients were generally satisfied with both methods, although a higher incidence of local and ring-related side effects (eg, vaginal discharge) led to a higher discontinuation rate in the ring group.",
"   </p>",
"   <p>",
"    Benefits, risks, and contraindications to use are similar to those with combined oral contraceptive pills, except for the convenience of monthly administration. The ring is made of plastic, not latex. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of the contraceptive vaginal ring is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/54/33640?source=see_link\">",
"     \"Contraceptive vaginal ring\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1598978136\">",
"    <span class=\"h4\">",
"     Progesterone contraceptive ring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Progering is a progesterone-releasing vaginal ring for nursing women. It is available in parts of South America. Each ring releases 10 mg of progesterone daily and lasts for four months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/80\">",
"     80",
"    </a>",
"    ], although it is approved for only three months of use. A ring that releases a synthetic progestin (Nesterone) is under development.",
"   </p>",
"   <p>",
"    Progesterone-only rings function primarily by thickening cervical mucus to prevent sperm penetration, but also inhibit ovulation and endometrial receptivity. Progesterone-only rings may be less effective over the long-term than rings containing both a progestin and an estrogen, but are still highly effective among breastfeeding women since breastfeeding provides some protection from pregnancy. Unscheduled bleeding, which is a common side effect of all progestin-only methods, is less likely to occur in breastfeeding women because of prolonged lactational amenorrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The progesterone vaginal ring contains 22.5 percent progesterone dispersed in silicone. The system delivers 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of the physiological hormone progesterone, but due to its homogeneous design, serum levels decline during its three-month duration of use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/54/33640?source=see_link&amp;anchor=H28792062#H28792062\">",
"     \"Contraceptive vaginal ring\", section on 'Progesterone-releasing vaginal ring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H880828\">",
"    <span class=\"h3\">",
"     Levonorgestrel-releasing intrauterine contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;(See",
"    <a class=\"local\" href=\"#H12170533\">",
"     'Intrauterine contraception'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12170533\">",
"    <span class=\"h2\">",
"     Intrauterine contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several terms are used to describe intrauterine contraception, including intrauterine device (IUD) and intrauterine contraceptive (IUC); the progestin-containing device is also referred to as an intrauterine system (IUS). In this topic, we use the term IUD for all types of intrauterine contraception.",
"   </p>",
"   <p>",
"    Intrauterine contraceptives are safe and effective methods of contraception (",
"    <a class=\"graphic graphic_table graphicRef70218 \" href=\"mobipreview.htm?12/56/13197\">",
"     table 4",
"    </a>",
"    ). Currently available IUDs release either copper or a synthetic progestin:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Copper",
"      </strong>",
"      <strong>",
"       IUDs",
"      </strong>",
"      release copper continuously into the uterine cavity; this interferes with sperm transport and prevents fertilization of ova [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/83\">",
"       83",
"      </a>",
"      ]. It is theoretically possible that an additional mechanism is prevention of implantation. One copper IUD (TCu380A) remains effective for at least 10 years.",
"     </li>",
"     <li>",
"      <strong>",
"       Progestin-releasing IUDs",
"      </strong>",
"      inhibit sperm transport and fertilization of ova, and partially inhibit ovulation. It is theoretically possible that an additional mechanism is prevention of implantation. The higher dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"       levonorgestrel",
"      </a>",
"      -releasing IUD (52 mg, initial release rate 20",
"      <span class=\"nowrap\">",
"       mcg/day)",
"      </span>",
"      remains effective for at least five years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/84\">",
"       84",
"      </a>",
"      ]. A lower dose levonorgestrel-releasing IUD (13.5 mg, initial release rate 14",
"      <span class=\"nowrap\">",
"       mcg/day)",
"      </span>",
"      remains effective for at least three years, thus it may be more appropriate for women planning pregnancy in less than five years. It has a smaller size and insertion tube diameter than the higher dose device, which may make it easier to insert in nulliparous women.",
"      <br/>",
"      <br/>",
"      Noncontraceptive benefits include a decrease in menstrual blood loss (amenorrhea is common) and relief of dysmenorrhea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/85\">",
"       85",
"      </a>",
"      ]; thus, they can be particularly useful in women with bleeding diatheses (",
"      <a class=\"graphic graphic_table graphicRef60293 \" href=\"mobipreview.htm?7/15/7419\">",
"       table 21",
"      </a>",
"      ), but not for those who dislike not having regular menstrual cycles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Current IUDs are not associated with the same problems (eg, high rate of expulsion, increased risk of pelvic inflammatory disease) that caused previous IUDs (eg, Dalkon shield) to acquire a poor reputation among many women. Women who are at low risk for sexually transmitted diseases do",
"    <strong>",
"     not",
"    </strong>",
"    have a higher incidence of pelvic inflammatory disease with use of an IUD and well-designed studies have found that IUDs do",
"    <strong>",
"     not",
"    </strong>",
"    have adverse effects upon fertility after removal. Consequently, the copper IUD revised its package label (September 2005) to remove the prior section on \"recommended patient profile\" that included multiparity, mutually monogamous relationship and history of PID. A detailed discussion of the IUD can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32058?source=see_link\">",
"     \"Overview of intrauterine contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The copper and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    -releasing IUDs decrease the overall risk of ectopic pregnancy compared with women who do not use contraceptives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. When pregnancy does occur, the site of pregnancy should be immediately determined because the risk of ectopic pregnancy is increased (",
"    <a class=\"graphic graphic_table graphicRef75321 \" href=\"mobipreview.htm?16/32/16907\">",
"     table 22",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12170555\">",
"    <span class=\"h2\">",
"     Fertility awareness based methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fertility awareness-based, or natural, methods are alternative methods of family planning for women who prefer a nonhormonal, nonsurgical form of contraception for health or personal reasons. These methods include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Standard days method",
"     </li>",
"     <li>",
"      Ovulation method",
"     </li>",
"     <li>",
"      TwoDay method",
"     </li>",
"     <li>",
"      Symptothermal methods",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The calendar rhythm and basal body temperature methods are no longer recommended. Fertility awareness-based methods of contraception are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/58/37800?source=see_link\">",
"     \"Fertility awareness-based methods of pregnancy prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Barrier methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Barrier methods of contraception have fewer side effects than hormonal contraception. Condoms (male and female), diaphragm, cervical cap, and contraceptive sponge are the most common forms of barrier contraception. Neither condoms nor the contraceptive sponge require a prescription. If a double barrier method is used (eg, condom and vaginal spermicide, diaphragm and condom), efficacy increases substantially [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/89\">",
"     89",
"    </a>",
"    ]. A male or female condom should only be used once and then discarded immediately.",
"   </p>",
"   <p>",
"    The two medical contraindications to use of barrier methods of contraception are (1) latex allergy for methods made of latex and (2) high risk of transmission of a sexually transmitted infection for methods other than male or female condoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Condom",
"    </span>",
"    &nbsp;&mdash;&nbsp;The theoretical and actual effectiveness of condoms is higher than for the other barrier contraceptives, although the actual effectiveness of all barrier methods of contraception is highly user-dependent (",
"    <a class=\"graphic graphic_table graphicRef70218 \" href=\"mobipreview.htm?12/56/13197\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef57795 \" href=\"mobipreview.htm?31/46/32488\">",
"     figure 2",
"    </a>",
"    ). The condom is indicated for preventing pregnancy,",
"    <span class=\"nowrap\">",
"     HIV/AIDS,",
"    </span>",
"    and other sexually transmitted infections.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Female condom",
"      </strong>",
"      <strong>",
"       &mdash;",
"      </strong>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5334?source=see_link\">",
"       \"Female condoms\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Male condom",
"      </strong>",
"      &mdash; (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30696?source=see_link\">",
"       \"Male condoms\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Diaphragm and cervical cap",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diaphragms and cervical caps provide a barrier between sperm and the cervical canal and serve as a reservoir for spermicide. They require fitting by a trained clinician and are only effective when used with a spermicide since the barrier is not secure (see",
"    <a class=\"local\" href=\"#H43\">",
"     'Spermicides'",
"    </a>",
"    below). They must be left in the vagina for six to eight hours after intercourse; the diaphragm needs to be removed after this period of time, while the cervical cap can be left in place for up to 48 hours. These considerations have caused them to be less desirable methods of contraception for many women. In the National Survey of Family Growth, only 0.4 percent of women ages 15 to 44 were using diaphragm as their method [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/90\">",
"     90",
"    </a>",
"    ]. In addition, using a diaphragm can increase the risk of urinary tract infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/38/20070?source=see_link\">",
"     \"Barrier contraception: Diaphragm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The only cervical cap available in the United States is made of silicone rubber (FemCap). It has a strap to facilitate removal and comes in three sizes, the appropriate size is based on the patient&rsquo;s obstetric history. It does not require a custom fitting, but can only be purchased with a prescription. In randomized trials, the FemCap was less effective in preventing pregnancy than the diaphragm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/91\">",
"     91",
"    </a>",
"    ]. However, these trials were performed with the first generation FemCap, which was not approved by the FDA; a second generation device has been approved by the FDA and is available for use in the United States and Europe.",
"   </p>",
"   <p>",
"    Diaphragms and cervical caps are not recommended as the only method of contraception for women at high risk for acquiring HIV, who are HIV infected, or who have AIDS, as these methods do not appear to prevent transmission of the virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/92\">",
"     92",
"    </a>",
"    ]. A trial is underway to determine whether diaphragms decrease the risk of male to female HIV transmission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Sponge",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only manufacturer of contraceptive sponges in the United States discontinued production in 1995, but in 2005 production was resumed. The Today sponge is a 2-inch wide circular disk,",
"    <span class=\"nowrap\">",
"     3/4",
"    </span>",
"    of an inch thick, containing 1000 mg of nonoxynol-9 and attached to a loop for removal. It is moistened with tap water before insertion deep in the vagina.",
"   </p>",
"   <p>",
"    The sponge does not require fitting or a prescription and can be left in place and used repeatedly for up to 24 hours. When compared to the diaphragm, the sponge was less effective and had a higher discontinuation rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/93\">",
"     93",
"    </a>",
"    ]. Both the contraceptive sponge and diaphragm may be linked to an increased risk of nonmenstrual toxic shock syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Emergency contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;All couples using a barrier contraceptive (eg, condom, diaphragm, cervical cap), as well as women using hormonal methods, should be informed about the use and nonprescription availability of emergency contraception for the female partner. Emergency contraception is indicated if there is failure of the barrier contraceptive method (broken condom, failure to use, etc). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/5/31833?source=see_link\">",
"     \"Emergency contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Withdrawal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The withdrawal method (coitus interruptus) requires men to withdraw from the vagina before ejaculation. Failure occurs if withdrawal is not timed accurately or if the preejaculatory fluid contains sperm. Failure rates as high as 18 to 20 percent have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Lactation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who breastfeed have a delay in resumption of ovulation postpartum due to prolactin-induced inhibition of pulsatile gonadotropin-releasing hormone release from the hypothalamus. While breastfeeding is associated with subfertility, it only can be relied upon to prevent pregnancy when specific conditions are met:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The woman is less than six months postpartum",
"     </li>",
"     <li>",
"      She is breastfeeding exclusively (ie, not providing food or other liquid to the infant)",
"     </li>",
"     <li>",
"      She is amenorrheic",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If these conditions are not met, the risk of unintended pregnancy while breastfeeding is high [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/96\">",
"     96",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/8/24713?source=see_link\">",
"     \"Postpartum and postabortion contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h4\">",
"     Contraceptive choices during lactation",
"    </span>",
"    &nbsp;&mdash;&nbsp;WHO and the American College of Obstetricians and Gynecologists (ACOG) have made recommendations for nonhormonal and hormonal contraception during lactation. This topic is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/1/32794?source=see_link&amp;anchor=H20#H20\">",
"     \"Principles of medication use during lactation\", section on 'Contraception'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Spermicides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spermicides are among the least effective methods of contraception (",
"    <a class=\"graphic graphic_figure graphicRef57795 \" href=\"mobipreview.htm?31/46/32488\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef70218 \" href=\"mobipreview.htm?12/56/13197\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/97\">",
"     97",
"    </a>",
"    ]. Spermicides containing nonoxynol-9 are available without a prescription and in a variety of forms including gel, foam, cream, film, suppository, and tablet. They are not a highly effective method of contraception when used alone (without a barrier method). This was illustrated in a trial which randomly assigned 1536 women willingly to accept a moderate risk of pregnancy to use of one of five spermicides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/98\">",
"     98",
"    </a>",
"    ]. The probability of pregnancy for each nonoxynol-9 preparation during six months of typical use was: 52.5 mg gel (22 percent), 100 mg gel (16 percent), 150 mg gel (14 percent), film (12 percent), suppository (10 percent). Although the risk of pregnancy was significantly higher with the 52.5 mg gel, none of the preparations reliably prevented pregnancy.",
"   </p>",
"   <p>",
"    Effectiveness is reduced if the patient does not wait long enough for the spermicide to disperse before having intercourse, if intercourse is delayed for more than one hour after administration, or if a repeat dose is not applied before each additional act of intercourse.",
"   </p>",
"   <p>",
"    Nonoxynol-9 preparations do not appear to significantly disturb the vaginal flora ecosystem, although a small increase in bacterial vaginosis associated flora has been observed in the highest quartile of users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Local irritation is not uncommon with spermicide use, and these agents tend to be messy.",
"   </p>",
"   <p>",
"    A meta-analysis concluded that maternal use of spermicides is not associated with adverse fetal outcomes, including congenital malformations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/100\">",
"     100",
"    </a>",
"    ]. A subsequent analysis of data from the National Birth Defects Prevention Study did not find significant associations between reported first trimester spermicide use and any birth defect, except perimembranous ventricular septal defects, which the authors noted may be a chance finding due to multiple comparisons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h4\">",
"     Lack of protection against STDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;It was thought that much of the protective effect of barrier methods such as the diaphragm, sponge, and cervical cap in preventing the spread of infection was due to the concomitant use of spermicides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/102-106\">",
"     102-106",
"    </a>",
"    ]. To provide data on this issue, a study was designed to maximize the potential for nonoxynol-9 gel to effectively prevent sexually transmitted infections by using a moderate dose of the gel (to avoid excess irritation that may promote infection), a true control group (no treatment), in a population of women that engaged in sexual intercourse with moderate frequency and with a high retention rate (&gt;90 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/107\">",
"     107",
"    </a>",
"    ]. Despite this optimal study design, there was no difference in the combined endpoint of gonococcal or chlamydial infection among the women randomly assigned to nonoxynol-9 plus condom use compared with condom use alone. Spermicides do not appear to protect against the spread of HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/106,108-110\">",
"     106,108-110",
"    </a>",
"    ], and may cause vaginal irritation thereby increasing susceptibility to HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/106,111\">",
"     106,111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spermicides are",
"    <strong>",
"     not",
"    </strong>",
"    recommended for the purpose of preventing the spread of sexually transmitted infections. These agents should not be used by women at high risk for HIV or women who are infected with HIV or have AIDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    New types of spermicides are being evaluated in phase III clinical trials and may be more effective in providing some protection against STDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2868648541\">",
"    <span class=\"h3\">",
"     Chemical methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sclerosing chemicals have been used to occlude the fallopian tubes, but are not popular because they require more than one application and because of safety concerns if the chemicals spill into the peritoneal cavity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h4\">",
"     Quinacrine sterilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quinacrine-induced tubal sclerosis is an alternative method of tubal sterilization which does not require surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/114,115\">",
"     114,115",
"    </a>",
"    ]. It has not been assessed by the Food and Drug Administration for use in the United States, but is widely used in developing countries because of its low cost and ease of use. Contraceptive effectiveness is lower than with other sterilization techniques (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/113\">",
"     113",
"    </a>",
"    ]. Over 100,000 procedures have been performed in over 30 countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The method involves transcervical insertion of seven 36 mg quinacrine pellets (252 mg total) into the uterine cavity on two occasions one month apart under hysteroscopic guidance and using a modified IUC insertion device. Histopathological studies in prehysterectomy volunteers showed that tubal occlusion occurred as a result of inflammation leading to fibrosis, which was limited to the cornual area and the intramural portion of fallopian tubes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/117\">",
"     117",
"    </a>",
"    ]. Endometrial changes included atrophy, polypoid reactions, and fine adhesions; long-term effects on the endometrium are not well-described, but available data are reassuring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/118-120\">",
"     118-120",
"    </a>",
"    ]. Cumulative pregnancy rates at one, 5, and 10 years postprocedure range from 0.3 to 3.3 percent, 1.1 to 10 percent, and 4.3 to 12.1 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disadvantages of the technique include the need for multiple applications and the lack of a reliable method for confirming tubal occlusion. Hysterosalpingography is not recommended because pressure from the dye may force open the scarred tube and allow recanalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/122\">",
"     122",
"    </a>",
"    ]. Although quinacrine appeared to be carcinogenic in rodents at doses higher than those used for human sterilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/123\">",
"     123",
"    </a>",
"    ], there is no evidence of an increased risk of cancer in human studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/120,124\">",
"     120,124",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h3\">",
"     Vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraceptive vaccines are under investigation; none are clinically available. These vaccines either target gamete production [luteinizing hormone-releasing hormone",
"    <span class=\"nowrap\">",
"     (LHRH)/GnRH,",
"    </span>",
"    FSH], gamete function [sperm antigens and oocyte zona pellucida (ZP)], or gamete outcome (HCG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18825998\">",
"    <span class=\"h3\">",
"     Intermittent hormonal contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is currently no hormonal contraceptive method approved for use only at the time of intercourse. A systematic review of mostly prospective observational studies of pericoital use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    as a method of contraception in women having infrequent intercourse found that it was moderately efficacious and safe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/126\">",
"     126",
"    </a>",
"    ]. A commonly used regimen was 0.75 mg of levonorgestrel within one hour after coitus and a repeat dose if additional intercourse occurred more than three hours later. For this dose, the pooled Pearl index was 5.1 pregnancies per 100 woman-years (95% CI 3.8-6.7), but ranged from 0 to 45.2. Limiting the analysis to three high quality WHO sponsored studies yielded a Pearl index of 8.9 pregnancies per 100 women years (95% CI 5.1-14.4). By comparison, for sexually active women using no contraception, the estimated Pearl index is approximately 85 pregnancies per 100 women years. The studies were generally of low quality and further research is needed before this approach can be recommended as a novel contraceptive method.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H878600\">",
"    <span class=\"h1\">",
"     EMERGENCY CONTRACEPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergency (postcoital) contraception is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/5/31833?source=see_link\">",
"     \"Emergency contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H878176\">",
"    <span class=\"h1\">",
"     CONTRACEPTION FOR MEN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H878393\">",
"    <span class=\"h2\">",
"     Condoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The condom is the only reversible method of contraception available to men. It prevents pregnancy in the female partner and provides protection from acquisition and transmission of sexually transmitted infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30696?source=see_link\">",
"     \"Male condoms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H878447\">",
"    <span class=\"h2\">",
"     Vasectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasectomy (ligation of the vas deferens) can be performed in a physician's office under local anesthesia. It is a safe, highly effective sterilization procedure. Although men should be counseled before vasectomy that the procedure is permanent, the procedure can often be reversed with a return of fertility. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39893?source=see_link\">",
"     \"Overview of vasectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H878534\">",
"    <span class=\"h2\">",
"     Future directions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H878371\">",
"    <span class=\"h3\">",
"     Hormonal methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;No male hormonal contraceptives are available for clinical use, although scientists have been attempting to develop them for many years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/127\">",
"     127",
"    </a>",
"    ]. The current approach to male hormonal contraception is based on the ability of exogenously administered sex steroids to suppress pituitary secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH): spermatogenesis is inhibited when the concentrations of these hormones are low. Endogenous testosterone production is also suppressed, so all of these regimens involve administration of exogenous testosterone. A variety of androgen preparations are available; most involve injections or implants, but a transdermal gel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/128\">",
"     128",
"    </a>",
"    ], a potent synthetic androgen (7a-methyl-19-nortestosterone [MENT]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/129,130\">",
"     129,130",
"    </a>",
"    ], and an oral formulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/131\">",
"     131",
"    </a>",
"    ] are being investigated and appear promising.",
"   </p>",
"   <p>",
"    Since testosterone alone does not completely suppress spermatogenesis in all men, most approaches to male hormonal contraceptive involve a combination regimen, such as testosterone and a progestin or testosterone and a GnRH analog, which synergistically suppress gonadotropins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/128,132,133\">",
"     128,132,133",
"    </a>",
"    ]. Combined regimens also enable use of lower doses of testosterone, although androgen exposure is still above physiologic levels. The testosterone-progestin regimen parallels the estrogen-progestin regimen that inhibits ovulation in hormonal contraceptives for women.",
"   </p>",
"   <p>",
"    In addition to problems with variable suppression of spermatogenesis, efforts to develop an acceptable male hormonal contraceptive regimen have also been hampered by the lack of long-acting, effective oral and transdermal testosterone preparations and undesirable side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/134\">",
"     134",
"    </a>",
"    ]. The current transdermal testosterone patch has not resulted in reliable sperm suppression, presumably due to suboptimal serum testosterone concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/24/39306/abstract/135\">",
"     135",
"    </a>",
"    ]. There is a theoretical concern that long-term administration of supraphysiological quantities of testosterone might increase the risk of prostate disease.",
"   </p>",
"   <p>",
"    An additional practical limitation of the use of male hormonal contraception is that it takes a few months to significantly reduce sperm counts, thus there is a considerable delay before the contraceptive becomes effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H878557\">",
"    <span class=\"h3\">",
"     Vas injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vas occlusion methods, such as injectable silicone plugs, block the vas deferens without disrupting it, making reversal easier. Reversible Inhibition of Sperm Under Guidance (RISUG) is another approach in which the vas is injected with a polymer gel that kills sperm. If reversal is desired, the polymer can be flushed out with an injection of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/22/33123?source=see_link\">",
"     dimethyl sulfoxide",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/56/14211?source=see_link\">",
"       \"Patient information: Choosing birth control (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/25/36242?source=see_link\">",
"       \"Patient information: Vasectomy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/60/9157?source=see_link\">",
"       \"Patient information: Birth control; which method is right for me? (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/2/29730?source=see_link\">",
"       \"Patient information: Vasectomy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Choosing a contraceptive depends upon a number of factors, including efficacy, reversibility, convenience, cost, availability (prescription versus nonprescription), and side effects. Thus, each patient's choice of contraceptive method should reflect her opinion of the utility of each of these variables and where she is willing to make tradeoffs between desirable and undesirable features of each method. Women should be counseled about the difference in typical use effectiveness between the methods, and should be counseled to consider a highly effective method such as one of the long-acting reversible contraceptives (LARCs) methods. Some generalizations can be made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In addition to any method of contraception, we recommend use of condoms for individuals at risk of sexually transmitted infections (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30696?source=see_link&amp;anchor=H8#H8\">",
"       \"Male condoms\", section on 'Protection from STIs'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5334?source=see_link&amp;anchor=H5#H5\">",
"       \"Female condoms\", section on 'Sexually transmitted infections'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For couples who desire permanent contraception (sterilization), we suggest vasectomy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Vasectomy is as effective, but less morbid and costly than tubal occlusion. (See",
"      <a class=\"local\" href=\"#H12169159\">",
"       'Sterilization'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12169534\">",
"       'Cost'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For women desiring tubal occlusion, hysteroscopic tubal occlusion does not require an incision and is usually performed using a local anesthetic, as opposed to laparoscopic tubal occlusion (eg, cautery, banding or clips), which often requires general or neuraxial anesthesia. However, at this time the laparoscopic approach is more widely available and most surgeons are experienced and facile with this technique. Women who request sterilization should be counseled about availability of IUC as a long-term method that rivals sterilization in terms of efficacy, but is non-surgical and reversible. (See",
"      <a class=\"local\" href=\"#H12169159\">",
"       'Sterilization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who desire reversible contraception, we suggest intrauterine contraception, or implants, given they are associated with pregnancy rates comparable to permanent methods and they are more convenient than combined estrogen-progestin methods (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Combined estrogen-progesterone hormonal methods (pills, patch, vaginal ring) are rapidly reversible, but less effective than the methods described above (although still highly effective when used properly). Hormone-related side effects are common. Convenience depends upon the specific method and varies from daily administration (oral contraceptive pills, standard or extended cycle), to weekly (patch), to monthly (vaginal ring). Patients should not use these methods if they have a contraindication to taking estrogen preparations. In particular, patch users may be at higher risk of thrombosis than pill users. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Oral contraceptives'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diaphragm and male condom are less effective and less convenient than hormonal methods. However, they are the most readily reversible methods and not associated with systemic side effects (except for individuals who are sensitive to latex products). Diaphragms are most effective when used with a spermicide. They are not recommended as the primary method for women with serious medical conditions in whom pregnancy is life-threatening. These women require use of the most effective methods of contraception. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Barrier methods'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women using a barrier contraceptive (eg, condom, diaphragm, cervical cap) or who are at risk for pregnancy should be informed about use of emergency contraception in case of failure of the barrier contraceptive method (broken condom, failure to use, etc). Women prescribed hormonal contraceptives should also be informed about use of emergency contraception since they may miss doses of their contraceptives and be at risk for unintended pregnancies. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Emergency contraception'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Progestin-only pills are an option for women who want a contraceptive pill, but need to avoid estrogen (",
"      <a class=\"graphic graphic_table graphicRef60293 \" href=\"mobipreview.htm?7/15/7419\">",
"       table 21",
"      </a>",
"      ). They are associated with more unscheduled bleeding and require a stricter schedule for perfect adherence (to be taken at the same time each day). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Progestin only pills'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/1\">",
"      Alkema L, Kantorova V, Menozzi C, et al. National, regional, and global rates and trends in contraceptive prevalence and unmet need for family planning between 1990 and 2015: a systematic and comprehensive analysis. Lancet 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/2\">",
"      Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception 2011; 84:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/3\">",
"      Kost K, Singh S, Vaughan B, et al. Estimates of contraceptive failure from the 2002 National Survey of Family Growth. Contraception 2008; 77:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/4\">",
"      Trussell J, Wynn LL. Reducing unintended pregnancy in the United States. Contraception 2008; 77:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/5\">",
"      Peipert JF, Madden T, Allsworth JE, Secura GM. Preventing unintended pregnancies by providing no-cost contraception. Obstet Gynecol 2012; 120:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/6\">",
"      Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long-acting reversible contraception. N Engl J Med 2012; 366:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/7\">",
"      Nettleman MD, Chung H, Brewer J, et al. Reasons for unprotected intercourse: analysis of the PRAMS survey. Contraception 2007; 75:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/8\">",
"      Halpern V, Grimes DA, Lopez L, Gallo MF. Strategies to improve adherence and acceptability of hormonal methods for contraception. Cochrane Database Syst Rev 2006; :CD004317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/9\">",
"      Trussell J, Hatcher RA, Cates W Jr, et al. A guide to interpreting contraceptive efficacy studies. Obstet Gynecol 1990; 76:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/10\">",
"      Steiner MJ. Contraceptive effectiveness: what should the counseling message be? JAMA 1999; 282:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/11\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 121: Long-acting reversible contraception: Implants and intrauterine devices. Obstet Gynecol 2011; 118:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/12\">",
"      Peipert JF, Zhao Q, Allsworth JE, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol 2011; 117:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/13\">",
"      Trussell J, Lalla AM, Doan QV, et al. Cost effectiveness of contraceptives in the United States. Contraception 2009; 79:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/14\">",
"      Jones J, Mosher W, Daniels K. Current Contraceptive Use in the United States, 2006&ndash;2010, and Changes in Patterns of Use Since 1995. Natl Health Stat Report 2012; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/15\">",
"      Moreau C, Cleland K, Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception 2007; 76:267.",
"     </a>",
"    </li>",
"    <li>",
"     Trussell J. Contraceptive efficacy. In: Contraceptive Technology, 19th, Hatcher, RA, Trussell, et al.  (Eds), Ardent Media, New York 2007. p.759.",
"    </li>",
"    <li>",
"     Australasian Menopause Society. Contraception for women approaching menopause. file://www.menopause.org.au/consumers/information-sheets/24 (Accessed on November 14, 2011).",
"    </li>",
"    <li>",
"     file://www.patient.co.uk/doctor/Contraception-and-the-Mature-Woman.htm (Accessed on November 14, 2011).",
"    </li>",
"    <li>",
"     Abma, JC, Chandra, A, Mosher, WD, et al and the National Center for Health Statistics. Fertility, family planning, and women's health: new data from the 1995 Survey of Family Growth. Vital Statistics; Series 23 No.19.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/20\">",
"      Peterson HB, Hulka JF, Phillips JM, Surrey MW. Laparoscopic sterilization. American Association of Gynecologic Laparoscopists 1991 membership survey. J Reprod Med 1993; 38:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/21\">",
"      Peterson HB, Xia Z, Hughes JM, et al. The risk of ectopic pregnancy after tubal sterilization. U.S. Collaborative Review of Sterilization Working Group. N Engl J Med 1997; 336:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/22\">",
"      Siegler AM, Hulka J, Peretz A. Reversibility of female sterilization. Fertil Steril 1985; 43:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/23\">",
"      Wilcox LS, Chu SY, Eaker ED, et al. Risk factors for regret after tubal sterilization: 5 years of follow-up in a prospective study. Fertil Steril 1991; 55:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/24\">",
"      Peterson HB, Xia Z, Hughes JM, et al. The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization. Am J Obstet Gynecol 1996; 174:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/25\">",
"      Chi IC, Laufe LE, Gardner SD, Tolbert MA. An epidemiologic study of risk factors associated with pregnancy following female sterilization. Am J Obstet Gynecol 1980; 136:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/26\">",
"      McCausland A. High rate of ectopic pregnancy following laparoscopic tubal coagulation failures. Incidence and etiology. Am J Obstet Gynecol 1980; 136:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/27\">",
"      Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/28\">",
"      Rulin MC, Davidson AR, Philliber SG, et al. Long-term effect of tubal sterilization on menstrual indices and pelvic pain. Obstet Gynecol 1993; 82:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/29\">",
"      Peterson HB, Jeng G, Folger SG, et al. The risk of menstrual abnormalities after tubal sterilization. U.S. Collaborative Review of Sterilization Working Group. N Engl J Med 2000; 343:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/30\">",
"      Stewart FH, Harper CC, Ellertson CE, et al. Clinical breast and pelvic examination requirements for hormonal contraception: Current practice vs evidence. JAMA 2001; 285:2232.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical Effectiveness Unit. Combined hormonal contraception. London (UK): Faculty of Sexual and Reproductive Healthcare; 2011 Oct. 28 file://guideline.gov/content.aspx?f=rss&amp;id=36071 (Accessed on June 25, 2012).",
"    </li>",
"    <li>",
"     WHO Medical eligibility criteria for contraceptive use. Fourth edition, 2009. file://whqlibdoc.who.int/publications/2010/9789241563888_eng.pdf. (Accessed on June 11, 2012).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report (MMWR). U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. Adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th edition. Early release - May 28, 2010. file://www.cdc.gov/mmwr/preview/mmwrhtml/rr59e0528a1.htm (Accessed on May 28, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/34\">",
"      Patel A, Schwarz EB, Society of Family Planning. Cancer and contraception. Release date May 2012. SFP Guideline #20121. Contraception 2012; 86:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/35\">",
"      Kuohung W, Borgatta L, Stubblefield P. Low-dose oral contraceptives and bone mineral density: an evidence-based analysis. Contraception 2000; 61:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/36\">",
"      Lopez LM, Grimes DA, Schulz KF, Curtis KM. Steroidal contraceptives: effect on bone fractures in women. Cochrane Database Syst Rev 2009; :CD006033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/37\">",
"      van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005; 72:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/38\">",
"      Barnhart KT, Schreiber CA. Return to fertility following discontinuation of oral contraceptives. Fertil Steril 2009; 91:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/39\">",
"      Mansour D, Gemzell-Danielsson K, Inki P, Jensen JT. Fertility after discontinuation of contraception: a comprehensive review of the literature. Contraception 2011; 84:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/40\">",
"      Sober SP, Schreiber CA. Controversies in family planning: are all oral contraceptive formulations created equal? Contraception 2011; 83:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/41\">",
"      Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998; 179:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/42\">",
"      Generic OCs bioequivalent, but much maligned. Contracept Technol Update 1989; 10:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/43\">",
"      Westhoff C, Heartwell S, Edwards S, et al. Initiation of oral contraceptives using a quick start compared with a conventional start: a randomized controlled trial. Obstet Gynecol 2007; 109:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/44\">",
"      Foster DG, Parvataneni R, de Bocanegra HT, et al. Number of oral contraceptive pill packages dispensed, method continuation, and costs. Obstet Gynecol 2006; 108:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/45\">",
"      ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107:1453.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Selected Practice Recommendations for Contraceptive Use, 2nd, WHO, Geneva, Switzerland 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/47\">",
"      Mansour D, Fraser IS. Missed contraceptive pills and the critical pill-free interval. Lancet 2005; 365:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/48\">",
"      Mansour D. Revision of the 'missed pill' rules. J Fam Plann Reprod Health Care 2011; 37:128.",
"     </a>",
"    </li>",
"    <li>",
"     Medicines and Healthcare products Regulatory Agency (MHRA) combined oral contraception Combined Oral Contraceptive (COC) Pill Advice",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/50\">",
"      Gerstman BB, Piper JM, Tomita DK, et al. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991; 133:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/51\">",
"      Kaunitz AM. Oral contraceptive estrogen dose considerations. Contraception 1998; 58:15S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/52\">",
"      Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations. Contraception 1999; 60:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/53\">",
"      Gallo MF, Nanda K, Grimes DA, Schulz KF. 20 mcg versus &gt;20 mcg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev 2005; :CD003989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/54\">",
"      Bachmann G, Korner P. Bleeding patterns associated with oral contraceptive use: a review of the literature. Contraception 2007; 76:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/55\">",
"      Milsom I, Korver T. Ovulation incidence with oral contraceptives: a literature review. J Fam Plann Reprod Health Care 2008; 34:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/56\">",
"      Jain J, Dutton C, Nicosia A, et al. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera. Contraception 2004; 70:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/57\">",
"      Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998; 57:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/58\">",
"      Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1991; 49:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/59\">",
"      Croxatto HB. Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care 2000; 5 Suppl 2:21.",
"     </a>",
"    </li>",
"    <li>",
"     Population Council. Jadelle&reg; Implants Frequently Asked Questions. www.popcouncil.org/biomed/jadellefaqgeninfo.html (Accessed 3/7/05).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/61\">",
"      Sivin I, Wan L, Ranta S, et al. Levonorgestrel concentrations during 7 years of continuous use of Jadelle contraceptive implants. Contraception 2001; 64:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/62\">",
"      Wan LS, Stiber A, Lam LY. The levonorgestrel two-rod implant for long-acting contraception: 10 years of clinical experience. Obstet Gynecol 2003; 102:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/63\">",
"      Hubacher D, Lopez L, Steiner MJ, Dorflinger L. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons. Contraception 2009; 80:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/64\">",
"      Steiner MJ, Lopez LM, Grimes DA, et al. Sino-implant (II)--a levonorgestrel-releasing two-rod implant: systematic review of the randomized controlled trials. Contraception 2010; 81:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/65\">",
"      Burkman RT. Transdermal hormonal contraception: benefits and risks. Am J Obstet Gynecol 2007; 197:134.e1.",
"     </a>",
"    </li>",
"    <li>",
"     Medical Letter 2002; 44:5.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/67\">",
"      Sonnenberg FA, Burkman RT, Speroff L, et al. Cost-effectiveness and contraceptive effectiveness of the transdermal contraceptive patch. Am J Obstet Gynecol 2005; 192:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/68\">",
"      Bakhru A, Stanwood N. Performance of contraceptive patch compared with oral contraceptive pill in a high-risk population. Obstet Gynecol 2006; 108:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/69\">",
"      Pierson RA, Archer DF, Moreau M, et al. Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error. Fertil Steril 2003; 80:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/70\">",
"      Creinin MD, Meyn LA, Borgatta L, et al. Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial. Obstet Gynecol 2008; 111:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/71\">",
"      Sitruk-Ware R, Plu-Bureau G, Menard J, et al. Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study. J Clin Endocrinol Metab 2007; 92:2074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/72\">",
"      Tourgeman DE, Slater CC, Stanczyk FZ, Paulson RJ. Endocrine and clinical effects of micronized estradiol administered vaginally or orally. Fertil Steril 2001; 75:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/73\">",
"      Goebelsmann U, Mashchak CA, Mishell DR Jr. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol. Am J Obstet Gynecol 1985; 151:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/74\">",
"      Brache V, Faundes A. Contraceptive vaginal rings: a review. Contraception 2010; 82:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/75\">",
"      Kerns J, Darney P. Vaginal ring contraception. Contraception 2011; 83:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/76\">",
"      Roumen FJ, Apter D, Mulders TM, Dieben TO. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod 2001; 16:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/77\">",
"      Bjarnad&oacute;ttir RI, Tuppurainen M, Killick SR. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am J Obstet Gynecol 2002; 186:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/78\">",
"      Oddsson K, Leifels-Fischer B, Wiel-Masson D, et al. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial. Hum Reprod 2005; 20:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/79\">",
"      Roumen FJ. The contraceptive vaginal ring compared with the combined oral contraceptive pill: a comprehensive review of randomized controlled trials. Contraception 2007; 75:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/80\">",
"      Massai R, Quinteros E, Reyes MV, et al. Extended use of a progesterone-releasing vaginal ring in nursing women: a phase II clinical trial. Contraception 2005; 72:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/81\">",
"      Nath A, Sitruk-Ware R. Progesterone vaginal ring for contraceptive use during lactation. Contraception 2010; 82:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/82\">",
"      Massai R, Miranda P, Vald&eacute;s P, et al. Preregistration study on the safety and contraceptive efficacy of a progesterone-releasing vaginal ring in Chilean nursing women. Contraception 1999; 60:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/83\">",
"      Ortiz ME, Croxatto HB. The mode of action of IUDs. Contraception 1987; 36:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/84\">",
"      Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994; 49:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/85\">",
"      Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril 1994; 61:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/86\">",
"      French, R, Cowan, F, Mansour, D, et al. Hormonally impregnated intrauterine systems (IUSs), versus other forms of reversible contraceptives as effective methods of preventing pregnancy. Cochrane Database Syst Rev. 2001; (2):CD001776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/87\">",
"      Sivin I. Dose- and age-dependent ectopic pregnancy risks with intrauterine contraception. Obstet Gynecol 1991; 78:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/88\">",
"      Mol BW, Ankum WM, Bossuyt PM, Van der Veen F. Contraception and the risk of ectopic pregnancy: a meta-analysis. Contraception 1995; 52:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/89\">",
"      Kestelman P, Trussell J. Efficacy of the simultaneous use of condoms and spermicides. Fam Plann Perspect 1991; 23:226.",
"     </a>",
"    </li>",
"    <li>",
"     www.CDC.gov.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/91\">",
"      Gallo MF, Grimes DA, Schulz KF, Lopez LM. Cervical cap versus diaphragm for contraception. Cochrane Database Syst Rev 2012; :CD003551.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization (WHO). Improving access to quality care in family planning. In: Medical Eligibility criteria for contraceptive use. 3rd edition, Geneva, Switzerland, 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/93\">",
"      Kuyoh MA, Toroitich-Ruto C, Grimes DA, et al. Sponge versus diaphragm for contraception. Cochrane Database Syst Rev 2002; :CD003172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/94\">",
"      Schwartz B, Gaventa S, Broome CV, et al. Nonmenstrual toxic shock syndrome associated with barrier contraceptives: report of a case-control study. Rev Infect Dis 1989; 11 Suppl 1:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/95\">",
"      Jones EF, Forrest JD. Contraceptive failure rates based on the 1988 NSFG. Fam Plann Perspect 1992; 24:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/96\">",
"      Shaaban OM, Glasier AF. Pregnancy during breastfeeding in rural Egypt. Contraception 2008; 77:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/97\">",
"      Raymond EG, Trussell J, Weaver MA, Reeves MF. Estimating contraceptive efficacy: the case of spermicides. Contraception 2013; 87:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/98\">",
"      Raymond EG, Chen PL, Luoto J, Spermicide Trial Group. Contraceptive effectiveness and safety of five nonoxynol-9 spermicides: a randomized trial. Obstet Gynecol 2004; 103:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/99\">",
"      Schreiber CA, Meyn LA, Creinin MD, et al. Effects of long-term use of nonoxynol-9 on vaginal flora. Obstet Gynecol 2006; 107:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/100\">",
"      Einarson TR, Koren G, Mattice D, Schechter-Tsafriri O. Maternal spermicide use and adverse reproductive outcome: a meta-analysis. Am J Obstet Gynecol 1990; 162:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/101\">",
"      Gallaway MS, Waller DK, Canfield MA, et al. The association between use of spermicides or male condoms and major structural birth defects. Contraception 2009; 80:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/102\">",
"      Kelly JP, Reynolds RB, Stagno S, et al. In vitro activity of the spermicide nonoxynol-9 against Chlamydia trachomatis. Antimicrob Agents Chemother 1985; 27:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/103\">",
"      Malkovsky M, Newell A, Dalgleish AG. Inactivation of HIV by nonoxynol-9. Lancet 1988; 1:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/104\">",
"      Rosenberg MJ, Rojanapithayakorn W, Feldblum PJ, Higgins JE. Effect of the contraceptive sponge on chlamydial infection, gonorrhea, and candidiasis. A comparative clinical trial. JAMA 1987; 257:2308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/105\">",
"      Louv WC, Austin H, Alexander WJ, et al. A clinical trial of nonoxynol-9 for preventing gonococcal and chlamydial infections. J Infect Dis 1988; 158:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/106\">",
"      Kreiss J, Ngugi E, Holmes K, et al. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 1992; 268:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/107\">",
"      Roddy RE, Zekeng L, Ryan KA, et al. Effect of nonoxynol-9 gel on urogenital gonorrhea and chlamydial infection: a randomized controlled trial. JAMA 2002; 287:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/108\">",
"      Roddy RE, Zekeng L, Ryan KA, et al. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 1998; 339:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/109\">",
"      Richardson BA, Lavreys L, Martin HL Jr, et al. Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial. Sex Transm Dis 2001; 28:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/110\">",
"      Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002; 360:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/111\">",
"      Niruthisard S, Roddy RE, Chutivongse S. The effects of frequent nonoxynol-9 use on the vaginal and cervical mucosa. Sex Transm Dis 1991; 18:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/112\">",
"      Potential spermicide enters clinical trial. Contraceptive Technology UpDate 2011; 32:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/113\">",
"      Abbott J. Transcervical sterilization. Curr Opin Obstet Gynecol 2007; 19:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/114\">",
"      Lippes J. Quinacrine sterilization: the imperative need for american clinical trials. Fertil Steril 2002; 77:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/115\">",
"      Lippes J, Brar M, Gerbracht K, et al. An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet 2003; 83 Suppl 2:S45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/116\">",
"      Informed Consent Working Group. Quinacrine sterilization (QS): informed consent. Int J Gynaecol Obstet 2003; 83 Suppl 2:S147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/117\">",
"      Merchant RN, Doctor VM, Thaku SS, et al. Clinico-pathological study of fallopian tubes after transcervical insertion of quinacrine hydrochloride pellets. Adv Contracept 1986; 2:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/118\">",
"      el Sahwi S, Kamel M, el Faham M, el Makhzangy I. Hysteroscopic and hysterosalpingographic study after intrauterine insertion of quinacrine pellets for non-surgical sterilization: results in 180 women. Int J Gynaecol Obstet 2003; 83 Suppl 2:S101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/119\">",
"      Sokal DC, Hieu do T, Loan ND, et al. Safety of quinacrine contraceptive pellets: results from 10-year follow-up in Vietnam. Contraception 2008; 78:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/120\">",
"      Sokal DC, Trujillo V, Guzm&aacute;n SC, et al. Cancer risk after sterilization with transcervical quinacrine: updated findings from a Chilean cohort. Contraception 2010; 81:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/121\">",
"      Sokal DC, Hieu do T, Loan ND, et al. Contraceptive effectiveness of two insertions of quinacrine: results from 10-year follow-up in Vietnam. Contraception 2008; 78:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/122\">",
"      Soroodi-Moghaddam S. Quinacrine sterilization (QS) in Iran and the use of HSG as a measure of success. Int J Gynaecol Obstet 2003; 83 Suppl 2:S93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/123\">",
"      Cancel AM, Dillberger JE, Kelly CM, et al. A lifetime cancer bioassay of quinacrine administered into the uterine horns of female rats. Regul Toxicol Pharmacol 2010; 56:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/124\">",
"      Sokal DC, Vach TH, Nanda K, et al. Quinacrine sterilization and gynecologic cancers: a case-control study in northern Vietnam. Epidemiology 2010; 21:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/125\">",
"      Naz RK, Gupta SK, Gupta JC, et al. Recent advances in contraceptive vaccine development: a mini-review. Hum Reprod 2005; 20:3271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/126\">",
"      Raymond EG, Halpern V, Lopez LM. Pericoital oral contraception with levonorgestrel: a systematic review. Obstet Gynecol 2011; 117:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/127\">",
"      Grimes DA, Lopez LM, Gallo MF, et al. Steroid hormones for contraception in men. Cochrane Database Syst Rev 2012; 3:CD004316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/128\">",
"      Page ST, Amory JK, Anawalt BD, et al. Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. J Clin Endocrinol Metab 2006; 91:4374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/129\">",
"      Cummings DE, Kumar N, Bardin CW, et al. Prostate-sparing effects in primates of the potent androgen 7alpha-methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. J Clin Endocrinol Metab 1998; 83:4212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/130\">",
"      Suvisaari J, Moo-Young A, Juhakoski A, et al. Pharmacokinetics of 7 alpha-methyl-19-nortestosterone (MENT) delivery using subdermal implants in healthy men. Contraception 1999; 60:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/131\">",
"      Attardi BJ, Hild SA, Reel JR. Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity. Endocrinology 2006; 147:3016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/132\">",
"      Bebb RA, Anawalt BD, Christensen RB, et al. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocrinol Metab 1996; 81:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/133\">",
"      Gu YQ, Tong JS, Ma DZ, et al. Male hormonal contraception: effects of injections of testosterone undecanoate and depot medroxyprogesterone acetate at eight-week intervals in chinese men. J Clin Endocrinol Metab 2004; 89:2254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/134\">",
"      Grimes DA, Lopez LM, Gallo MF, et al. Steroid hormones for contraception in men. Cochrane Database Syst Rev 2007; :CD004316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/24/39306/abstract/135\">",
"      Gonzalo IT, Swerdloff RS, Nelson AL, et al. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J Clin Endocrinol Metab 2002; 87:3562.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5459 Version 57.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-996A9847C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_24_39306=[""].join("\n");
var outline_f38_24_39306=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H49\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHOOSING A METHOD OF CONTRACEPTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12170197\">",
"      Factors to consider",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12168818\">",
"      Effectiveness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11463800\">",
"      - Long-acting reversible contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12169534\">",
"      Cost",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12168768\">",
"      CONTRACEPTIVE USE IN THE UNITED STATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3617390\">",
"      Prevalence by method",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12496697\">",
"      Adherence by contraceptive method",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12169638\">",
"      HOW TO SWITCH FROM ONE METHOD TO ANOTHER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12168946\">",
"      WHEN IS IT SAFE TO STOP USING CONTRACEPTION?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12168953\">",
"      Hormonal contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12169710\">",
"      CONTRACEPTIVE OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12169159\">",
"      Sterilization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12169250\">",
"      - Women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12169257\">",
"      - Men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hormonal methods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3077748\">",
"      - Patient assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3870905\">",
"      - Contraception for women with medical issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3870962\">",
"      World Health Organization tables",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3870998\">",
"      CDC tables",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H33310319\">",
"      Other guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3871489\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27579201\">",
"      - Estrogen-progestin versus progestin-only contraceptives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31525262\">",
"      - Return to fertility after discontinuation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35252209\">",
"      - Counseling and strategies to enhance compliance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Oral contraceptives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Combined (estrogen-progestin) pills",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H19642726\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H19642791\">",
"      - Noncontraceptive benefits",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Initiation and administration of combined OCs",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Missed pills",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H3818891\">",
"      - Extra pills",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Risks and side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Progestin only pills",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Injectable contraceptives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Depot medroxyprogesterone acetate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Contraceptive implants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H655813722\">",
"      Etonogestrel implant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H655813729\">",
"      Levonorgestrel implants",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H17361816\">",
"      - Jadelle",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H655813736\">",
"      - Sino-implant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Transdermal contraception",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Contraceptive vaginal ring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1598978121\">",
"      Estrogen-progestin contraceptive ring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1598978136\">",
"      Progesterone contraceptive ring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H880828\">",
"      - Levonorgestrel-releasing intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12170533\">",
"      Intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12170555\">",
"      Fertility awareness based methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Barrier methods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Condom",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Diaphragm and cervical cap",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Sponge",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Emergency contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Withdrawal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Lactation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Contraceptive choices during lactation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Spermicides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Lack of protection against STDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2868648541\">",
"      - Chemical methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Quinacrine sterilization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      - Vaccines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18825998\">",
"      - Intermittent hormonal contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H878600\">",
"      EMERGENCY CONTRACEPTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H878176\">",
"      CONTRACEPTION FOR MEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H878393\">",
"      Condoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H878447\">",
"      Vasectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H878534\">",
"      Future directions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H878371\">",
"      - Hormonal methods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H878557\">",
"      - Vas injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5459\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5459|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?17/45/18129\" title=\"algorithm 1\">",
"      Quick start method",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5459|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/38/36461\" title=\"figure 1\">",
"      Most popular birth control methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/46/32488\" title=\"figure 2\">",
"      Comparison of effectiveness of contraceptive methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5459|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/62/1006\" title=\"table 1\">",
"      Epidemiology of unintended pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/22/5486\" title=\"table 2\">",
"      Comparison of selected hormonal contraceptives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/1/24603\" title=\"table 3\">",
"      Contraceptive counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/56/13197\" title=\"table 4\">",
"      Pregnancy rate during first year of contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/46/4846\" title=\"table 5\">",
"      Switching between different methods of contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/13/12506\" title=\"table 6\">",
"      CDC Medical Eligibility Criteria for Contraceptive Use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/60/4044\" title=\"table 7\">",
"      Medical conditions associated with adverse events in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/51/21311\" title=\"table 8\">",
"      WHO MEC Personal characteristics and reproductive history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/25/40350\" title=\"table 9\">",
"      WHO criteria for contraceptive use in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/61/37853\" title=\"table 10\">",
"      WHO MEC for neurologic conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/1/1052\" title=\"table 11\">",
"      WHO MEC for Depressive disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/28/34255\" title=\"table 12\">",
"      WHO MEC for reproductive tract infections and disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/20/39245\" title=\"table 13\">",
"      WHO MEC for women with HIV AIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/40/5774\" title=\"table 14\">",
"      WHO MEC for gastrointestinal disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/49/23324\" title=\"table 15\">",
"      WHO MEC for thalassemia and sickle cell disease and anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/34/20013\" title=\"table 16\">",
"      WHO MEC for patients with endocrine disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/54/37741\" title=\"table 17\">",
"      WHO MEC for potential drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/14/42220\" title=\"table 18\">",
"      WHO MEC for patients with systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/59/11184\" title=\"table 19\">",
"      Estrogen and progestin types and doses in hormonal contraceptive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/23/9595\" title=\"table 20\">",
"      Questions used to assess possibility of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/15/7419\" title=\"table 21\">",
"      Indications for progestin only contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/32/16907\" title=\"table 22\">",
"      Ectopic risk by contraceptive",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/38/20070?source=related_link\">",
"      Barrier contraception: Diaphragm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/8/4233?source=related_link\">",
"      Contraception counseling for obese women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26759?source=related_link\">",
"      Contraception for women with inherited thrombophilias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/54/33640?source=related_link\">",
"      Contraceptive vaginal ring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/0/32777?source=related_link\">",
"      Counseling women considering combined hormonal contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/45/34522?source=related_link\">",
"      Depot medroxyprogesterone acetate for contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/5/31833?source=related_link\">",
"      Emergency contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/52/17224?source=related_link\">",
"      Epithelial ovarian cancer: Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/27/3512?source=related_link\">",
"      Etonogestrel contraceptive implant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5334?source=related_link\">",
"      Female condoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/58/37800?source=related_link\">",
"      Fertility awareness-based methods of pregnancy prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3832?source=related_link\">",
"      Hormonal contraception for suppression of menstruation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/23/12665?source=related_link\">",
"      Hysteroscopic sterilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30696?source=related_link\">",
"      Male condoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/10/22698?source=related_link\">",
"      Management of unscheduled bleeding in women using contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32058?source=related_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=related_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39893?source=related_link\">",
"      Overview of vasectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/60/9157?source=related_link\">",
"      Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/56/14211?source=related_link\">",
"      Patient information: Choosing birth control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/2/29730?source=related_link\">",
"      Patient information: Vasectomy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/25/36242?source=related_link\">",
"      Patient information: Vasectomy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/8/24713?source=related_link\">",
"      Postpartum and postabortion contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/1/32794?source=related_link\">",
"      Principles of medication use during lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/52/9031?source=related_link\">",
"      Progestin-only pills (minipills) for contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15018?source=related_link\">",
"      Surgical sterilization of women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41127?source=related_link\">",
"      Transdermal contraceptive patch",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_24_39307="ACC AHA ESC precardioversion";
var content_f38_24_39307=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA/ESC guideline summary: Antiarrhythmic drug enhancement of direct-current (DC) cardioversion in atrial fibrillation (AF)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence",
"or opinion is in favor of the usefulness of the following approaches to",
"the pharmacologic enhancement of DC cardioversion in AF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Pretreatment with amiodarone, flecainide, ibutilide, propafenone, or sotalol, which may also prevent recurrent AF.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; In patients who relapse after successful cardioversion prior to repeat DC cardioversion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence",
"or opinion is less well established for the usefulness of the following",
"approaches for the pharmacologic enhancement of DC cardioversion in AF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Among patients with persistent AF, beta blockers, disopyramide, diltiazem, dofetilide, procainamide, or verapamil; the ability of these drugs to increase the success of DC cardioversion or to prevent early AF recurrence is uncertain.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Out-of-hospital initiation of antiarrhythmic drugs in patients without heart disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Out-of-hospital initiation of antiarrhythmic drugs in patients with certain forms of heart disease if the safety of drug has been verified for the patient.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Fuster, V, Ryden, LE, Cannom, DS, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol 2006; 48:e149.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_24_39307=[""].join("\n");
var outline_f38_24_39307=null;
var title_f38_24_39308="Definitions of esophageal pressure topography metrics";
var content_f38_24_39308=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F86119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F86119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Definitions of esophageal pressure topography metrics",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        EPT metric",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Conventional manometry correlate",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         IRP",
"        </strong>",
"        (mmHg)",
"       </td>",
"       <td>",
"        Average minimum EGJ pressure for four contiguous or noncontiguous seconds of relaxation within 10 seconds of swallow (upper sphincter relaxation) (&gt;15 mmHg is abnormal)",
"       </td>",
"       <td>",
"        LES relaxation measured with best estimate position through the EGJ (&gt;8 mmHg is abnormal)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Peristaltic breaks",
"        </strong>",
"        (cm)",
"       </td>",
"       <td>",
"        Gap in the 20 mmHg isobaric contour of the peristaltic contraction between the UES and EGJ, measured in axial length",
"        <ul>",
"         <li>",
"          Small break: 2 to 5 cm in length",
"         </li>",
"         <li>",
"          Large break: &gt;5 cm in length",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Utilizes the 30 mmHg amplitude in positions 3 and 8 cm above the LES to distinguish a swallow as ineffective",
"        <ul>",
"         <li>",
"          Ineffective &lt;30 mmHg at 3 and/or 8 cm recording sites above the LES",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         DCI",
"        </strong>",
"        (mmHg-s-cm)",
"       </td>",
"       <td>",
"        Amplitude x duration x length (mmHg-s-cm) of the distal esophageal contraction greater than 20 mmHg measured between the proximal and distal pressure troughs",
"        <ul>",
"         <li>",
"          Hypertensive: mean DCI of 10 swallows &gt;5000 mmHg-s-cm",
"         </li>",
"         <li>",
"          Hypercontractile: at least one swallow with a DCI &gt;8000 mmHg-s-cm",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Average of 10 swallows at two recording sites positioned 3 and 8 cm above the LES",
"        <ul>",
"         <li>",
"          Nutcracker &gt;180 mmHg",
"         </li>",
"         <li>",
"          Revised definitions &gt;220 to 260 mmHg",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         CFV",
"        </strong>",
"        (cm/second)",
"       </td>",
"       <td>",
"        Slope of the tangent to the 30 mmHg isobaric contour between the proximal pressure trough and the CDP (&gt;9 cm/second is abnormal)",
"       </td>",
"       <td>",
"        Peristaltic progression from the UES to the LES at a rate of 2 to 8 cm/second",
"        <ul>",
"         <li>",
"          Greater than 8 cm/second is abnormal",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         DL",
"        </strong>",
"        (seconds)",
"       </td>",
"       <td>",
"        Interval between UES relaxation and the CDP (&lt;4.5 seconds is abnormal)",
"       </td>",
"       <td>",
"        No correlate in conventional manometry",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     EPT: esophageal pressure topography; IRP: integrated relaxation pressure; EGJ: esophagogastric junction; LES: lower esophageal sphincter; UES: upper esophageal sphincter; DCI: distal contractile integral; CFV: contractile front velocity; CDP: contractile deceleration point; DL: distal latency.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Spechler SJ, Castell DO. Classification of oesophageal motility abnormalities. Gut 2001; 49:145.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_24_39308=[""].join("\n");
var outline_f38_24_39308=null;
var title_f38_24_39309="Prognosis ETT asymptomatic men";
var content_f38_24_39309=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abnormal ETT predicts risk in asymptomatic men with risk factors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 323px; background-image: url(data:image/gif;base64,R0lGODlhvwFDAeYAAP///4CAgAAAAP+AgMDAwICZ/0BAQICzmaCgoCAgIPDw8DAwMBAQEMDZzdDQ0MDN/7CwsHBwcABmM/8AAAAz///AwODg4FBQUGBgYJCQkLDQwP9AQBBwQODs5vD28zCDWUBm/0CMZnCpjaDGs1CWcyB5Tb+Mv9Dj2WCggDBZ///g4PDz///Q0P/w8ODm/9DZ/2CA/3CN/5Cm/yBN//9gYKCz//8gIP9wcP8QEP+QkP8wMJC8pv+goLDA//9QUL9NgL+AgA8v70BWrxBA/z8MP4BAQABcWU8jr0CGgI+W78+JrwA/zP+wsABJpUBzzAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAC/AUMBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8AAwocSLCgwYMIEypcyBARAQeDFCAIgEDBIAgBMlhoyBGTigogK6hoETIki5IgE50EqWIQyhbOHAQQYGDQApoCFgiKkJMBg40dg0oaMKHohAEVjBrdoLRoIqZGbwhqWsGZAQE0BUEQcAHABQEQFAhgACCDgAhC0z4iSoMlyaQT/0CezDFBR0pETEU6BVA0JExnBLICmBlgsIAAgWsmFkQggOPHAYCYKEC5sokBmDNjnly5M+XLmjNz9mw5tGjSSZSYXs26tevXrHO8VBuJ6AbMLadOIJR0w6K8LCbY0J0Z2mLDhQkvPt4YsuMiRIR4Bm16NOkC1ENbJ51d83YnTZYEOfIDtvnz6DHT2MCefVMc7dnfSE8fNhOT2D6G5IG5aiGiRvnH124uTeAbAADGRQhUE+DAgm5GDWjgMseZhRZPGTiQEwBbdZVIAAswAJEuDaDwgQRGINHAIQ/I8IAgD3j2IovXVTZjJvqFVN+OrcVng1I6tOcDj0QWadp67f1oFP98QvZnCFEDGLKXIL0JkuNfgjB1Q1EPDsibXMo4YNYCBChggQAJEJCAAButCcFXCCjiWAYMWNRLAzusaMgDMKRAQQozgNDZjYXEWGMBhBLSYqLIlMSfkZASKRt+QxnopG68TahIXkTZANOUz1yFlQAEAIDAmgnECYADNzGAlpyFYbCAnb80MEIHLLoYCp9+pgCDjLRNkuBRg4Ba5aYK6jABDV6+45ggBmAQTAMkSPDBASew0iKwNB7KKIyHIhpsQM8CoMACrwajAQollICCBrkYWuO3AMh7Hb32kkbvuOSUuyoDqg5zwgEnkqAnN/lyy286/q4qwIjFdDCCng0cYPH/xRhTjPHGB2jM8cUef9yxIBVbLAK8scTYwwMrLNxNw6aKuEzJIof8sc0c47yxzSWEgOsrD8QAgp9/ghADZfu6zAzMAEQw60EeHCDBAR7MssIDPdiISMKDKg0M0wBgUBNCHYRQAsq/cK11t/O+4sIDcD/gwtVxw/1C3XAncjfcLgyCd8vrgH2utAlpgLY0aiO9dbj4FlBD3o0UQMHkFCBKOeUgXD55IplTHoMgmt/4+Dlgm8tABgwZbk7i4tIIAggzTB6ooN9KDgPfdE9ud4t/Qn5I5nJvDoDucAMOgKCkF4aIAwxAsJAGHIgAENw1tF6I5IIW0DfoFChKAQiLAP8C/wUzcF8ZIcibU7pWzi/UwQcf/IyQ5JTfKDyM3wtCPwWEdk7BEC/gHuXqpbnu9Ut5CxMBBw5XEMkVwBD3IyD4APC24qGPAjGYXACHZ0BB0M1XvhPH+tICPekdBHuK4573Jsg5/kluBi2L4CDSV44RpuV98TPI/io3iAg+IH+KAB4A/AQDDh4iBjVIniMg0D6GKJCBXuOHDS/yE46oLor/mOIgnJaWEYwAi/vQok3SxZERSEAENyOZyCyms4yBsRpiFIQFmieUEaAxZ2pcYxtBJogrvtEZcdRKFf94CehVjZBLQ+AjuIhIS4TAhI1MRiDHGElKdIADB6tkMSYpR1c5B/8ypdLkIQgmSmNwUiufBCUhmhOBgDXyWqUkxikj0ZwAJIBMkWwAB+QXy1/MshIIYIABQklIEYSgl8H4ZSUUEAAGXAAob/TAApHpS0WigpkCwAA0sehHau5CmZiwAAYOQytvmpMV4MyEBS7AgACU85zwLEU6NUEAAwCMm1CMpyYkEoAm8jMD7zTEPDdBgAUkoIkLM6Q+O3GunJzFXDe5Sp1gZQsEIHRhj1woJywEgDVZIDA6uUooawkZA1hTo5u4ZCZRWomZoEWkDTUo4QBA0seYdBcIcCVtSMnSS5yJJgwglQIwwIA1Pe1DJ60FAgSgU7XAsqeWkMmpBFCWw3jFqkj/5UUwkxoUXfISqpFAAAG+gpalkukmTSXEQEfBqgsENCjGBCslsJIABEYgqHVdxFpHoYALLABiaZFmPuUqir2SopkXDUo3CXtYruYCAu1krGQNW4q2vlWyC6VsKfr6V7UsFrOe0KwpEEvCXYI2FKI1BWQdmxARfOC0oEitKSwrlA9AErabkK0pOAtYhlxysLilhG5PQdqOQO+rwW0pa4PBRKG4NrmZGC5hbQvdS0h3Fc317TSrK9zlFuNUVgQud/Xq3WLkdbyEvO4qTpWqhtAsjQB47wHEy1j1soK9aSWIfHeWR4uxq7r2bQV+sViCLyY3wK4YsNJGUALoIvgVCl5Y/4EPXF5nRDhYn8Xsg2VxYfR2ZMOzYG9iPawQENPCopBwAAFWjJHHEDMfDVjpZCucjeZcwAA4vsmoEoBjHKtyEI15CD1G8FqhTAQyvW3sOZoj1hW/2BEEiIABUGWACCAmyegogYwXIqpRkQoVJsaGigMgZSpjYMTiOAAJhGKADKy4ygnw0Ghp7I8x83ib45AmchUCFkEEwKRjm3NQsOlOc6AABUFJQDvveoE/g5nOArHAlNHcjUsesiGQxYqIIoA64kJ6INklBwkOMOgVL3MiCOXncsNMYpI1mCMOuDGOyeiImD70XzRJAHldFupvfMDADFnTqAL9CI56tKMPK0RNHf9z04VB1gB43kaMOcIVS7gUACLVUALWJOdl//nTCFHAXcHdakhcgNaR+Kk9SQXSgjKVol4rKC7L/Qmi9hjdjZDqmhxWE8LAO4rNjMBlqTFthnRZMGEd663ddJMnF4LV75A0HbVBZE3SFYGsGkt+BwFxeEB249LQskLKpGInY3kUHYcH8/A9DTXzuZ5eJragEWmBBczUGnpOSAAscGTHgDy25B70Ao5qjUMvpEyuSPk8ZBXtaFhaIVc5MzqDnpa7nvwZo1YIAnScgE4/upTBpHQzGvBqhTjgKjKXJ9XVAoGfM+PXCdm6pr3uaXrTouAHibrYC7t2fuXU7lAeuNrNuVT/t9Ob5E4WciqUvo/CSwPvAiHVwdOu5HM6HhojWDNBdt5ziqiC8fy4vDM8IIFLDwTprQB96N+NdWAPRO9TX6jomZF5g8gdTXSfuT5nrwzSm34gZ0d43TXK+2SQwPUBuf3pPt93MAZT4LTX/OuzuXfUNh+MCjBAZ3tfeoKgPvZQNUvujXF8guA46df/I6sMIPhabbkfjk59+v8o7om3mif3Zr5ke+3hyesf8LgAeeakegAIAGgkEFKWf4s3f5X0d8UAPdkCEP63gLAVTIaXCyPAAb/3Dwf1f6fFPBeICyaygf2wAJSHcgyoScwzfsBAAtLHDwl4E3I2fLjFPDcXDB7w/wGI1g9dlgBXZ33QVXM3CAzShHxCwU8XpWJNp1YpWEqDUwwnsF36YGXMkwDtdwi2li7Mg1VZVV3nwn7EkGH1ADDs5CqSYGxsIgg6hkDe1mxeqH1XiFKkEmfxBwnXJlKD4Spc2IZNiEyyEoe3IIbyEGeHIWWSoG5B9RBg4W//Nl5MNwwKhQ9m8RMJwHKLoG9UNRNexloESBtE9YO54IL64AAWoADfBwliRVYA8FEEME7a1IjoRSegeAuCJRQX93BciAidGCzBNIu2EImVtIu8eE/BIIqaJIy8GIKzUIv1IFbs44EFCAzAKA/NZogUGI3CYIzxEBheVm3XGI0O2AvMqP9y9sRjBnABvtgJyOgyFvgLgrgOzih/2CgIK6hRsaaAXzeP/zKEufCO6CBsWHGCfKePcmRzvnBc8eCN4EeQXwiIr/Bc8HBu6EeQEQGHvUBd72BvswaNFPmIu/Bb7zCB+UiRg/CJvICQWLSOhCSLvACRhdABMRZjHeABMRmTJ1CTAogINymTg4CTJBgL4mYAsVZ9odWHoNWOu4CRhCA1EtCUHdOUUCkBIRCVTTkIHUBqhzCVUGlCVPl+sPAVpIIBM6h7JEkIwbSEswCSSykBKCCTNNkATRljN7kD1oJ3cIkIU9kAHVCVABCXMfaTsCAAGTBMdUiDZUkIjKQLiyU1IWD/MfLDlyQjlYVwl1kpAQ1wAhLwak5pMbkAFsN0jhx5mGpoibnAlHE5CJAZX5IpCFoJlVg5CK3JARFIlX3ZlMc0C0RVVKw3kqI5CHNElLQgNa+JmhJACHB5mwAwl5apl4UwlSLQlLNZnD0pl7TQV2NBmkDYm4XAf7zAmGxEnMa5mj0pnYaQl1JTAlWTmriAEasYAOnICSqpnYpgmlMDnuOJnIJwAvhJCHkJACeCaOp5C+cFmt8on8j0ZYMhkNlpoNsJnOOSABigAE9YoAwqSO9JG5qIFQ5XeRVqloNESAhwjg4Kn0bpiETnfMpYlB16CGJDSDc2kStaCBPqfGmyYheq/wnxSU0KcF5YJJKGGaODAILOBxkpKghI6JsZkBHtl6PepCE32hCmGKWSkIXQMio6AYtAOgi9GEVLRSrocoYPdWxhsaMIyodZqotW6DW3lCaF6Qh3iKCCcGw0lUpueKaF8IdKI3lRpqCIgIhwylFYaqfQwo9qAaELEHCTgIlblE2MwKTwNKPjshWahpaKkIq39hV1hRiBKqirSIz8IhMaMVdogkDdyIklCoDMM6IGYQFKKo+cigjc2RFzpGkOqY6n+qr8YCEYspC46jXxV6e82auHEKs6J0zlWGWhKayEAFlPCn/dKHxkqayGcJYcwYqJ16zWdasEiacapq3byqca5f+ocgWpciWu48qj5eqtFCmkhGWuhOWk7aquJLmlYOWu9ZWmUGWvjMWtLKWvjBUt+Sqvh0mu+uSvjDVHRRpJBstYqYpSC8tYxOpNDyut5CKwFItIE3ux/pCx+6eqf8SxjAVe8ASyjNVe50SyhCWyA2ixFWqyEsuyDKqy1ISyJZuwvgqzMatr43KkRjoRFbFrGpsJLpsWVAoAEbUhmxq0YaWzaoGGFtAhV9U+Zqq0mDC0QfGmjWFVjDi1VGsJMhsUfpq1yZGLAoWzHWq1HaGoHLWrXdi1Xsu0RqZwaHEmaSKnumi2Z2uz/3CLgjBVaPtweFuhXxuMgduyeouhhZuzsUT/s7D1t+mVuAwasW/EuG4bD5Rbuc4CuZj7YZobuR6LuJubCYP7sZ3LoI6bkqVroKMLRpeLW6d7s6GrCasLcKlruofbEK2LW7OrNLnrure7EL1bgXDLurVruI8bu5ywu9ZKAKWYeDbqvBtqCCXHvECWeLWKDcHrux+yidwYc8/qm1x1cK/SjcQUj+GQvcK7vRiwYs3Ljc87JqbGGFR1CCL1U4KgoStGK8DqDejbuPk1Eya1c4OAFasErYGBCNmGJvd7GA2zvy9TvB26uhkKpwQMZAh3cGTbZTIDAN1IU98LDv3rv4fAiIRQwfIbaCpmFuxbCFfBE8nGwfNrpCtmc/H7/w0hfFqjC8COQUwm7MEyd8D0SyozkaY9PAgOzA03fFpoO8GkGsM+XAhnh8BfdhPSUsQ78bvLkMSgJblqocXIy78Q/MXs8E92QsZAK8aI1FASJaFHO1Fti8Z/BFLYxm4bgodvDMfYdxMyBVE5AaFARqcBnEqCPMiEXMiGfMiInMiKvMiM3MiO/MiQHMmSPMmaCg9DpZuzcslGZSdtGMiU/MmgzMg+FsqkXMqCPMqmnMqqfMTpYBaF8RUZYVWwnLQPPA5ezITxYFbullM5scu0jMRhHKwgHMy2cFejuhN4tWrETKFgXEPLnMXP/KPNfEA6F83ROs22bM3IcMu4LELajP+C1aw+3wx0zpwQNTwO5/wN6QwO64zH7vzO8BzP8jzPzcBPPysOzusNimcuPnu9zbDP+RwQR3ul4dDB2yATCDfQ3IDQgWbQ/wC1X/G5z4C/0UsNojI2EN1n2nDRA8xuFY0P/kbC3xCQF/DR03AcIU2213AcMHyOJm0PKT3OntBo4/ShNSYYMc0NLE3TY0Gp9rC2glkOdqwNFfJQbEvU0DrHL00PdKsmacjOh1rT/pwMYtLLZoImTu3T0FDVZGKKUT0WU+0OfovFyVBzWLF9G+1lpTLW3HBwzKtjaE3Pcj3XdF3Xdn3XeJ3Xer3XfN3Xfv3XgB3Ygj3YhF3Yhn3YiO3/zs77Vsgaotia2PVAvoeQFTOx1JC9DxRtEYN5Ae1D2V8WlBgAERNhEZ4nE0/WGBuB2kF2AeiICEnqZ6jDTCK6EzgW2nPqAGIVlKx82bWAFY/RNGcR0Rzcb1PcTiFiAWYBAWdCFjzRW5VtGFlrUj6BCOPkABoiLSECIslWV3elazMRVLa0aMPL27jQwQygE2LRFZ6tiGixFRpxFhnQcAY1xwT83JX93DyxoYERAc2tISY1ToWxp0FlGO3jExggwOS9Cz0sGFmx3oER4FZ1S1Vmcw81vdAN3fYNp4WgaLfkwy7WIRBwExe+KhewJjad4LbQwxE9E6iz3gBQVAoHES6MmtAaTQhjYktCLJiQRRYaYk2a2Gk+IVYZMBGHAQH79tzYJlZX8dgoTgo9bJ1mONwXnnEmqyE8PhZYeBUL8BVZiyoQYRZ49lN2Emt0FRY3sW2ZiKBg+bpNbsMafgFDuBWE2ub6gOSC8EyGwOV0vud83ud+/ueAHuiCPuiEXuiGfuiInuiKvuiM3uiO/uiQHumSPumUXumWfunBEggAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of 25,927 asymptomatic men followed for an average of 8.4 years, the prognostic importance of a positive exercise test (ETT) was related to the presence and number of cardiac risk factors (RF). The risk factors included hypertension, hypercholesterolemia, smoking, a family history of premature CHD, diabetes mellitus, and an abnormal resting ECG.",
"    <div class=\"footnotes\">",
"     ETT+: positive exercise test; ET-: negative exercise test; RF-: no risk factors; RF+: risk factors present.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Gibbons LW, Mitchell TL, Wei M, et al. Am J Cardiol 2000; 86:53.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_24_39309=[""].join("\n");
var outline_f38_24_39309=null;
var title_f38_24_39310="Clostridium difficile";
var content_f38_24_39310=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Clostridium difficile",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 239px; height: 194px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram positive rods characteristic of Clostridium difficile.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of J Thomas LaMont, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_24_39310=[""].join("\n");
var outline_f38_24_39310=null;
var title_f38_24_39311="Neonatal BP birth weight";
var content_f38_24_39311=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Neonatal blood pressure based on birth weight",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 449px; height: 588px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Linear regression of mean systolic and diastolic blood pressure on birth weight in 329 infants admitted to NICU on day 1 of life. The mean systolic and diastolic blood pressure, and 95 percent confidence limit (CL) for incremental birth weight are plotted about the respective regression lines.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with&nbsp;permission from: Macmillan Publishers Ltd. Zubrow AB, Hulman S, Kushner H, Falkner B. Determinants of blood pressure in infants admitted to neonatal intensive care units: a prospective multicenter study. Philadelphia Neonatal Blood Pressure Study Group. J Perinatol 1995; 15:470. Copyright &copy;1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_24_39311=[""].join("\n");
var outline_f38_24_39311=null;
